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Congenital heart disease (CHD), defined as any structural abnormality of the heart or great 
vessels, is a leading cause of morbidity and mortality in infants and young children.  Even as 
survival rates for the most severe forms of CHD improve, patients still face a lifetime of 
monitoring, diagnostic procedures, and possible additional surgeries to address these defects or 
related issues.  Compounding matters is recent evidence suggesting CHD patients may have an 
increased lifetime risk of developing cancer either due to some of the same genetic mutations that 
caused the CHD or as a result of other extrinsic factors such as repeated exposure to radiation 
during diagnostic or interventional procedures.  The genetic etiology of CHD is quite complex 
with both sporadic and familial forms as well as monogenic forms with simple Mendelian 
inheritance and multigenic forms with complex inheritance patterns.  This study investigated 
whether CHD patients have an increased burden of rare pathogenic or highly damaging variants 
in genes known to be associated with congenital heart defects or cancer.  My results indicate 
pathogenic and highly damaging variants in some genes with a known association with CHD, but 
not in genes associated with cancer play a role in the etiology of heart development.  Furthermore, 
these results appear to be consistent with a complex multigenic model of CHD.  Finally, they 
suggest that variants in genes related to response to oxygen levels may serve as a prognostic 
indicator.  However, this study has several limitations, the most notable being a nonrandom sample 
population and a lack of control for population substructure.  In spite of these limitations, I feel 
Cecilia Lo, PhD 
v 
that this research provides a good foundation on which to base future more in-depth analyses with 
more statistical power.  This research is of public health importance as it can help shed light on 
the genetic etiology of CHD and provide insight into which patients may be at greater risk for later 
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1.0 Introduction 
1.1 Congenital Heart Disease: Definition and Prevalence 
Congenital heart disease (CHD) refers to any structural abnormality of the heart or great 
vessels and can range from relatively benign small septal defects or bicuspid aortic valve to highly 
complex defects involving multiple structures that require open-heart surgery in the immediate 
neonatal period.  Presently the incidence of CHD is estimated at between four and ten per 1000 
live births, though this value has increased from an estimated 0.6 per 1000 live births in the 1930s 
until plateauing at around 9.1 per 1000 around 1995 (Pierpont et al., 2007; van der Linde et al., 
2011).  This increase has been attributed to improved diagnostic technologies rather than a true 
increase.  Asian populations seem to show a higher incidence of CHD with an increased prevalence 
of pulmonary outflow defects and fewer left ventricular outflow defects (van der Linde et al., 
2011).  The overall prevalence of CHD has also been reported to be from 2.5-13.8 per 1,000 births 
with severe CHD accounting for 0.5-5.1 per 1,000 (Reviewed in van der Bom et al., 2011).  A 
study from Malaysia reported a prevalence of 6.7 per 1000 livebirths with 38% classified as 
“severe”, 15% as “moderate” and 47% as “mild” while also noting a significant increase from 
2005 to 2015 (Mat Bah et al., 2018). 
An American study reported a slight decrease in the prevalence of severe CHD from 168.9 
per 100,000 births in 1999 to 129.3 per 100,00 births in 2008 (A. Egbe, Uppu, Lee, Ho, & 
Srivastava, 2014).  In particular, significant decreases in the prevalence of persistent truncus 
arteriosus (PTA), tetralogy of Fallot (TOF), and hypoplastic left heart syndrome (HLHS) were 
noted during this period.  This decrease was thought to be related to increased termination of 
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pregnancy for severe CHD with possible influences of socioeconomic status and access to 
specialized pre- and perinatal care.  Conversely, a German study reported an increased prevalence 
of severe CHD in recent decades (Pfitzer et al., 2017).  This increase was attributed to 
improvements in detection and treatment leading to increased survival.  They also reported 
ventricular septal defect (VSD), atrial septal defect (ASD), TOF, univentricular heart, and 
coarctation of the aorta (CoA) were the most commonly seen types of CHD. 
There are many different types of structural heart defects that can be grouped into several 
categories that are not necessarily mutually exclusive including septal defects, right ventricular 
outflow tract obstruction (RVOTO) defects, left ventricular outflow tract obstruction (LVOTO) 
defects, conotruncal defects, valve defects, and heterotaxy spectrum defects.  Atrial septal defects 
are the third most common type of CHD with a prevalence of 56-100 per 100,000 live births and 
can be subdivided into primum, secundum, and sinus venosus defects (Reviewed in Geva, Martins, 
& Wald, 2014).  While secundum defects show a female predominance, primum and sinus venosus 
defects show near equal prevalence to a slight male predominance.  Primum ASD can be 
considered a variant of common atrioventricular canal in which there is an interatrial 
communication between the anterior-inferior margin of the foramen ovale and the atrioventricular 
valve while secundum ASD are defects in the foramen ovale arising from one or more defects in 
the septum primum.  The foramen ovale is a normal interatrial connection during fetal life that 
normally closes after birth when increased left atrial pressure presses the septum secundum over 
the septum primum, though it can remain patent in a small percentage of the population.  Sinus 
venosus defects involving the venae cavae or coronary sinus are rare (Thiene & Frescura, 2010).  
These defects involve a communication between one or more of the right pulmonary veins with 
the cardiac orifice of the superior vena cava (superior defect) or with the posterior-inferior wall of 
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the right atrium just above the inferior vena cava orifice (inferior defect) (Geva et al., 2014).  
Approximately 87% of these defects occur between the upper right pulmonary vein and superior 
vena cava.  Finally, a coronary sinus defect occurs when there is a partial or complete absence of 
the tissue that normally separates the coronary sinus from the left atrium (unroofed coronary sinus) 
and can be associated with persistent left superior vena cava. 
Atrioventricular septal defects (AVSD) refer to a spectrum of defects characterized by a 
common atrioventricular connection with interatrial and interventricular connections (Calkoen et 
al., 2016; Thiene & Frescura, 2010).  These defects are seen in 4-5.3 per 10,000 livebirths and 
comprise 7% of all CHD but approximately 50% of CHD seen in Down syndrome patients 
(Reviewed in Calkoen et al., 2016).  A complete AVSD is defined as co-occurrence of a primum 
ASD, a non-restrictive VSD, and a common pentacuspid atrioventricular valve with shunting at 
the atrial and ventricular levels.  There are two forms of partial AVSD with the more common 
variant consisting of an isolated primum ASD with the bridging leaflets of the common 
atrioventricular valve attached to the ventricular septum and shunting only at atrial level while the 
less common variant has the bridging leaflets attached to the atrial septum and shunting only at the 
ventricular level.  A transitional AVSD comprises a primum ASD, restrictive VSD, and fusion of 
the bridging leaflets resulting in two orifices.  Finally, an unbalanced AVSD occurs when the 
common atrioventricular valve is not evenly positioned above the ventricles such that one ventricle 
receives a dominant portion of the blood flow and can occur concurrently with any of the other 
three types.  Complete AVSD are more common accounting for 56-75% of all AVSD and are more 
frequently seen in syndromic patients while 8-10% of complete AVSD are of the unbalanced type 
and are more commonly seen in non-syndromic patients (Calkoen et al., 2016).  Malformation of 
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the endocardial cushions, abnormal formation of the mesenchymal cap or dorsal mesenchymal 
protrusion, or looping defects may all contribute to the etiology of AVSD. 
Ventricular septal defects account for up to 40% of all cardiac anomalies, though the 
smallest ones may be asymptomatic and close spontaneously making the true incidence difficult 
to ascertain (Reviewed in Penny & Vick, 2011).  They can occur in isolation or in conjunction 
with and as an integral component of other CHD such as TOF, double outlet right ventricle 
(DORV), and transposition of the great arteries (TGA).  Defects can occur in the membranous 
septum (perimembranous) or within the inlet, outlet, or apical portion of the muscular septum 
(Thiene & Frescura, 2010).  Incomplete formation of the primitive interventricular septum may 
contribute to trabecular septal defects while muscular defects are thought to arise from excessive 
undermining beneath and between trabeculae (Penny & Vick, 2011).  Inlet VSD arise from failed 
fusion of the atrioventricular cushions with each other or with the primitive septum while outlet 
VSD result from poor development or malalignment of the outlet cushions.  Incomplete closure of 
the region forming the membranous septum coupled with underdevelopment of parts of the 
muscular septum result in perimembranous defects.  Finally, infundibular septal defects occur just 
below the semilunar valves and may or may not extend into the membranous septum (Thiene & 
Frescura, 2010). 
Right ventricular outflow tract obstruction comprises abnormalities of the outlet portion of 
the right ventricle, pulmonary valve, and main pulmonary artery.  Stenosis or narrowing of the 
pulmonary outflow can be classified as subvalvar, valvar, or supravalvar and can occur with or 
without septal defects (Thiene & Frescura, 2010).  Valvar pulmonary stenosis is relatively 
common, accounting for ∽10% of CHD and can have a wide range of presentations from unicuspid 
to tricuspid and with varying degrees of dysplasia (Reviewed in Kwiatkowski, Hanley, & 
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Krawczeski, 2016).  Pulmonary atresia with intact ventricular septum accounts for less than 10% 
of cyanotic CHD and is often characterized by membranous pulmonary atresia, hypoplastic 
pulmonary root, small right ventricle, and abnormal tricuspid valve.  Accompanying coronary 
artery anomalies can lead to right ventricle-dependent coronary circulation (Kwiatkowski et al., 
2016). 
Left ventricular outflow tract obstruction involves abnormalities of the outlet portion of the 
left ventricle, aortic valve, ascending aorta, and aortic arch.  As with pulmonary stenosis, aortic 
stenosis can be divided into subvalvar, valvar, and supravalvar types.  Subaortic stenosis is present 
in 6.5% of adults with CHD and is twice as common in males as in females (Reviewed in 
Aboulhosn & Child, 2015).  This defect most commonly arises due to a fibrous membrane or 
muscular narrowing of the left ventricular outflow tract but can rarely be caused by attachment of 
accessory mitral chordae to the base of the ventricular septum.  Bicuspid aortic valve (BAV) is 
seen in 25% of patients and other obstructive lesions may also occur such as Shone’s complex 
which includes mitral valve stenosis and coarctation of the aorta.  Supravalvar aortic stenosis is 
defined as a focal or diffuse narrowing of the ascending aorta and, rarely, the aortic arch.  It is very 
rare in the general population, but 50% of patients also have BAV (Aboulhosn & Child, 2015).  
With a prevalence of 4.6 per 1000, bicuspid aortic valve is the most prevalent CHD and is much 
more common in males than females.  This defect can range from a severely obstructive unicupsid 
valve to an almost normal appearance with only partial fusion of two leaflets but is often 
accompanied by dilation of the aortic root.  Coarctation of the aorta occurs when the aorta becomes 
pinched off in the area around the insertion of the ligamentum arteriosusm likely due to excess 
ductal tissue, though hemodynamics may also play a role,  and is associated with BAV in 40-63% 
of cases (Aboulhosn & Child, 2015; Hanneman, Newman, & Chan, 2017; Thiene & Frescura, 
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2010).  This defect is relatively common accounting for 4-8% of CHD and approximately 4 in 
10,000 livebirths overall and is more prevalent in males (1.5:1) than females (Aboulhosn & Child, 
2015; Hanneman et al., 2017).  Many patients develop collateral vessels connecting upper body 
vessels to lower body vessels below the level of the coarctation (Hanneman et al., 2017).  A 
pseudocoarctation can arise when an abnormally long segment of the aortic arch at the level of 
ductus arteriosus collapses or becomes kinked (Hanneman et al., 2017).  HLHS is a severe and 
rare form of CHD occurring in 0.016-0.036% of all livebirths and accounting for 3.8% of all CHD 
with up to 70% of cases being male (Connor & Thiagarajan, 2007).  This defect is characterized 
by underdevelopment of the left ventricle, aortic valve, and aortic arch accompanied by mitral 
stenosis or atresia.  Interrupted aortic arch (IAA) is a relatively rare (approximately 2 per 100,000 
livebirths) defect characterized by a complete disconnection of flow between the ascending and 
descending aorta (Reviewed in Hanneman et al., 2017).  Connection between the upper and lower 
body is usually via ductus arteriosus with a large accompanying VSD, though rarely it can be 
through persistence of the 5th pharyngeal arch artery.  IAA can be classified into three types based 
on the location of the interruption with type A having an interruption distal to the left subclavian 
artery and being the 2nd most common type occurring in 30-40% of cases.  Type B IAA is the most 
common occurring in 50-60% of cases and has an interruption between the left subclavian and left 
common carotid arteries.  This form is often seen with 22q11.2 microdeletion and accompanying 
extracardiac anomalies and is associated with BAV, outlet VSD, and aortic stenosis.  Accounting 
for less than 5% of cases, IAA-C is the least common form with the interruption occurring between 
the brachiocephalic and left common carotid arteries (Hanneman et al., 2017). 
Conotruncal defects are those involving malformations of the ventricular outlets and 
arterial trunk with the most common defects including TOF, PTA, TGA, and DORV (T. R. 
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Johnson, 2010).  Persistent truncus arteriosus accounts for 1.1-2.5% of CHD and occurs when the 
outlet (aortopulmonary) septum fails to form and the aorta and pulmonary arteries persist as a 
common arterial trunk with a common truncal valve and large VSD (T. R. Johnson, 2010; Thiene 
& Frescura, 2010).  There are several different types based on the branching pattern, but in most 
cases the truncal valve is abnormal ranging from unicommisural  to five cusps (T. R. Johnson, 
2010).  It sometimes occurs with IAA-B and 35% of patients also have a right aortic arch.  
Sometimes a small aortopulmonary window may allow communication between an otherwise 
normally septated aorta and pulmonary artery (Thiene & Frescura, 2010).  Double outlet right 
ventricle accounts for less than 1.5% of CHD and can be classified based on whether the 
accompanying VSD is subaortic, subpulmonic, or doubly-committed while the great arteries can 
be normally related, side-by-side, or malposed (Reviewed in T. R. Johnson, 2010).  The most 
common type of DORV is characterized by a subaortic VSD with side-by-side great arteries and a 
concern for pulmonary stenosis.  The Taussig-Bing form has a subpulmonic VSD, side-by-side 
great arteries, and often subaortic stenosis with a concurrent coarctation or interruption of the arch.  
The Remote VSD form is rare, but may occur with complete AVSD or heterotaxy or in the setting 
of straddling atrioventricular valve and hypoplastic ventricle (T. R. Johnson, 2010).  Tetralogy of 
Fallot is the most common form of cyanotic CHD accounting for 3.5-9% of patients and is defined 
by the four cardinal features of infundibular VSD, overriding aorta, pulmonary stenosis, and right 
ventricular hypertrophy (T. R. Johnson, 2010; Thiene & Frescura, 2010).  The pulmonary valve 
may be fully atretic resulting in a ductus-dependent pulmonary circulation (Thiene & Frescura, 
2010).  TOF is often accompanied by other heart defects including right aortic arch (25%), absent 
pulmonary valve (2.5%), AVSD, or anomalous coronary artery (T. R. Johnson, 2010; Thiene & 
Frescura, 2010). 
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In addition to AVSD, a variety of other defects can affect the atrioventricular valves.  In 
tricuspid atresia, the tricuspid valve is atretic with right-to-left shunting at the atrial level and 
pulmonary circulation dependent on a restrictive VSD (Thiene & Frescura, 2010).  Straddling 
tricuspid valve arises when the chordae tendinae or a papillary muscle of the tricuspid valve 
straddle or override the ventricular septum (Dodge-Khatami, Mavroudis, Frost, Jacobs, & 
Mavroudis, 2014).  Ebstein’s anomaly of the tricuspid valve is a rare defect affecting one in 10,000 
infants and characterized by septal and posterior leaflets that are dysplastic and displaced 
downward into the right ventricle possibly leading to subvalvular pulmonic stenosis or atrialization 
of the ventricle (Kwiatkowski et al., 2016; Thiene & Frescura, 2010).  The majority of patients 
have a concurrent ASD and it has been associated with left ventricular noncompaction.  Double-
orifice tricuspid valve is a very rare defect that can be isolated or occur in conjunction with other 
forms of CHD (Dodge-Khatami et al., 2014).  The defect can involve a simple leaflet fenestration 
(type 1), fusion of leaflet tissue bridging the valve resulting in two orifices but with normal 
papillary muscles (type 2), or two orifices each supported by their own annulus (type 3). 
A cleft mitral valve is commonly seen in conjunction with AVSD, but can also occur in 
isolation and is characterized by a cleft in the anterior leaflet often accompanied by abnormal 
attachment of chordae to the membranous septum (Fishbein & Fishbein, 2019).  Parachute mitral 
valve occurs when chordae from both leaflets attach to a single papillary muscle and can cause 
stenosis.  Finally, double-orifice mitral valve involves an abnormal opening in one of the leaflets 
with chordae attaching the edge of the defect to the underlying papillary muscle (Fishbein & 
Fishbein, 2019). 
Heterotaxy or situs ambiguous refers to the randomized positioning of organs with respect 
to the right/left axis and is often accompanied by complex CHD.  In right isomerism, both atrial 
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appendages have a right-sided morphology and this is often accompanied by supra- or 
infradiaphragmatic total anomalous pulmonary venous return (TAPVR) which occurs when the 
pulmonary veins insert into the vena cava instead of the left atrium.  Left isomerism is 
characterized by both atrial appendages having a left-sided morphology and is often accompanied 
by an interrupted inferior vena cava with azygous continuation (Thiene & Frescura, 2010).  A 
common atrium due to absence of the primum, secundum, and atrioventricular septa is often seen 
(Geva et al., 2014; van Praagh, 2006).  Discordant atrioventricular connection is often 
accompanied by a univentricular heart with one ventricle being fully developed and functional and 
the other being rudimentary or absent (Thiene & Frescura, 2010).  Common atrioventricular valve 
is seen in 69% of patients with asplenia (absent left-sided structures) with normal atrioventricular 
valves being rare (van Praagh, 2006).  TGA accounts for 5-7% of all CHD with 60-70% of cases 
being male and can be accompanied by VSD, coronary artery anomalies, or patent ductus 
arteriosus (PDA) (T. R. Johnson, 2010).  Dextro-TGA is characterized by concordant 
atrioventricular connections but discordant ventriculoarterial connection while levo-TGA 
(congenitally corrected TGA) occurs when both the atrioventricular and ventriculoarterial 
connections are discordant (Thiene & Frescura, 2010).  Asplenia is associated with conotruncal 
and atrioventricular canal defects, bilateral superior vena cava to the ipsilateral atrium, bilateral 
venous connections from the lower body and TAPVR (van Praagh, 2006).  Pulmonary outflow 
obstruction is common while DORV/TGA are nearly universal.  Polysplenia (absent right-sided 
structures) is associated with an interrupted inferior vena cava with azygous or hemiazygous 
continuation and occasional ipsilateral drainage of the pulmonary veins (van Praagh, 2006).  
Pulmonary outflow obstruction is less common than in asplenia and DORV/TGA occur in less 
than 50% of cases.  There is a high incidence of underdeveloped left ventricle in all heterotaxy 
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patients.  Dextrocardia is also frequent and is thought to be related to an L-looped heart rather than 
atrial situs inversus (van Praagh, 2006). 
A variety of other defects can also occur.  There can be a univentricular atrioventricular 
connection due to tricuspid or mitral atresia or a double-inlet ventricle resulting from misalignment 
of the atrioventricular valves (Thiene & Frescura, 2010).  There can be atresia of the aorta or 
pulmonary artery or the ductus arteriosus can remain open after birth.  Cor triatriatum sinister 
occurs when an abnormal membrane separates the left atrium into two chambers (Thiene & 
Frescura, 2010).  Coronary artery anomalies such as anomalous origin or high takeoff of a coronary 
artery can lead to an increased risk of myocardial infarction and sudden death.  Wolf-Parkinson-
White syndrome occurs due to an abnormal muscle bundle creating a reentrant electrical pathway 
leading to arrhythmia (Thiene & Frescura, 2010).  Finally, there can be a variety of abnormal aortic 
arch branching patterns such as right aortic arch, double aortic arch, and anomalous origin of the 
subclavian artery (Hanneman et al., 2017). 
1.2 Heart Development 
As the most asymmetric organ in the body, heart development is highly complex involving 
extensive structural rearrangements and tissue remodeling under the control of numerous genes 
and signaling pathways.  This complex process has been extensively reviewed (Bruneau, 2013; 
Campione & Franco, 2016; Gittenberger-de Groot, Bartelings, Deruiter, & Poelmann, 2005; 
Hanneman et al., 2017; Ramsdell, 2005; Rochais, Mesbah, & Kelly, 2009; Sylva, van den Hoff, & 
Moorman, 2014).  The first progenitors of cardiac mesoderm become specified around the time of 
gastrulation in response to high levels of the transforming growth factor (TGF)-β superfamily 
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transcription factor, Nodal (Bruneau, 2013; Ramsdell, 2005).  These mesoderm-derived precursors 
comprising the first heart field (FHF) then unite anteriorly at the midline forming the cardiac 
crescent which, in response to ectoderm- and endoderm-derived signals that modify bone 
morphogenetic protein (BMP), fibroblast growth factor (FGF) and wingless-insert (WNT) 
signaling, begin to differentiate into cardiomyocytes (Sylva et al., 2014).  Other molecules that 
play a role in specification and expansion of the early cardiac mesoderm include the T-box 
transcription factor Eomes which leads to Mesp1 activation, Flk1, PDGFRA, Wnt/β-catenin 
signaling, and BMP signaling (Bruneau, 2013).  Newly committed cardiomyocytes then being 
expressing cardiac-specific genes including NKX2.5 and GATA4 (Gittenberger-de Groot et al., 
2005) 
Embryonic folding brings the lateral edges of the cardiac crescent together at the midline 
where they fuse to form the linear heart tube with a cranial arterial pole and a caudal venous pole, 
a process that is dependent on Mesp1, Gata4, Furin, and Bmp2 (Bruneau, 2013; Sylva et al., 2014).  
The heart tube then grows through the addition of cells from an adjacent rapidly proliferating pool 
of cells around the venous pole, the second heart field (SHF), that migrate into the heart and 
differentiate into cardiomyocytes.  Ultimately the FHF will contribute primarily to the left ventricle 
and parts of the atria in the mature heart while SHF-derived cells will contribute to the mature 
outflow tract, right ventricle, and venous pole.  The SHF as a whole can be molecularly identified 
by the expression of Isl2 while its anterior component which gives rise to the outflow tract and 
right ventricle is identified by the expression of Fgf10, an enhancer of Mef2c and the sinus venosus 
is marked by Tbx18 expression (Bruneau, 2013).  Hedgehog signaling is required for the survival 
and deployment of SHF cells while their recruitment into the linear heart tube and subsequent 
differentiation into cardiomyocytes is regulated by BMP and FGF signaling (Rochais et al., 2009).  
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Ultimately, many different transcription factors play a key role in early heart development 
including Nkx2.5, GATA factors, T-box transcription factors, and Hand factors (Bruneau, 2013).  
An additional layer of regulation is provided by epigenetic factors including chromatin remodeling 
complexes such as Baf60c and the Brg1/Brm-associated factor (BAF) complex that interact with 
transcription factors, histone acetyltransferases, histone deacetylases, and histone 
methyltransferases such as the polycomb repressive complex 2 (PRC2) (Bruneau, 2013). 
The symmetrical heart tube must then be reorganized into the mature four-chambered heart 
divided by septa and valves.  In vertebrate development symmetry is first broken by the generation 
of leftward fluid flow by motile cilia at the embryonic node which activates the Nodal/Pitx2/Lefty 
signaling cascade leading to asymmetric gene expression (Sylva et al., 2014).  In the developing 
heart, the first molecular signs of asymmetry can be identified in the FHF shortly after gastrulation 
(Ramsdell, 2005).  The first morphological breaking of symmetry occurs with the rightward 
looping of the ventricles, a process that has been shown to be independent of Pitx2 but that does 
require Cited2 (Sylva et al., 2014).  Though not directly involved in looping, expression of the 
Pitx2 isoform, Pitx2c identifies the sinus venosus, left side of the atrioventricular canal, the ventral 
portion of the ventricles, and the left-ventral portion of the outflow tract (Campione & Franco, 
2016). 
Looping results in the formation of an S-shaped heart with an inner curvature and an outer 
curvature from which the chambers balloon (Sylva et al., 2014).  This process is thought to be 
driven in part by a combination of Nodal signaling in the left myocardium coupled with BMP 
signaling on the right both interacting with the transcription factor FOXH1 to coordinate 
differential cell migration (Campione & Franco, 2016).  The atrial chambers form from the 
dorsolateral side of the heart tube with Pitx2 playing a role in specifying left vs. right atrium as 
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well as differentiation of pulmonary vein myocardium (Bruneau, 2013; Sylva et al., 2014).  The 
process of ventricle ballooning from the outer curvature involves a combination of the reinitiation 
of proliferation and the initiation of chamber-specific gene expression programs (Sylva et al., 
2014).  Determination of left ventricular identity and the interventricular boundary are dependent 
on Tbx5 while HAND1 and HAND2 are required for proper formation of the left and right ventricles 
respectively (C. J. Lin, Lin, Chen, Zhou, & Chang, 2012; Sylva et al., 2014).  The outflow tract 
must undergo elongation and rotation to ensure its proper alignment, a process in which Pitx2 and 
Wnt11 play a role (Campione & Franco, 2016). 
T-box transcription factors play an important role in chamber formation and identity.  Tbx5 
and Tbx20 are expressed in most parts of the heart while Tbx2 and Tbx3 act to maintain the primary 
myocardium phenotype of the venous pole, atrioventricular canal, inflow tract, and outflow tract 
allowing them to ultimately become non-working myocardium while Tbx1 is expressed at the 
venous pole (Sylva et al., 2014).  In addition to chambers, the heart must also form transition zones 
that will eventually contribute to the formation of valves, septa, and the conduction system.  
Looping brings these transition zones together along the inner curvature while the chambers 
balloon from the outer curvature (Gittenberger-de Groot et al., 2005).  Finally, maturation of the 
chamber myocardium must occur.  This involves a process of thickening and trabeculation of the 
primitive myocardium followed by remodeling and compaction of the trabeculae to form the 
compact myocardium of the mature heart (Sylva et al., 2014).  This process is coordinated through 
the action of numerous signaling pathways including Notch, Neuregulin/ErbB, EphrinB2/B4, 
BMP, FGF, semaphorins, retinoic acid, endothelin, and extracellular matrix signaling (Bruneau, 
2013). 
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The primitive heart must then be divided into four chambers through formation of 
interatrial, atrioventricular, and interventricular septa while the primitive common outflow tract 
must be divided into aorta and pulmonary arteries through formation of the outflow and 
aortopulmonary septa.  Atrial septation is a complex process and occurs in two phases.  The 
precursors of the atrial septum are established early in a process requiring Tbx5 (Bruneau, 2013).  
The septum primum originates right of the midline at the cranio-dorsal wall of the common atrium 
and grows toward the atrioventricular canal (Sylva et al., 2014).  Eventually, the continued growth 
of the septum primum closes off the foramen primum, however openings form in the septum 
primum and eventually coalesce to form the ostium secundum which remains open until birth 
allowing continued interatrial communication.  The septum secundum is formed from an infolding 
of the muscular right atrial wall.  Finally, after birth changes in intraatrial pressure presses the 
primum and secundum septa together closing the ostium secundum and completing the process of 
atrial septation (Sylva et al., 2014). 
The muscular ventricular septum forms at the region of the heart tube between the 
ballooning ventricles and grows mainly through apposition by the addition of cells from the 
adjacent left ventricular free wall (Sylva et al., 2014).  Several different mechanisms have been 
proposed for the formation of the muscular ventricular septum; the coalescence of a portion of the 
ventricular wall interposed between the ballooning ventricles or the active expansion of a 
“primitive interventricular septum” toward the atrioventricular canal (Penny & Vick, 2011).  The 
membranous portion of the ventricular septum forms from remnants of the fused atrioventricular 
and outflow cushions which then fuse with the muscular septum to complete ventricular septation 
(Krishnan et al., 2014; Sylva et al., 2014).  Tbx5, Gata4, Nkx2-5, Sall4, and Hand transcription 
factors play an important role in ventricular septation (Bruneau, 2013) 
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The process of atrioventricular septation begins with the formation of an endocardial 
cushion at the atrioventricular junction at the looped heart stage (Krishnan et al., 2014).  
Endocardial  cells first undergo epithelial-to-mesenchymal transition (EMT) and  then migrate into 
the cardiac jelly in part through signaling by Bmp2, Tbx2, Notch, and Vegf as well as the activation 
of Snail1/2 through TGF-β signaling that is essential to confer invasive properties on the migrating 
cells (Bruneau, 2013; Calkoen et al., 2016).  This results in the formation of the inferior, superior, 
and two lateral atrioventricular cushions.  The muscular portion of the septum primum grows 
toward the atrioventricular canal where its mesenchymal cap ultimately fuses with the superior 
and inferior cushions followed by their mutual fusion with the dorsal mesenchymal protrusion at 
the base of the atrial septum (Calkoen et al., 2016).  Atrioventricular septation is completed 
following delamination of the tricuspid valve cusps when the membranous portion of the 
ventricular septum forms.  The inferior and superior cushions ultimately contribute to both the 
tricuspid and mitral valves while the right lateral cushion contributes to the tricuspid valve and the 
left to the mitral valve (Calkoen et al., 2016). 
Outflow septation begins with the formation of mesenchymal ridges that grow and spiral 
in a clockwise direction to separate the distal common outflow tract into aorta and pulmonary 
artery (Krishnan et al., 2014).  Septation of the proximal outflow tract begins with the formation 
of endocardium-derived conal cushions which then fuse to form the conus septum separating the 
ventricular outflow tracts (C. J. Lin et al., 2012).  Cardiac neural crest cells play a critical role in 
outflow septation and valve formation.  These cells originate in rhombomeres 6-8 in the hindbrain 
and first migrate to a region between pharyngeal arch arteries four and six where they form a mass 
of condensed mesenchyme and then migrate into and populate the proximal outflow cushions 
(Gittenberger-de Groot et al., 2005; C. J. Lin et al., 2012).  SHF-derived outflow tract myocardium 
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secretes chemotactic molecules such as Sema3c that attract migrating neural crest cells into the 
outflow cushions while Wnt/β-catenin, Pitx2, Notch, TGF, BMP, and Hedgehog pathways also 
play a role in the migration and survival of neural crest cells and outflow septation (C. J. Lin et al., 
2012; Rochais et al., 2009).  VEGF signaling plays a more important role in outflow septation than 
in atrioventricular septation while FGF signaling under the control of Tbx1 is essential for initiation 
of a signaling loop that ultimately reaches the adjacent neural crest and endothelial cells (Bruneau, 
2013). 
Concurrently with septation of the outflow tract, the paired pharyngeal arch arteries are 
extensively remodeled to form the main pulmonary arteries, aortic arch, and its branches.  
Formation of the pharyngeal arch arteries begins with the fusion of ventral segments of the 
primitive paired aortae to form the aortic sac while fusion of the dorsal segments gives rise to the 
descending aorta (Hanneman et al., 2017).  Six pairs of pharyngeal arch arteries develop between 
the ventral and dorsal aortae and then regress or remodel in a cranial to caudal direction.  The first 
and second arch arteries largely regress, but remnants remain as parts of the maxillary, stapedial, 
and hyoid arteries.  The common carotid artery and the proximal portion of the internal carotid 
artery form from the third arch.  The right fourth arch forms the right subclavian artery while the 
left fourth arch contributes to the definitive aortic arch.  The fifth arch arteries either do not develop 
or partially develop and then regress.  Finally, the right sixth arch artery gives rise to the right 
pulmonary artery while the left sixth arch gives rise to the main and left pulmonary arteries as well 
as the ductus arteriosus (Hanneman et al., 2017). 
Valve formation begins with the remodeling of cardiac jelly at the venous pole, 
atrioventricular junction, and outflow tract.  Under the regulation of BMPs, TGF-β, and Notch 
signaling, the overlying endocardium undergoes EMT and migrates into the cardiac jelly (Sylva et 
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al., 2014).  The atrioventricular valves form by detachment of the cushions from the endocardium 
and remodeling into valve leaflets while the semilunar valves form from intercalated ridges within 
the outflow tract with a significant contribution from migrating neural crest cells (Gittenberger-de 
Groot et al., 2005; Sylva et al., 2014).  Many genes have key roles in valve formation including 
extracellular matrix proteins, the connective tissue transcription factor Sox9, and the Notch and 
BMP signaling pathways (Sylva et al., 2014). 
1.3 The Genetic Causes of Congenital Heart Disease 
Congenital heart disease can occur in isolation or as part of a syndromic condition and it 
can also occur sporadically or segregate within families.  A growing number of genes have been 
identified as causing or contributing to the etiology of CHD through a variety of different study 
types including whole exome/genome sequencing, family and linkage studies, genome wide 
association studies (GWAS), and mouse mutagenesis screens and these have been extensively 
reviewed (Aburawi, Aburawi, Bagnall, & Bhuiyan, 2015; Andersen, Troelsen Kde, & Larsen, 
2014; Azhar & Ware, 2016; Chaix, Andelfinger, & Khairy, 2016; Fahed, Gelb, Seidman, & 
Seidman, 2013; LaHaye, Lincoln, & Garg, 2014; Lalani & Belmont, 2014; Lebo & Baxter, 2014; 
Muntean, Toganel, & Benedek, 2017; Pierpont et al., 2007; Prendiville, Jay, & Pu, 2014; Williams, 
Carson, & Lo, 2019).  The following sections will review just some of the primary literature to 
provide an idea into the scope of research being conducted into the genetic causes of CHD. 
18 
1.3.1 Isolated CHD 
Atrial septal defects:  A candidate gene case-control study identified an extremely rare 
heterozygous Arg47Trp missense mutation in CCN1 associated with severe ASD in a patient while 
an earlier study showed that Ccn1-null mice had severe AVSD while haploinsufficiency resulted 
in delayed ventricular septation and a primum ASD in 20% of mice (Mo & Lau, 2006; Perrot et 
al., 2015).  CCN1 (Cellular communication network factor 1) encodes a matricellular protein that 
regulates cell adhesion, migration, proliferation, and survival.  Sequencing in 150 probands with 
isolated ASD identified three mutations in a conserved region of the NEXN gene encoding the 
Nexin F actin-binding protein that were not found in 500 healthy controls (F. Yang et al., 2014).  
All three of these mutations were found to inhibit GATA4 expression. 
Ventricular septal defects:  Sequencing of the coding region of the extracellular matrix 
protein HAS2 (Hyaluronan synthase 2) gene in 100 patients with non-syndromic VSD identified a 
Glu499Val mutation in one patient that was not observed in 200 controls and was shown to 
diminish enzyme activity (Zhu et al., 2014).  An earlier study showed that Has2-/- mice have absent 
endocardial cushions, absent trabeculae, and hypoplasia of the right ventricle and outflow tract 
(Camenisch et al., 2000).  A case-control mutational analysis of 400 patients with isolated VSD 
plus 400 healthy controls identified two novel heterozygous mutations in highly conserved 
residues of the HOMEZ (Homeodomain leucine zipper-encoding) gene (Xuan et al., 2013).  In a 
study of 467 patients with conotruncal or related CHD, missense mutations in neurotrophic 
receptor tyrosine kinase 3 (NTRK3) were identified in four patients with either conoventricular, 
posterior malalignment, or conoseptal hypoplasia type VSD (Werner et al., 2014).  These variants 
were predicted to be deleterious and were not present in ethnically matched controls.  However, 
an earlier study had shown decreased NTRK3 expression and reduced protein levels in cardiac 
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biopsy samples from patients with TOF compared to isolated VSD or controls (Kong, Liu, & Lu, 
2009).  An earlier study found that Ntrk3 null mice had a variety of valve, septal, and outflow tract 
defects attributed to premature fate restriction of migrating cardiac neural crest cells (Tessarollo 
et al., 1997).  Variants in FOXH1 (Forkhead factor H1) have been associated with VSD in a 
Chinese population (B. Wang et al., 2010). 
Atrioventricular septal defects: A study of 13 parent-offspring trios as well as 112 
unrelated probands identified an excess of rare missense variants in NR2F2 (Nuclear Receptor 
Subfamily 2 Group F Member 2) in patients with AVSD (Al Turki et al., 2014).  NR2F2 is a 
member of the steroid/thyroid hormone nuclear receptor superfamily of transcription factors and 
was found to be expressed in the atria, coronary vessels, and aorta of fetal human hearts. Of the 
five variants detected in patients, two were found to have been inherited from unaffected parents 
suggestive of either incomplete penetrance or that the variants were possibly benign, though all 
five mutations appeared to have an effect on the transcriptional activator function of NR2F2 while 
leaving its repressor function intact.  NR2F2 mutations were also identified in patients with TOF, 
aortic stenosis with VSD, coarctation of the aorta, and HLHS (Al Turki et al., 2014).  In an 
unrelated study, myocardiocyte-specific knockout of Nr2f2 in mice was found to result in 
ventricularized atria (S. P. Wu et al., 2013).  A whole exome sequencing (WES) study of  81 
unrelated probands with AVSD found significant enrichment for rare and damaging variants in 
cases relative to controls in a set of 112 candidate genes (D'Alessandro et al., 2016).  This 
enrichment was found to be specific to AVSD probands compared to a separate cohort with TOF 
and included the NIPBL, CHD7, CEP152, BMPR1A, ZFPM2, and MDM4 genes.  The authors 
were then able to confirm these findings in a replication cohort of 81 AVSD probands.  Several 
mouse mutagenesis studies have also identified causative genes for AVSD.  An ethylnitrosourea 
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(ENU) mutagenesis screen identified mutations in dynein axonemal heavy chain 11 (Dnah11) that 
caused AVSD with heterotaxy and mutations in MKS transition zone complex subunit 1 (Mks1) 
that caused AVSD without heterotaxy (Burnicka-Turek et al., 2016).  Mice with null mutations in 
the Klf2 (kinesin family member 2) gene were found to have disorganized and hypocellular 
atrioventricular cushions possibly due to defective EMT (Chiplunkar et al., 2013). 
Conotruncal defects:  GATA4, NKX2.5, JAG1, FOXC2, TBX5, and TBX1 are well-
characterized causes of TOF (Reviewed in Morgenthau & Frishman, 2018).  Sequencing of 231 
unrelated probands with TOF or related defects plus 11 patients from families with TOF including 
eight trios found that loss-of-function variants in FLT4 (Fms Related Receptor Tyrosine Kinase 4) 
and KDR (Kinase insert domain receptor) are significant contributors to the genetic cause of TOF 
(Reuter et al., 2018).  Furthermore, the authors noted that the presence of variants in VEGF 
signaling pathway genes were associated with an increased prevalence of absent pulmonary valve.  
Sequencing of the entire coding sequence and splice junctions of the BVES (Blood vessel 
epicardial substance) gene in 114 unrelated Chinese patients with TOF and 400 controls identified 
four novel mutations in cases that were not present in controls (M. Wu et al., 2013).  A homozygous 
Arg1299Cys variant in PLXND1 has been associated with truncus arteriosus (Ta-Shma et al., 2013).  
Variants in MEF2C, NKX2.5, GATA4, and GATA6 were identified in individuals with conotruncal 
heart defects with functional assays showing significant changes in transcriptional or synergistic 
activity in the proteins harboring these variants (Kodo et al., 2012).  Furthermore, the Ala103Val 
variant found in MEF2C (Myocyte enhancer factor 2C) was shown to perturb early cardiogenesis 
when overexpressed in a zebrafish system.  A GWAS case-control study identified 52 significant 
genotypes including 49 intronic to the MGAT4C gene in conotruncal heart defect patients (Agopian 
et al., 2017). 
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Left ventricular outflow tract defects:  A noncoding variant 151 kilobases from the GATA4 
gene was found to be associated with BAV with a Ser377Gly  missense variant trending toward 
significance in a GWAS of 466 BAV cases plus 4,660 matched controls and replicated in up to 
1,326 cases and 8,103 controls (B. Yang et al., 2017).  Next-generation sequencing (NGS) of 63 
patients with BAV requiring aortic root replacement yielded rare, potentially pathogenic variants 
in 19 patients with NOTCH1 variants being the most common and variants also identified in AXIN1, 
NOS3, ELN, FBN1, and FN1 (Girdauskas et al., 2017).  Targeted NGS of 97 candidate genes in 
78 unrelated patients with BAV with or without coarctation of the aorta identified 42 rare 
nonsynonymous exonic variants in 35 of 97 genes (Bonachea et al., 2014).  In silico analysis 
classified 33 of these variants as disease-causing of which 31 variants in 16 patients were 
confirmed by Sanger sequencing while pathway analysis suggested a role for WNT signaling.  A 
GWAS of an Icelandic population found a rare mutation in myosin heavy chain 6 (MYH6) 
associated with coarctation of the aorta (Bjornsson et al., 2018) . Missense, loss-of-function, and 
intronic variants in NOTCH1 have been shown to confer different risks for LVOTO (Helle et al., 
2018).  Additionally, variants in NOTCH1 as well as FOXC2 and FOXL1 have been found in 
patients with HLHS (Iascone et al., 2012).  Variants in MIB1 (Mindbomb E3 Ubiquitin Protein 
Ligase 1), an activator of Notch signaling have been shown to cause CHD with the 
Thr312Lysfs*55 and Trp271Gly variants shown to significantly reduce MIB1 function resulting 
in reduced JAG1 ubiquitination and induction of Notch signaling (B. Li et al., 2018).  A GWAS 
of multiple cohorts with LVOTO or conotruncal defects identified multiple single nucleotide 
polymorphisms (SNPs) with a suggestive association with LVOTO including inherited SNPs in in 
LRP1B and MGATA4 along with maternal SNPs in in SLC38A3, HIVEP3 and PKD1L2 (Agopian 
et al., 2017).   
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Other CHD candidate genes: In a study of 26 patients with TAPVR, one patient was found 
to have a translocation that disrupted the ANKRD1 (Ankyrin repeat domain 1) gene and another 
patient was found with a missense mutation in the same gene (Cinquetti et al., 2008).  Mouse in 
situ hybridization analysis showed this gene to be highly expressed in developing pulmonary veins 
while functional analysis suggests that the missense mutation ultimately enhances its 
transcriptional repression activity on atrial natriutretic factor (ANF).  Sequencing of DLC1, a 
GTPase activating protein highly expressed in the heart, in 151 patients with sporadic CHD 
revealed 13 nonsynonymous rare variants of which nine were predicted to be damaging (B. Lin et 
al., 2014).  Dlc1-/- mice have incomplete and abnormal chamber morphogenesis as well as brain 
defects while mice homozygous for a gene-trapped Dlc1gt/gt allele had enlarged, thin-walled hearts, 
abnormal yolk sac and placental vasculature, and neural tube defects (Durkin et al., 2005; Sabbir 
et al., 2010).  Variants in the IRX1 gene, which is important for heart and limb development, have 
been detected in patients with a variety of CHD but were found to be absent in controls (C. Guo et 
al., 2017).  Iroquois homeobox transcription factors in general have been shown to play a role in 
the establishment of ventricular chamber properties and of the conduction system (Reviewed in 
Kim, Rosen, Bruneau, Hui, & Backx, 2012).  A TPM1 (Tropomyosin 1) mutation was identified 
in a child with severe Ebstein’s anomaly and left ventricular noncompaction (Kelle, Bentley, 
Rohena, Cabalka, & Olson, 2016).  Additionally, screening of 380 patients with a variety of CHD 
identified four variants in four patients with different types of CHD (England et al., 2017).  The 
latter group showed that morpholino knockdown of tpm1 in zebrafish resulted in defects in looping, 
atrial septation, and trabeculation while also affecting sarcomere assembly.  Variants in UGDH, 
UDP glucose 6 dehydrogenase, were found in patients with cardiac valve defects which could be 
recapitulated by morpholino knockdown in zebrafish (Hyde et al., 2012).  Furthermore, the 
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morpholino-induced defects could not be rescued by injection of human UGDH transcripts 
carrying the identified mutations.  Variants in MIB1, an activator of Notch signaling, cause CHD 
through a decreased level of JAG1 ubiquitination and reduced Notch signaling induction (B. Li et 
al., 2018).   
Pathways contributing to CHD: A number of signaling pathways have been shown to play 
key roles in the etiology of CHD.  Functionally abnormal gene products have been identified in 
multiple Nodal pathway genes including FOXH1, CFC1, SMAD2, NODAL, GDF1, and TDGF1 
that are associated with CHD, laterality defects, and holoprosencephaly (Roessler et al., 2008).  
Abnormal Nodal pathway gene products have more commonly been detected in patients with a 
small spectrum of conotruncal defects and less frequently in isolated laterality defect and 
holoprosenccephaly patients. 
Wnt/β-catenin signaling also plays a role.  β-catenin has been shown to form a signaling 
gradient that is positively correlated with proliferation of ventricular wall cardiomyocytes with 
APC, a negative regulator of Wnt, having the reverse distribution (Ye et al., 2015).  
Cardiomyocyte-specific deletion of Apc was shown to result in activation of canonical Wnt/β-
catenin signaling leading to ventricular hypertrophy whereas cardiac deletion of β-catenin lead to 
ventricular hypoplasia.  Mutations in Bcl9/Bcl9l and Pygo1/2, factors engaged in assembly of a 
Wnt-specific enhanciosome, result in valve, septal, and other cardiac defects (Cantu et al., 2018).  
Mutant mice broadly maintain canonical Wnt expression but show dysregulated expression of key 
pathway regulators.  Dkk1/2 interact with Lrp5/6 to modulate canonical Wnt signaling during 
development and are expressed in the developing heart (Phillips, Mukhopadhyay, Poscablo, & 
Westphal, 2011).  Dkk1/2 act to inhibit Wnt signaling to regulate myocardial proliferation and, 
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though neither single null mutant shows an abnormal phenotype, double null mice show 
myocardial and epicardial hyperplasia during the early stages of development and VSD later on. 
Sonic hedgehog (Shh) signaling has been shown to be required for normal cardiac septation 
(Goddeeris et al., 2008).  Mef2c-AHF-Cre; Smoflox/- mutants were shown to survive to term but 
with failure of outflow tract septation and other intracardiac defects similar to those seen with Shh 
null mutants.  Loss of Shh signaling was also shown to result in aberrant differentiation and 
migration of the dorsal mesocardium (Goddeeris et al., 2008).  Additionally, Nkx2.5Cre/+; Shhflox/- 
double mutants were shown to have an unseptated outflow tract as well as a reduced right ventricle, 
complete AVSD, and incompletely penetrant arch artery defects (Goddeeris, Schwartz, 
Klingensmith, & Meyers, 2007).  Finally, loss of primary cilia in mouse Ift88cbs/cbs mutant hearts 
was shown to result in a loss of downstream Shh signaling and a loss of Isl1 expression in the SHF 
and reduced or absent BMP signaling in the outflow tract and atrioventricular cushions resulting 
in atrial and ventricular septal defects and severe outflow tract defects (Willaredt, Gorgas, Gardner, 
& Tucker, 2012). 
1.3.2 Syndromic CHD 
Congenital heart disease is a major or minor component of many syndromic conditions of 
which Down syndrome (AVSD) and DiGeorge syndrome (Conotruncal defects) are probably the 
most well-known.  Down syndrome is the most common chromosomal anomaly and the condition 
most frequently associated with CHD which is present in about 50% of cases (Reviewed in 
Versacci, Di Carlo, Digilio, & Marino, 2018).  In a study of patients with complete trisomy 21 
with or without AVSD, 26 candidate genes were sequenced based on their potential association 
with AVSD and potentially damaging variants in VEGF-A pathway genes including COL6A1, 
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COL6A2, CRELD1, FBLN2, FRZB, and GATA5 were found in 20% of cases with a complete 
balanced AVSD compared to only 3% for patients with structurally normal hearts (Ackerman et 
al., 2012).  Of these genes, only CRELD1 has previously been associated with AVSD.  Furthermore, 
significant missense variants in CITED2, CTGF, TBX20, and VTN were found only in controls and 
could represent protective alleles.  Another study found that no chromosome 21 copy number 
variations (CNVs) were associated with the risk of AVSD in Down syndrome nor were any 
individual genes intersected by these CNVs (Rambo-Martin et al., 2018).  Additionally, Caucasian 
cases (Down syndrome with AVSD) had more genes intersected by rare duplications than controls 
(Down syndrome without AVSD), while in African Americans cases had more bases covered by 
rare deletions than controls.  In a mouse study, overexpression of Col6a2 and Dscam together but 
not individually resulted in 50% mortality with severe defects including ASD and cardiac 
hypertrophy (Grossman et al., 2011). 
DiGeorge syndrome has a prevalence of one in 3,000-6,000 live births and is the second 
most common cause of CHD accounting for 52% of patients with IAA type B, 34% of patients 
with truncus arteriosus, 16% of patients with TOF, and 5-10% of patients with VSD (Reviewed in 
McDonald-McGinn et al., 2015).  Historically DiGeorge syndrome has been lumped together with 
the phenotypically very similar 22q11.2 deletion syndrome and velocardiofacial syndrome, 
however more recently it has been used to refer only to those cases with a single gene mutation 
within the TBX1 (T-box transcription factor 1) gene.  The typical 3 Mb deletion and the less 
common nested 1.5 and 2 Mb deletions occur within a group of low-copy repeats and arise from 
non-allelic homologous recombination (McDonald-McGinn et al., 2015) 
Though mutations in TBX1 have long been known to be the major cause of the  
DiGeorge/22q11.2 deletion syndrome phenotype (Hisato Yagi et al., 2003), more recent work has 
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largely focused on investigating if other genes within the deletion can produce or modify the 
phenotype particularly in patients with smaller deletions that do not involve TBX1.  Copy number 
analysis of DiGeorge patients without the typical deletion  who have normal TBX1 expression 
revealed small deletions or duplications in the proximal end of the critical region containing the 
PRODH and DGCR6 genes (Gao et al., 2015).  Attenuation of Dgcr6 expression in chick had 
previously been shown to result in cardiovascular system defects similar to those seen in DiGeorge 
syndrome as well as altering the expression profile of Tbx1 (Hierck, Molin, Boot, Poelmann, & 
Gittenberger-de Groot, 2004).  Sequencing of the remaining TBX1 allele in 360 patients with 
DiGeorge/Velocardiofacial syndrome found an increased number of very rare SNPs in patients 
with normal hearts compared to patients with CHD suggesting that these SNPs may have 
protective effects (T. Guo et al., 2011). 
A variety of mouse mutants that model or recapitulate the cardiovascular phenotype in 
DiGeorge syndrome have also been identified.  Inactivation of Dgcr8 in mouse cardiac neural crest 
cells produces a wide spectrum of malformations including PTA and VSD (Chapnik, Sasson, 
Blelloch, & Hornstein, 2012).  A significant proportion of these Dgcr8-null cells were found to 
undergo apoptosis resulting in a progenitor pool insufficient for outflow tract remodeling.  Loss of 
Tbx1 and its transcriptional target Wnt5a was found to cause severe hypoplasia of structures 
dependent on the SHF (L. Chen et al., 2012).  Tbx1 was shown to occupy a T-box binding element 
within Wnt5a and to interact with Baf60a/Smarcd1 subunit of the BAF chromatin remodeling 
complex as well as Setd7 histone H3K4 monomethyltransferase.  Mice with heterozygous deletion 
of Hic2, a transcription factor lost in most distal and some typical DiGeorge syndrome deletions, 
have a partially penetrant late lethality with one-third having overriding aorta and VSD (Dykes et 
al., 2014).  Conditional targeting indicated that this gene is required in cardiac progenitors 
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expressing Nkx2.5 and Mesp2.  Compound heterozygous mutations of Crkl and Tbx1 result in 
increased penetrance of DiGeroge-like phenotypes  compared to either single heterozygote (Guris, 
Duester, Papaioannou, & Imamoto, 2006).  These genes were shown to have a dose-dependent 
function in pharyngeal arch segmentation and patterning as well as a role in local regulation of 
retinoic acid metabolism.  Reducing the dosage of β-catenin was shown to significantly reduce the 
outflow tract anomalies in conditional Tbx1-null mice (Racedo et al., 2017).  Tri- or tetrallelic loss 
of Spry1/Spry2 results in pharyngeal arch artery defects and other phenotypes reminiscent of 
DiGeorge syndrome (Simrick et al., 2012).  The severity of the defects was significantly 
exacerbated by heterozygous loss of Tbx1 which was also correlated with an increase in receptor 
tyrosine kinase signaling.  Finally, mutations in Six1 and Eya1, both of which genetically interact 
with Fgf8 and Tbx1, were found to recapitulate most features of human 22q11.2 deletion syndrome 
including outflow tract and aortic arch malformations (C. Guo et al., 2011). 
The RASopathies are a collection of syndromes with overlapping features that include 
cardiac malformations, craniofacial dysmorphism, cutaneous, musculoskeletal, and ocular 
anomalies, neurocognitive impairment, and a predisposition to certain cancers (Reviewed in Rauen, 
2013).  These disorders are characterized by mutations in genes within the RAS/MAPK pathway 
which has a role in regulating the cell cycle and cell growth, differentiation, and senescence.  
Noonan syndrome is the most common of the RASopathies with a prevalence of one in 1,000-
2,000 newborns with approximately 80% having CHD, particularly pulmonary valve stenosis 
(Rauen, 2013; Romano et al., 2010).  Mutations in the PTPN11 (Protein Tyrosine Phosphatase 
Non-Receptor Type 11) gene account for about 50% of all cases (Rauen, 2013).  More recently, a 
Gly231Val variant in MRAS was identified in a patient with Noonan syndrome and cardiac 
hypertrophy (Higgins et al., 2017).  A sequencing study in several families with Noonan-like 
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syndrome including one patient with pulmonary valve stenosis identified mutations in A2ML1           
(Alpha-2-Macroglobulin Like 1) (Vissers et al., 2015).  Characterization of the identified 
mutations in zebrafish produced multiple Noonan-like features including heart defects.  In a mouse 
model of Noonan syndrome, creation of an allelic series of Ptpn11 knock-in mice showed that 
Noonan syndrome-related CHD including valvular hyperplasia, ASD, VSD, DORV, and 
myocardial thinning resulted from abnormal expression in endocardium but not myocardium or 
neural crest (Araki et al., 2009).  Penetrance was shown to be affected by the mouse strain 
background and the specific Ptpn11 allele and the pathogenic mechanism was shown to involve 
elongation of the time during which endocardial cells undergo EMT. 
Many other causes of syndromic CHD have been identified. Gain-of-function mutations in 
ABL1 (ABL Proto-Oncogene 1, Non-Receptor Tyrosine Kinase) that increase phosphorylation 
activity were found to cosegregate with an autosomal dominant syndrome consisting of CHD 
including ASD, VSD and aortic dilation, and skeletal malformations (X. Wang et al., 2017).  An 
earlier Abl1-null mouse model revealed severe cardiac hypertrophy due to increased 
cardiomyocyte proliferation indicating that this gene does play a role in heart development (Qiu, 
Cang, & Goff, 2010).  A recessive syndrome consisting of joint dislocation and CHD including 
BAV and aortic root dilation was attributed to variants in Beta-1,3-Glucuronyltransferase 3 
(B3GAT3) which is expressed in heart, aorta, and bone (Baasanjav et al., 2011).  Variants in the 
collagen proteins COL1A1 and COL1A2 are associated with a form of osteogenesis imperfecta that 
includes valvular heart disease (Vandersteen et al., 2014).  Mutations in IRX5, which modulates 
progenitor migration in branchial arches and directly interacts with GATA3 and TRP51, have been 
implicated in a syndrome affecting blood, brain, face, heart, and gonad (Bonnard et al., 2012).  
Mutations in SMAD2, a downstream effector in the TGF-β signaling pathway have been linked to 
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phenotypes ranging from complex CHD with heterotaxy and other extracardiac findings to aortic 
aneurysm with signs of connective tissue disease (Granadillo et al., 2018).  The 
VATER/VACTERL association of Vertebral Anomalies, Cardiac defects, Tracheo-Esophageal 
fistula, Renal anomalies, and Limb defects has been linked to mutations in ZIC3 (Gly17Cys) and 
FOXF1 (Gly220Cys) (Hilger et al., 2015).  Homozygous missense mutations in CHST3 
(carbohydrate sulfotransferase 3) are associated with Omani-type spondyloepiphyseal dysplasia 
with valvular heart disease (P. Srivastava, Pandey, Agarwal, Mandal, & Phadke, 2017; Tuysuz et 
al., 2009). 
1.3.3 Familial Occurrence of CHD 
Though most CHD is isolated, there is growing evidence that at least some forms can be 
inherited or run in families.  Additionally, as more children with severe CHD are surviving into 
adulthood and having children of their own, it is important to know how often these defects are 
inherited by their children.  One study found that 727 individuals surviving major CHD produced 
393 live offspring, 71 miscarriages, and five termination-of-pregnancy (Burn et al., 1998).  A total 
of sixteen liveborn offspring had CHD for a recurrence risk of 4.1% with CHD occurring in the 
offspring of affected women more than affected men.  A study of 6,640 pregnancies undergoing 
prenatal echocardiography due to a history of CHD in a parent or sibling found recurrent CHD in 
178 (2.7%) cases (Gill, Splitt, Sharland, & Simpson, 2003).  The recurrent defects were identical 
in 37% of cases while 44% of recurrent defects were developmentally similar.  Of the families 
with two or more occurrences, the exact recurrence rate with 55% with the exact recurrence rate 
being highest for isolated AVSD and laterality defects.  Inheritance analysis of probands with 
LVOTO and their families yielded a relative risk of 36.9 with an estimated heritability of 0.70-
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0.90 (McBride et al., 2005).  Segregation analysis suggested that one or more minor loci with rare 
dominant alleles may be segregating in a subset of families while results also suggested significant 
heritability of several aortic arch and valve measurements. 
A Danish population study found that first degree relatives of probands with CHD had a 
recurrence risk of 79.1 for heterotaxy, 11.7 for conotruncal defects, 24.3 for AVSD, 12.9 for 
LVOTO, 48.6 for RVOTO, 7.1 for isolated ASD, and 3.4 for isolated VSD (Oyen et al., 2009).  
The authors noted a recurrence risk ratio of 8.15 for identical defects but only 2.68 for different 
defects while concluding that, excluding chromosomal defects, only 2.2 percent of CHD in the 
population is attributable to a family history of CHD in first degree relatives.  An epidemiologic 
study from Norway found that, among sibling pairs, the younger sibling had a 4.1% chance of 
having CHD if the older sibling had CHD compared to 1.1% if the older sibling did not have CHD 
for a recurrence risk of 3.6 (Brodwall et al., 2017).  The recurrence risk ratio for same-sex twins 
was reported to be 14.0 while opposite-sex twins had a recurrence risk ratio of 11.9 with 50% of 
sibling pairs with recurrent CHD having similar types of defects.  A large study of 1163 families 
with 3080 individuals with verified CHD reported reduced penetrance in 32% of families while 
also noting that a high degree of discordant phenotypes was common though some families with 
many affected members showing a high concordance rate for certain defects including ASD, VSD, 
CoA, persistent ductus arteriosus, and TOF (Ellesoe et al., 2018).  They reported a rate of first-
degree relatedness that was higher for concordant that discordant pairs and showed that specific 
groups of phenotypes co-occur within families. 
A large study estimated that 1.8% of CHD are attributable to rare inherited mutations while 
also noting a recessive founder mutation in GDF1 (growth differentiation factor 1) may account 
for about 5% of severe CHD in the Ashkenazi Jewish community, a recessive MYH6 phenotype 
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may account for 11% of Shone’s complex cases, and a dominant FLT4 mutations may account for 
about 2.3% of TOF cases (Jin et al., 2017).  A family-based WES study including 182 individuals 
from 51 families with multiple members affected by LVOTO-spectrum defects identified disease-
associated variants co-segregating within 12 families (Preuss et al., 2016).  These variants were 
found to cluster in the Notch signaling pathway including NOTCH1, ARHGAP31, MAML1, 
SMARCA4, JARID2, and JAG1 and showed significant enrichment for high-pathogenicity variants.  
Targeted NGS of 57 previously implicated CHD genes in 16 families and 15 controls identified 
13 potential causative variants in 9 families of which five co-segregated with the disease (Blue et 
al., 2014).  The authors noted an increased incidence of insertions/deletions, nonsense variants, 
and splice variants as well as variants classified as “probably damaging” in cases relative to 
controls as well as an increased number of “rare” and “low-frequency” variants in cases. 
In addition to these epidemiological and large-scale studies, causative variants have also 
been identified in small single-family studies.  Intragenic mutations within the eleastin (ELN) gene 
have been identified in cases of familial aortic stenosis (Hayano et al., 2019).  A dominant and 
fully penetrant form of familial VSD was found to segregate with a Leu38Pro variant in CASZ1 
which codes for a zinc finger transcription factor essential for cardiogenesis (Huang et al., 2016).  
A luciferase assay was used to show that the mutant protein had significantly reduced 
transcriptional activity.  A variant in DCHS1 (Dachsous Cadherin-Related 1) was found to 
segregate with mitral valve prolapse in several families (Durst et al., 2015).  Morpholino 
knockdown of zebrafish dchs1 resulted in an atrioventricular canal defect that could be rescued by 
wildtype human DCHS1 transcripts but not by transcripts containing the variant found in affected 
family members.  A Gly83Ter mutation in NR2F2 shown to completely abolish transcriptional 
activity and synergistic activity with GATA4 was found to segregate with DORV and VSD in a 
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family while being absent in 230 ethnically matched healthy controls (Qiao et al., 2018).  A 
frameshift mutation in NOTCH1 was identified in a patient with HLHS and DORV and found to 
be inherited from the father who had VSD and pulmonary stenosis (Zahavich, Bowdin, & Mital, 
2017).  The proband also had a paternal uncle with TOF and paternal grandmother with a history 
of valve surgery.  Finally, a nonsense variant in PITX2 was found to segregate with disease in a 
family with 100% penetrant endocardial cushion defect and Axenfeld-Rieger syndrome (C. M. 
Zhao et al., 2015).  This variant was absent in 800 ethnically matched controls and functional 
analysis showed that the mutant protein had no transcriptional activity and could not 
synergistically activate transcription with NKX2.5. 
1.3.4 Mouse Models of CHD 
Mouse mutagenesis studies have long been used both to confirm the pathogenicity of 
variants first identified in human patients and to identify new genes that may contribute to heart 
development and CHD.  There are likely hundreds of such models and what follows is just a small 
sample to provide an idea of the scope of research being done using mouse models.  Adam19 
(ADAM Metallopeptidase Domain 19) is highly expressed in the conotruncus and endocardial 
cushions during mouse development and mutant mice are perinatal lethal with VSD, abnormal and 
stenotic semilunar valves, and abnormal cardiac vasculature (Zhou et al., 2004).  Mice with null 
mutations in A-Kinase Anchoring Protein 13 (Akap13) had thin-walled hearts and died at E10.5-
11.0 while also showing reduced Mef2c expression (Mayers et al., 2010).  Arid3b (AT-Rich 
Interaction Domain 3B) is expressed in the heart tube, myocardium, and SHF progenitors with 
mutant mice displaying shortened arterial and venous poles, absent myocardial differentiation, and 
altered atrioventricular canal patterning with absent EMT (Uribe et al., 2014).  Labeling of SHF 
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progenitors revealed a defect in the addition of cells to the heart.  Autophagy Related 13 (Atg13) 
knockout mice are embryonic lethal and show myocardial growth defects (Kaizuka & Mizushima, 
2015).  Bmp10, a member of the TGF-β superfamily of transcription factors, was found to have a 
crucial role at mid-gestation when the heart transitions from patterning to growth and maturation 
(H. Chen et al., 2004).  Null mice were shown to have ectopic and elevated expression of p57Kip2 
and a dramatic reduction in cardiomyocyte proliferation activity at E9.0-E9.5.  These mice had 
dysplastic ventricular walls that lacked trabeculae as well as abnormal endocardial cushions.  The 
authors showed that Bmp10 is expressed in ventricular trabecular myocardium at E9.0-E13.0 but 
becomes restricted to the atria by E16.0 and concluded that it is required for maintaining normal 
expression of cardiogenic factors including Nkx2.5 and Mef2c during mid-gestation. 
Simultaneous deletion of the executioner caspases Cas3 and Cas7 was shown to result in 
reduced expression of genes that promote DNA replication and cell cycle progression and resulted 
in mice with hypoplastic hearts at birth (Cardona et al., 2015).  Neural crest-specific knockout of 
Cdc42 (Cell division cycle 42) was shown to cause embryonic lethality with craniofacial and 
conotruncal defects (Y. Liu et al., 2013).  Col14a1-/- mice were shown to have dysregulated mRNA 
levels of other collagen types and remodeling enzymes within ventricular myocardium as early as 
E11.5 (Tao et al., 2012).  Though these mice were adult viable, they showed disarrayed collagen 
fibril organization and defective ventricular morphogenesis resulting in cardiac dysfunction.  The 
ENU-induced Ddx11cetus mutant as well as Ddx11KO DEAD/H-box helicase 11 mutants result in a 
severe phenotype with developmental arrest at E7.5-E8.5 and cardiogenesis arrested at the linear 
heart tube stage as well as failure of somitogenesis and failure of chorioallantoic fusion (Cota & 
Garcia-Garcia, 2012).  Endothelium-specific knockout of Furin, a proprotein convertase, results 
in neonatal lethality with VSD and/or valve defects (W. Kim et al., 2012). 
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Galnt1 which encodes a glycosyltransferase involved in initiating mucin-type O-
glycosylation was shown to be essential for normal valve development and cardiac function (Tian 
et al., 2015).  Mutant embryos showed aberrant valve formation as a result of increased cell 
proliferation within the outflow cushions with the developing valves showing reduced levels of 
Adamts1 and Adamts5, decreased versican cleavage, increased levels of other extracellular matrix 
(ECM) proteins, and increased BMP and MAPK signaling.  Adult null mice have compromised 
heart function including semilunar valve stenosis or regurgitation, an altered ejection fraction, and 
dilation of the heart. 
Heterozygous Gata4+/- mice were shown to have outflow tract defects including DORV 
and VSD (J. Liu et al., 2019).  They showed that Gata4 is required by Hedgehog-responsive 
progenitors within the SHF for normal outflow tract development.  In support of this, Gata4+/-
/Smo+/- mice displayed a more severe phenotype including PTA.  Furthermore, there was enhanced 
Gata6 expression in Gata4+/- SHF due to a lack of repression by Gata4 which binds repressor sites 
upstream of the Gata6 transcription start site.  These results led the authors to conclude that outflow 
tract development is controlled by a Gata4-Gata6-Hedgehog regulatory network.  Creation of 
Gata4-/-/Gata6-/- embryos through a tetraploid embryo complementation strategy to circumvent 
their requirement in extra-embryonic endoderm resulted in acardiac embryos that only generated 
SHF progenitors (R. Zhao et al., 2008). 
Ventricular expansion has been shown to be regulated by Hand1 and Hand2 in a dose-
dependent manner (McFadden et al., 2005).  Hand1 knock-in mice were shown to have increased 
expansion of the outer curvature of both ventricles with absent formation of the interventricular 
groove and septum (Togi et al., 2004).  They showed that expression of Hand1 within the entire 
ventricle altered the expression pattern of Chisel, ANF, and Hand2, but not Tbx5.  Furthermore, 
35 
the interventricular groove formed in transgenic mice that overexpressed Hand1 in the right 
ventricle but not the border region.  An earlier study showed that Hand1 null mice were embryonic 
lethal between E8.0-E9.5 with heart development arresting at the looping stage (Firulli, McFadden, 
Lin, Srivastava, & Olson, 1998). 
Deletion of Ino80, a chromatin remodeling protein, in vascular endothelial cells was shown 
to prevent ventricular compaction and was also associated with defective coronary angiogenesis 
(Rhee et al., 2018).  Furthermore, specific deletion in the sinus venosus and endocardium which 
are major contributors to the coronary vasculature produced an intermediate phenotype.  In vitro 
experiments revealed that endothelial cells exert an effect on myocardial expansion that is 
dependent on Ino80 but independent of blood flow. 
Nipbl+/- and NipblFLEX/+ NIPBL cohesion loading factor mutant mice generated as a model 
for human Cornelia-de Lange syndrome have ASD with delayed ventricular septation and small 
hearts (Santos et al., 2016).  Expression analysis showed dysregulation of Hand1, Pitx2c, and c-
Myc.  Additionally, lineage-specific knockout indicated that cardiomyocytes, non-cardiac 
mesoderm, and endoderm lineages, but not neural crest contribute to the heart defects seen in these 
mutants.  The authors thus concluded that there is a complex interaction between multiple tissue 
types where the risk conferred by a genetic abnormality in one lineage can be modified by the 
genetic status of another lineage in a non-additive manner. 
Cardiac-selective overexpression of Nexn, an F-actin binding protein that functions as a 
negative regulator of cardiac contractile markers by inhibiting Gata4, was shown to result in ASD 
(F. Yang et al., 2014).  Cardiomyocyte-specific conditional knockdown of Nr2f2 results in 
ventricularized atria (S. P. Wu et al., 2013).  In vitro modeling of the human NKX2.5R142C/+ 
mutation in mouse (Nkx2.5141C/+) embryonic stem cells revealed that this mutation caused altered 
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expression of genes essential for normal cardiac development (Zakariyah et al., 2018).  Reduced 
cardiomyogenesis was found to correlate with reduced Nkx2.5 nuclear import and downregulation 
of BMP and Notch signaling.  Finally, expression analysis at the early stages of cardiac 
differentiation revealed a profound dysregulation of genes involved in differentiation and function.  
Mice with anterior SHF-specific deletion of Rac1, a small GTPase, had outflow tract and aortic 
valve defects (Leung et al., 2015).  Disrupted Slit/Robo signaling, which likely acts as a regulator 
of Notch signaling, results in membranous VSD and BAV (Mommersteeg, Yeh, Parnavelas, & 
Andrews, 2015).  The proper differentiation of cardiac neural crest cells in the outflow tract has 
been shown to be dependent on Sox4 and Sox11 (Paul, Harvey, Wegner, & Sock, 2014).  They are 
thought to participate in regulation of cytoskeletal cell adhesion and ECM molecules and deletion 
of both in mesoderm and/or cardiac neural crest leads to outflow tract abnormalities ranging from 
DORV to PTA.  Deletion of Yap1 in cardiac and smooth muscle was found to result in multiple 
CHD including hypoplastic myocardium, membranous VSD, DORV, and severe vascular 
anomalies (Y. Wang et al., 2014).  Mutations in the retinaldehyde reductase gene, Dhrs3, result in 
outflow tract defects as well as defects in atrial and ventricular septation (Billings et al., 2013). 
1.4 The Role of Cilia in Heart Development and CHD 
Cilia are microtubule-based projections from the cell surface that can be either motile or 
nonmotile (primary) that have a variety of functions including signaling, detection of different 
types of stimuli, and movement of fluid.  Defects in cilia formation, structure, and/or function can 
lead to a variety of diseases collectively terms the ciliopathies.  The functions and related 
pathologies of both primary and motile cilia have been extensively reviewed (Ishikawa, 2017; 
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Malicki & Avidor-Reiss, 2014; Mitchison & Valente, 2017; Nachury, 2018; Pala, Alomari, & 
Nauli, 2017; Reiter & Leroux, 2017).  Motile cilia at the embryonic node generate a leftward fluid 
flow that initiates a left-sided signaling cascade leading to specification of the left-right axis.  
Mutations in genes involved in the formation, structure, and/or function of these nodal cilia lead 
to abnormal left/right patterning and heterotaxy-spectrum CHD including abnormal heart looping, 
atrial isomerism, and other complex defects (Barratt, Glanville-Jones, & Arkell, 2014; Boskovski 
et al., 2013; Del Viso et al., 2016; Field et al., 2011; Francis, Christopher, Devine, Ostrowski, & 
Lo, 2012; Hartill et al., 2018; Kamura et al., 2011; Kinzel et al., 2010; Larkins, Long, & Caspary, 
2012; Robson et al., 2019; Simms et al., 2012). 
A variety of studies have looked at the contribution of cilia genes to CHD.  One study 
found that heterotaxy patients with CHD are enriched for genes known to cause primary ciliary 
dyskinesia (PCD) (Nakhleh et al., 2012).  Heterotaxy patients have been found to have a two-fold 
excess of CNVs compared to controls with these CNVs including cilia genes such as NEK2, 
ROCK2, GALNT11, and NUP188 which all disrupt left/right determination and Pitx2 expression 
when knocked down in Xenopus (Fakhro et al., 2011).  A phenotype-driven mouse mutagenesis 
screen with the goal of identifying genes associated with CHD recovered a large proportion of 
cilia-related genes (Klena, Gibbs, & Lo, 2017).  Of the 91 recessive mutations recovered in 61 
genes, 34 were cilia-related, 16 were involved in cilia-transduced cell signaling, and 10 were 
involved in vesicular trafficking.  The cilia-associated CHD genes had a variety of functions 
including signal transduction, vesicle trafficking, and left/right patterning.  Finally, a recessive 
mouse forward screen showed that cilia and cilia-transduced cell signaling play a significant role 
in the etiology of CHD (Y. Li et al., 2015). 
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Among PCD patients, 46% have situs solitus while 47.7% have situs inversus and 6.3% 
have heterotaxy (Kennedy et al., 2007).  While defects in the inner dynein arms and central 
apparatus are more prevalent in PCD patients with situs solitus, PCD patients with heterotaxy or 
situs inversus more commonly have outer dynein arm defects.  Another study found that 50% of 
PCD patients have laterality defects of whom 3.5-6% have cardiovascular malformations with 
2.6% of those being complex CHD (Harrison, Shapiro, & Kennedy, 2016).  Additionally, 2.3% of 
patients with situs ambiguous also have complex CHD while 4.6% of patients had no CHD 
(Shapiro et al., 2014).  Ultimately, it is thought that the prevalence of CHD with heterotaxy is 200-
fold higher in PCD patients than in the general population (Kennedy et al., 2007). 
Mutations in a variety of genes needed for cilia assembly, motility, or transduction of the 
Nodal signaling cascade have been shown to result in laterality defects and associated CHD in 
model organisms.  Mutations in Zic2, a component of a regulatory network that drives ciliation of 
nodal cells, have been associated with randomized cardiac situs and loss of asymmetric gene 
expression in the early somite stage node and lateral plate mesoderm (Barratt et al., 2014).  Though 
not expressed in these tissues, Zic2 is transiently expressed in the embryonic node during mid to 
late gastrulation and mutants have short, abnormal nodal cilia along with downregulated 
expression of genes required for ciliogenesis (Noto, Rfx3, Foxj1) and cilia function (Pkd1l1).  
Galnt11-mediated Notch signaling mediates the distribution of motile to immotile cilia at the 
Xenopus tropicalis left/right organizer (Boskovski et al., 2013).  Depletion of galnt11 or notch1 
was shown to increase the ratio of motile cilia and produces laterality defects reminiscent of those 
seen in Pkd2 mutants while Notch overexpression decreases the ratio and produces a phenotype 
reminiscent of PCD.  Inner ring nucleoporins nup93 and nup188 have been shown to localize to 
the ciliary base in Xenopus with their depletion leading to loss of pitx2 expression and loss of 
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asymmetric coco (dand5, cerl2) expression at the left-right organizer and reduced cilia density 
leading to abnormal heart looping (Del Viso et al., 2016).  DNAAF1 (Dynein axonemal assembly 
factor 1) is required for dynein heavy chain assembly and mutations cause PCD with or without 
heterotaxy and associated CHD in humans while zebrafish mutants display randomized heart 
looping (Hartill et al., 2018; van Rooijen et al., 2008).  Pitchfork (Pifo) has been shown to associate 
with ciliary targeting complexes and accumulate at basal bodies during cilia disassembly with 
haploinsuffiency shown to cause duplicated node cilia and left-right patterning defects in mice 
(Kinzel et al., 2010).  The authors also reported finding mutations in this gene in a fetus with situs 
inversus totalis and renal and liver cysts as well as a patient with DORV.  Mice harboring the 
Arl13bhnm mutation in ADP Ribosylation Factor Like GTPase 13B have short node cilia leading 
to an inability to maintain asymmetric Nodal expression ultimately downregulating Cerl2 
expression at the node leading to heterotaxy and abnormal heart looping (Larkins et al., 2012).  
Mutations in the zebrafish ortholog of AHI1 (Abelson helper integration site 1), a cause of Joubert 
syndrome in humans, result in absent cilia in Kupffer’s vesicle leading to cardiac looping defects 
(Simms et al., 2012) 
Mice harboring mutations in Dnaic1 (Dynein axonemal intermediate chain 1) have 
immotile nodal cilia with half showing situs solitus or inversus and the other half showing 
heterotaxy including bias towards an L-looped heart (Francis et al., 2012).  Mice with normal or 
mirror-image situs had normal hearts or only mild defects such as azygous continuation or septal 
defects whereas heterotaxy mice all had complex CHD.  Mutations in Xenopus rnf20, a member 
of the H2Bub1 complex that regulates inner dynein arm assembly, result in abnormal cilia motion 
(Robson et al., 2019).  Mutations in murine Pkd1l1 and Pkd2, encoding polycystin 1-like 1 and 
polycystin 2 respectively,  result in failed activation of asymmetric gene expression at the node 
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and right isomerism (Field et al., 2011).  These proteins are thought to form a complex that serves 
as a “nodal flow detector” with Medaka embryos harboring the abecobe mutant (pkd1l1) 
displaying defective asymmetric expression of southpaw, lefty, and charon in the context of normal 
nodal flow (Kamura et al., 2011). 
Two patients have been reported with a heterozygous non-synonymous 455G>A mutation 
in the functional domain of DAND5, a master regulator of Nodal signaling (Cristo et al., 2017).  
The first patient had left isomerism with VSD, overriding aorta, and pulmonary atresia while the 
second patient had a VSD, overriding aorta, pulmonary atresia, and hypertrophy of the right 
ventricle.  Functional analysis showed the mutant protein had significantly decreased activity 
compared to wild type.  A Lys132Ter nonsense variant in HAND1 was identified in a patient with 
DORV (L. Li et al., 2017).  This variant was not found in 600 controls and was shown to have no 
transcriptional activity and disrupted synergistic activation with GATA4.  Mutations in MEGF8 
(Multiple EGF-like domains 8) have been associated with a form of Carpenter syndrome 
(Acrocephalopolysyndactyly type II) that includes laterality defects including situs inversus totalis, 
dextrocardia, and TGA (Twigg et al., 2012).  ZIC3 is one of the better known causes of heterotaxy 
and CHD accounting for 5.2% of sporadic cases in males (Cowan, Tariq, & Ware, 2014).  A study 
of probands with TGA and a family history of concordant or discordant CHD identified sequence 
variants in FOXH1, ZIC3, and NODAL (De Luca et al., 2010). 
Primary cilia have been known to exist in the embryonic and adult heart for over 40 years 
(Myklebust, Engedal, Saetersdal, & Ulstein, 1977; Rash, Shay, & Biesele, 1969).  In the rat, 
primary cilia have been identified from all stages of development from embryo to subadult (Kaur, 
McGlashan, & Ward, 2018).  Monocilia have been noted on most regions of the heart except for 
the atrial septum and their presence has been correlated with the amount of shear stress with high 
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shear stress noted to induce deciliation and EMT (Egorova et al., 2011; Van der Heiden et al., 
2006).  Cilia have been shown to be present on non-cardiomyocyte cells in embryonic and adult 
mouse heart, but absent from cardiomyocytes at all stages instead being exclusive to cardiac 
fibroblasts where they have a key role in the cardiac fibrosis pathway (Villalobos et al., 2019).  
Another study noted that cilia are observed infrequently on the mitral valve endocardium but are 
found on most interstitial cells of the embryonic, fetal, and neonatal mitral valve and that their 
presence correlates with the type of extracellular matrix being produced (Toomer et al., 2019). 
It is now known that primary, but not motile, cilia play a key role in the later stages of heart 
development after the left/right axis has been specified.  One study showed that cilia motility genes 
are not expressed in SHF whereas genes needed for cilia structure and function are expressed while 
another study showed that knockdown of primary cilia in P19 CL6 cells using Ift88/20 siRNA or 
cyclopamine blocks hedgehog signaling and prevents these cells from differentiating into beating 
cardiomyocytes (Burnicka-Turek et al., 2016; Clement et al., 2009).  At E9.5 of mouse 
development cilia line the endothelium of the developing atria and the ventricular trabeculations 
and less prominently on the compact myocardium and are also present within the cushion 
mesenchyme and on the atrial side of the overlying endothelium (Slough, Cooney, & Brueckner, 
2008).  Primary cilia are found at distinct regions of the developing atria and ventricles at E10.5-
E12.5 (Gerhardt, Lier, Kuschel, & Ruther, 2013).  From E11.5 to E13.5 primary cilia are present 
on interstitial cells of the developing outflow cushions but rare on valve endocardium (Toomer et 
al., 2017).  Cilia expression is temporally regulated and restricted to specific extracellular matrix 
zones of the developing aortic valve where they grow to a maximum length of 2.5-3 µm by E17.5 
before gradually shortening postnatally being mostly lost from the interstitial cells of adult 
atrioventricular valves.  Cilia-mediated Hedgehog signaling through desert hedgehog (Dhh) which 
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is robustly expressed in cushion endocardium is thought to play an important role in aortic valve 
development (Toomer et al., 2017).  It is thought that cilia aid in restraining valve size and 
modulate the production of components of the extracellular matrix.  Primary cilia have been shown 
to frequently occur on the atrioventricular and conotruncal cushions at E12.5 (Willaredt et al., 
2012).  In these tissues, mesenchymal cells were shown to have randomly oriented cilia while 
endocardial cells oriented their cilia towards the lumen of the inflow or outflow tract.  Cilia remain 
present on the atrial endocardium at E12.5, though not as prominently as at E9.5 (Slough et al., 
2008).  Cilia also persist on the ventricular surface of trabeculations within both ventricles as well 
as being prominent on the epicardium extending toward the pericardial space. 
Mutations in a number of genes affecting both primary and motile cilia, some of which are 
known to cause ciliopathies, have been linked to CHD in humans.  A patient with PDA, VSD, 
dextroversion, pulmonary artery hypoplasia, and other extracardiac findings was found to have 
compound  heterozygous variants in CRBS2, a Crumbs family protein implicated in the planar cell 
polarity pathway and needed for proper cilia alignment, and a heterozygous variant in TTCB21 
(Jaron et al., 2016). Orofaciodigital syndrome type VI, caused by mutations in the  ciliogenesis 
and planar polarity effector (CPLANE) genes INTU and WDPCP, can have TOF and coarctation 
of the aorta (Toriyama et al., 2016).  Mutations in the actin proteins ACTB and ACTG1 are 
associated with Baraitser-Winter cerebrofrontofacial syndrome which can include BAV, VSD, 
ASD, PDA, and mitral regurgitation (Verloes et al., 2015).  INVS and NPHP3 mutations, though 
more commonly associated with nephonophthisis, can also be associated with CHD (Wolf, 2015).  
Ellis-van Crevald syndrome caused by mutations in the EVC1 or EVC2 genes has been associated 
with common atrium, persistent left superior vena cava, and atrioventricular canal defects (Digilio 
et al., 1999).  Evc1/2 have been shown to be expressed in the developing atrioventricular cushions 
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and outflow tract around the time of atrioventricular septation in mouse studies (Sund, Roelker, 
Ramachandran, Durbin, & Benson, 2009).  Patients with AVSD have been shown to be enriched 
for rare variants in centrosomal protein 152 (CEP152) compared to controls (D'Alessandro et al., 
2016).  A GWAS of patients with BAV revealed significant SNPs in or near genes involved in 
regulation of ciliogenesis through the exocyst (Fulmer et al., 2019).  Disruption of the exocyst in 
zebrafish resulted in defective ciliogenesis and cilia signaling as well as a variety of heart defects 
while mouse mutants had aortic valve defects including BAV, stenosis, and calcification.  
Mutations in DZIP1, a regulator of ciliogenesis and/or cilia signaling, have been shown to 
segregate with mitral valve prolapse in a large family and have also been found in several unrelated 
individuals with isolated mitral valve prolapse (Toomer et al., 2019).  Dzip1S14R/+ neonatal mice 
have a mitral valve phenotype associated with cilia that are shorter in length compared to wild type 
littermates. 
A number of cilia genes have also been found to cause heart defects in mice.  Loss of Ftm 
(Rpgrip1l) results in shortened cilia and reduced proliferation in ciliated areas ultimately leading 
to reduced ventricular wall thickness and VSD (Gerhardt et al., 2013).  The authors hypothesized 
that cilia-mediated hedgehog and PDGFR signaling regulate ventricular proliferation.  
Examination of E9.5 Lrd-/- (immotile nodal cilia), Pkd2-/- (defective ciliary mechanosensation), 
and Kif3a-/- (absent cilia) mice revealed decreased cellularity of the endocardial cushions and 
thinning of the compact myocardium with increasing severity (Slough et al., 2008).  The authors 
only examined D-looped hearts to control for defective left/right determination and hypothesized 
that cardiac cilia function as flow sensors with a vital role in the regional control of EMT and may 
sense myocardial function in ventricles and/or epicardium to regulate proliferation during 
development. 
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Ift88tm1Rpw mutant mice (a null allele) lack cilia and have dilated ventricles with decreased 
trabeculation and abnormal outflow tract development at E11.5 (Clement et al., 2009).  
Additionally, knockdown of Ift20 and Ift88 by siRNA or cyclopamine was found to block 
hedgehog signaling.  Conditional knockout of Ift88 in cardiac endothelium results in shortening or 
loss of primary cilia and a highly penetrant BAV phenotype (Toomer et al., 2017).  Homozygous 
cobblestone (cbs) mutants, encoding a hypomorphic Ift88 allele, result in a variety of heart defects 
including PTA with malposition of the common trunk, abnormal arch artery patterning, ASD, VSD, 
and a hypoplastic myocardium (Willaredt et al., 2012).  Mutant hearts showed a substantial loss 
of primary cilia in the atrioventricular cushions and pericardium as well as loss of Isl1 expression 
in SHF, downregulation of downstream targets of Shh signaling and reduced Bmp2/4 expression. 
Pkd1del17-21βgeo-/- mice at E13.5-14.5 have CHD including DORV, disorganized 
myocardium, and abnormal atrioventricular septation (Boulter et al., 2001).  Pkd1 is expressed in 
the aorta at E9.5 later becoming expressed in all major vessels and throughout the heart, 
particularly in the outflow tract, endocardial cushions, and valve leaflets by E10.5.  Pkd1 is also 
expressed at high levels in the adult mouse aortic outflow tract and atrial appendages as well as 
expression in vascular endothelial and smooth muscle cells of the major vessels (Boulter et al., 
2001).  Pkd2-/- mice exhibit completely penetrant VSD with some also having ASD or AVSD (G. 
Wu et al., 2000).  A mouse ENU screen identified Dnah11 and Mks1 as causing recessive AVSD 
phenotypes (Burnicka-Turek et al., 2016).  Mutations in Dnah11, an axonemal protein required 
for cilia motility, were shown to not disrupt SHF Hedgehog signaling and caused AVSD with 
concurrent heterotaxy whereas mutation in Mks1, encoding a basal body protein, disrupted 
Hedgehog signaling within the SHF and caused isolated AVSD without heterotaxy.  Finally, the 
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mouse Beetlejuice Prickle1 mutant has defective planar cell polarity leading to outflow tract 
shortening and malalignment as well as motile and primary cilia defects (Gibbs et al., 2016). 
1.5 Public Health Significance and Objectives 
Congenital heart disease is one of the most common birth defects with an estimated 
prevalence of 4-10 per 1000 live births (Pierpont et al., 2007).  These defects can range from simple 
and sometimes asymptomatic septal defects or bicuspid aortic valve to highly complex 
malformations involving multiple structures.  Sequencing and genome association studies in 
humans as well as mutagenesis studies in mice and other model organisms have identified a 
growing number of genes that either directly cause or modify the risk or phenotype of congenital 
heart disease.  With improvements in the diagnosis and surgical management of these defects, the 
rate of long-term survival has steadily increased.  One review reported that mortality rate for CHD 
decreased by 40% from 1979-1997 and by a further 24% by 2006 (Mazor Dray & Marelli, 2015).  
This review also notes that the average age of patients with severe CHD has increased from 11 in 
1985 to 17 in 2000 and 25 in 2010.  A Norwegian study reported that survival to age 16 in children 
with severe CHD increased from 62% from 1971-89 to 87% from 1999-2011 (Erikssen et al., 
2015).  By 2000 the global population of adults with CHD was estimated at 40,000 per 10,000,000 
with this number expected to increase (Marelli, Mackie, Ionescu-Ittu, Rahme, & Pilote, 2007).  
Despite the increased survival, CHD patients still face a lifetime of follow-up that may include 
various diagnostic procedures or possible repeat surgeries as well as the risk of late complications 
such as atrial arrhythmias, pulmonary arterial hypertension, infectious endocarditis, and heart 
failure (Bouma & Mulder, 2017; Mazor Dray & Marelli, 2015).  In addition, there is increasing 
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evidence that some of the same genetic defects that cause CHD as well as extrinsic factors such as 
radiation exposure from interventional procedures and chronic hypoxia may increase the lifetime 
risk of developing cancer for these patients (Botto et al., 2013; Fisher et al., 2012; Gurvitz et al., 
2016; Moore, 2009; Nishi, Miyake, Takeda, & Hatae, 2000; Olsen et al., 2014; Opotowsky et al., 
2015).  With these factors in mind, a better understanding of the genetic etiology is of public health 
relevance as knowledge of the genetic causes of CHD may lead to improved preventative and 
interventional strategies as well as better risk assessment for early and late complications.  To this 
end, this study was untaken with the following objective in mind. 
1) Show that CHD patients have an increased burden of rare pathogenic and highly 
damaging variants in genes known to be associated with heart development. 
2) Examine if CHD patients have an increased burden of genes known to be associated 
with cancer 
3) Identify novel genotype-phenotype correlations in our patient cohort 
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2.0 Enrichment for Rare Pathogenic and Highly Damaging Variants 
2.1 Introduction 
Recent evidence has increasingly pointed to a complex origin for CHD that goes beyond 
simple Mendelian inheritance with variants in multiple genes often acting to modify expressivity 
and penetrance of phenotypes.  A prime example of this comes from a recently published case that 
describes a child and fetus with severe left ventricular noncompaction who inherited a variant in 
MYH7, known to cause cardiomyopathies, from their father who was only mildly affected as well 
as an NKX2.5 variant from their unaffected mother (Gifford et al., 2019).  The authors propose that 
the MYH7 variant which arose de novo in the father drives the noncompaction phenotype while 
the NKX2.5 variant inherited from the mother dramatically increased the severity.  This evidence 
was supported by the observation of left ventricular noncompaction in mice that were triply 
heterozygous for the MYH7 and NKX2.5 variants as well as a variant in MKL2 which is involved 
in transcriptional regulation of cardiac genes and was present in the father and children as well as 
the paternal grandfather who had a history of arrhythmia but no structural abnormalities. 
A WES study of patients with left-sided heart defects detected a great deal of genetic 
heterogeneity as well as complex inheritance involving dominant, recessive, and X-linked models 
(A. H. Li et al., 2017).  The authors also found that a majority of the detected heterozygous loss-
of-function variants were inherited from presumably unaffected parents, though it was noted that 
cardiac examinations were not performed on the parents so subclinical defects such as BAV could 
not be ruled out.  Another WES study found that patients with severe CHD had a significant excess 
of protein-altering variants in genes expressed in the heart (Zaidi et al., 2013).  A large study of 
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parent-child trios of syndromic and non-syndromic CHD cases reported a significant enrichment 
for de novo but not inherited protein-truncating variants in syndromic cases but conversely an 
excess of protein-truncating variants inherited from unaffected parents in non-syndromic cases 
(Sifrim et al., 2016).  A GWAS of patients with 22q11.2 deletion identified SNPs intronic to 
GPR198 associated with TOF and that may have a regulatory role with the nearby MEF2C gene 
(T. Guo et al., 2017).  Another GWAS of Han Chinese cases and controls identified SNPs in TBX15 
and MAML3 that were associated with risk of CHD (Hu et al., 2013). 
A study of parent-child trios of patients with AVSD found that 32% of trios carried at least 
1 disease-causing variant across 19 loci suggesting AVSD can be caused by a heterogeneous group 
of genes (Priest et al., 2016).  In a study of event-free survival in a cohort of patients with acute 
aortic dissection (AAD), patients with three or more variants in genes known to be associated with 
AAD had shorter event-free survival than patients with fewer variants (Zheng et al., 2018).  
Another study showed that variants in PLOD1 may predispose BAV patients to aortic dilation due 
to impaired collagen cross-linking (Wagsater et al., 2013).  A multi-level study found that isolated 
TOF is caused by a combination of deleterious, rare, and private mutations in genes essential for 
apoptosis, cell growth, sarcomere assembly, neural crest, and SHF (Grunert et al., 2014).  
Nonsynonymous variants in the transcription factor PBX3 was found to be present in 5.2% of CHD 
patients compared with 1.3% of controls suggesting they may act as modifiers or risk alleles for 
CHD, especially outflow tract defects (Arrington, Dowse, Bleyl, & Bowles, 2012).  A study found 
that different missense, loss-of-function, and intronic variants within NOTCH1 confer different 
risks for LVOTO (Helle et al., 2018).  Finally, it has been observed that CHD patients frequently 
have ciliary dysfunction and are enriched for de novo mutations in cilia-related pathways (Klena 
et al., 2017). 
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Several studies in mice have also found evidence of the complex genetic nature of CHD.  
A mouse forward genetic screen found a multigenic etiology for HLHS with mutations in Sap130 
driving left ventricular hypoplasia and mutations in Pcdha9 increasing penetrance of aortic valve 
defects while also finding enrichment for variants in 10 human chromosomal regions hinting at 
complex inheritance (X. Liu et al., 2017; H. Yagi et al., 2018).  Intercrossing different strains of 
mice with a heterozygous Nkx2.5+/- mutation produced phenotypes with differing severity based 
on co-inheritance of different quantitative trait loci from different strain backgrounds (Akhirome 
et al., 2019).  Finally, several studies have indicated that mutations in genes that interact with Tbx1 
can modify the severity of CHD in mouse models of DiGeorge syndrome (L. Chen et al., 2012; C. 
Guo et al., 2011). 
Adding another layer to this complexity is the finding that epigenetics, particularly 
chromatin modifiers, play an important role in CHD.  One study found that CHD patients had a 
significant excess of mutations in genes involved with histone H3 lysine 4 (H3K4) methylation 
and H2BK120 ubiquitination (Zaidi et al., 2013).  Another study found significant enrichment for 
loss-of-function and protein altering variants in genes encoding components of the H2Bub1 
complex, a regulator of tissue-specific expression of cilia genes through histone H2B 
monoubiquitination, in CHD patient with laterality defects but not controls (Robson et al., 2019).  
The authors, through knockdown of complex protein rnf20 in zebrafish and Xenopus, showed that 
laterality defects resulted from impaired motile cilia motion and that this gene regulates assembly 
of inner dynein arms.  Rare variants in SMYD4, a lysine methyltransferase that interacts with 
HDAC1 and may also modulate histone acetylation, were found in a cohort of CHD patients (Xiao 
et al., 2018).  Knockout of smyd4 in zebrafish was found to cause heart defects including abnormal 
left/right patterning, abnormal looping, and hypoplastic ventricles. 
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In mice, inactivation of CHD7 encoding an ATP-dependent nucleosome remodeling factor 
impairs multiple BMP signaling-dependent cardiogenic processes (Y. Liu et al., 2014).  The 
authors showed that CHD7 interacts with canonical BMP signaling pathway nuclear mediators 
Smad1/5/8 as well as associating with Nkx2.5 in a BMP-dependent manner.  Fam60a interacts 
with components of the Sin3a HDAC transcriptional corepressor complex and Fam60a-/- mice 
have hypoplastic right ventricles, TGA, DORV, and other extracardiac anomalies reminiscent of 
laterality defects albeit with normal Pitx2 expression (Nabeshima et al., 2018).  Mutations in 
Sap130, a component of the Sin3a HDAC corepressor complex cause HLHS in conjunction with 
mutations in Pcdha9 (H. Yagi et al., 2018).  Mice with mutations in Brg1, part of the BAF 
chromatin remodeling complex, have a variety of heart defects as well as dysregulated expression 
of multiple cardiac genes including Nppa, Tbx5, and Bmp10 (Takeuchi et al., 2011).  Finally, 
knockdown of zebrafish and Xenopus orthologs of the DNA methyl transferases DNMT1 and 
DNMT3B result in abnormal heart jogging and heterotaxy (L. Wang et al., 2017). 
Considering these factors, the aim of this portion of the study was to determine if CHD 
patients have an enrichment of any particular type of variants or in any particular class of gene. 
2.2 Materials and Methods 
2.2.1 Study Design and Objectives 
This research was undertaken as part of a study titled “Analysis of the Genetic Basis of 
Congenital Heart Disease” (Pitt Protocol STUDY19030229) with the primary goal of investigating 
whether ciliary dysfunction plays a role in CHD. For this study, 1500 CHD patients aged 0 to 65 
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including 500 with heterotaxy were to be recruited from the University of Pittsburgh Medical 
Center and the Children’s National Medical Center in Washington D.C.  Patients without heart 
disease but with confirmed or suspected PCD or symptoms consistent with a ciliopathy were also 
recruited.  Some relatives, both affected and unaffected, of patients recruited at the University of 
Pittsburgh Medical Center were also recruited.  Additionally, specimens from 29 patients 
undergoing heart transplant for hypoplastic left heart syndrome were obtained from the University 
of California at San Diego and a small number of samples were obtained from the University of 
Minnesota.  For patients recruited at the University of Pittsburgh a detailed medical history 
including the nature of the structural heart defects, presence of extracardiac defects, and family 
history were obtained through patient questionnaires administered by a clinical research 
coordinator and review of medical records by a cardiac pathologist.  One or more cardiac 
“phenotype constellations” were then assigned to each patient by the cardiac pathologist based on 
detailed review of medical records. 
2.2.2 Characteristics of the Study Cohort 
To date over 800 participants including probands and family members both affected and 
unaffected have been recruited for this study of whom good whole exome sequencing data has 
been obtained for 651.  For the purposes of this project, only 586 sequenced probands with 
structural heart defects were included while relatives of probands were excluded regardless of 
CHD status.  The study population included 362 males and 224 females (ratio 1.6161) of whom 
the vast majority (505) identified as White.  These patients had a wide range of structural heart 
defects ranging from relatively simple isolated septal defects or bicuspid aortic valve to highly 
complex defects involving multiple structures (Appendix Table 1).  It should be noted that only 
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the patients recruited from Children’s Hospital of Pittsburgh received the questionnaire and had 
their records reviewed by a cardiac pathologist and that not all patient medical records had been 
reviewed at the time of writing this dissertation.  For the non-Children’s patients, phenotypes were 
assigned based only on the information that was available. 
2.2.3 Whole Exome Sequencing and Data Cleaning 
Whole exome sequencing was performed using the Illumina HiSeq2000 platform 
(Illumina, San Diego, CA) and Agilent SureSelect V4 and V5 exon capture kits (Agilent 
Technologies, Santa Clara, CA) at 100x coverage.  Alignment of Fastq files to hg19 was carried 
out using BWA 0.5.9-r16 (H. Li & Durbin, 2009).  For quality assessment, FREEMIX (Jun et al., 
2012) was used to check for contamination and SAMtools 1.9. (H. Li et al., 2009) was used to 
check for proper alignment.  Single nucleotide and insertion deletion variant calling, genotyping, 
and filtering of BAM files at population level utilizing the GATK 4.0.8.1 best practices pipeline 
(DePristo et al., 2011; Van der Auwera et al., 2013).  Bcftools 1.9 was used for additional site-
specific filtering such that SNPs within 10 base pairs of an indel, clusters of indels within 5 base 
pairs of each other, sites with missing rate (genotype quality < 20) greater than 10%, sites with a 
Hardy Weinberg p-value of less than 10e-6, and sites less available for sequencing and mapping 
based on ExAC (Lek et al., 2016) are excluded.  Variant annotation was carried out using Ensembl 
(Hunt et al., 2018) VEP26 with predicted transcript and protein changes in the Ensembl known 
gene table (hg19 accessed 24 March 2019), allele frequency in GnomAD (Karczewski et al., 2019), 
and predicted deleteriousness based on Combined Annotation-Dependent Depletion (CADD) 
score (Kircher et al., 2014). 
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Tab-delimited .txt files were generated with additional filters applied such that calls with 
genome quality < 20 and depth < 20 as well as variants with a GnomAD (version r2.1.1) allele 
frequency > 0.01, a CADD score < 10, or those that were present in > 20% of our samples were 
excluded.  Patient information including unique identifier, race, sex, and cardiac defects were 
added.  Because demographic information was not available for some of the non-Pitt samples, this 
information was calculated based on principal component analysis (PCA) of the exome data for 
all patients.  Additional annotations from ClinVar (Landrum et al., 2016) (v.20190422), dbNSFP 
(X. Liu, Wu, Li, & Boerwinkle, 2016) (v3.5a for hg19) and additional damage metric scores were 
downloaded and integrated.  Annotations from the Human Gene Mutation Database (HGMD) 
(Stenson et al., 2014) v.2019.3 were added manually using the batch search feature.  The 
phenotypes associated with variants curated in ClinVar and HGMD were later used as part of the 
data analysis. 
2.2.4 Gene Lists 
Several lists of genes were used to prioritize candidate genes.  The CHD100 list is a set of 
100 genes that have been identified to cause congenital heart defects in mice though mutagenesis 
screens carried out in the Lo Lab (Y. Li et al., 2015 and unpbulished data).  The CHD-ome list is 
a collection of genes that have been associated with congenital heart defects in humans, mice, or 
other model organisms.  This list includes genes from the CHD100 as well as genes identified to 
cause heart defects in human from two large studies (Jin et al., 2017; Sifrim et al., 2016), a set of 
genes associated with heart development generated though gene ontology (GO) search on the 
Mouse Genome Informatics database (Eppig et al., 2017) carried out by a study collaborator, and 
extensive literature review.  It should be noted that not all CHD-ome genes have been reported as 
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causing heart defects in the literature, particularly some of those obtained from the GO search, and 
that some associations may be dubious. 
The Ciliome gene list is a set of genes that have been associated with ciliogenesis, cilia 
function, or cilia-mediated signaling.  This list was compiled from multiple sources including an 
ongoing mouse mutagenesis study being carried out in the Lo Lab, the LoFullCiliome list of cilia-
associated genes generated through a past literature search, a list of 40 genes known to cause 
primary ciliary dyskinesia (Zariwala, Knowles, & Leigh, 2007) the Syscilia list of cilia-associated 
genes (van Dam, Wheway, Slaats, Huynen, & Giles, 2013), and more recent literature searches. 
For this dissertation, attention will be paid to the CHD-ome and Ciliome as a whole plus 
the CHD100 subset within the CHD-ome.  The CHD-ome consists of 1405 genes and loci with the 
CHD100 nested completely within it while the Ciliome list consists of 1280 genes.  Figure 1, 
generated using Venny (Oliveros, 2007-2015), illustrates the degree of overlap.  There are 277 
genes in common between the CHD-ome and Ciliome with 65 of them also being CHD100 genes 
while 35 CHD-ome genes are in the CHD100 but not the Ciliome. 
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Figure 1 Overlap of gene sets used in this dissertation 
2.2.5 Control Cohort 
For a control cohort, datasets were downloaded from the UK10K consortium (The UK10K 
Consortium et al., 2015).  This dataset comprises three different study populations; whole exome 
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data from ∼3,000 participants in a study on schizophrenia and autism spectrum disorder, whole 
exome data from ∼1,000 individuals from the Severe Childhood Onset Obesity Project (SCOOP) 
as well as obese adults from several population cohorts, and whole genome data from the Avon 
Longitudinal Study of Parents and Children (ALSPAC).  For this dissertation, the SCOOP/obesity 
dataset, henceforth referred to as SCOOP, was used for a control population.  The VCF files for 
the SCOOP cohort and our patient cohort, henceforth referred to as CHD, were combined and 
processed as a single dataset to ensure that calls were over the same intervals and that the data was 
all identically filtered. 
2.2.6  “Pathogenic” and “Highly Damaging” Variants 
Pathogenic variants were defined as those being curated as “Likely pathogenic” or 
“Pathogenic” by ClinVar and as “DM” (Disease-associated mutation) by HGMD.  As ClinVar is 
a freely accessible database, variant data including “clinical significance” which provides a 
pathogenicity rating as well as associated phenotypes was downloaded from the database and 
incorporated into the spreadsheets.  HGMD is a subscription-based service with a substantial fee 
and the database files were not available for download.  Therefore, it was necessary to manually 
look up variants by hg19 coordinates using the ‘batch search’ feature which can look up 500 
variants at a time. 
Highly damaging variants were defined as those with a CADD score ≥ 30 corresponding 
to the top 0.1% most damaging variants.  In short, CADD scores are generated by contrasting the 
annotations of fixed or nearly fixed alleles with simulated variants (Kircher et al., 2014; Rentzsch, 
Witten, Cooper, Shendure, & Kircher, 2019).  While fixed alleles will be depleted for variants with 
a severely negative impact on organismal fitness by natural selection, this will not occur in 
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simulated variants.  Scores are generated through a machine learning algorithm that integrates 
information from multiple annotations.  CADD scores are represented in a phred-like log10 scaled 
C-score based on the C-score rank of each individual variant relative to the 8.6 billion possible 
variants such that C-scores ≥ 10 represent the top 10% of damaging variants, scores ≥ 20 represent 
the top 1%, and so forth.  Nonsense variants tend to have the highest C-scores followed by 
missense and canonical splice variants.  The advantages of CADD include the ability to merge 
information from multiple annotations into a single value while also being able to accommodate 
expansions to these annotations as well as combining the generality of conservation metrics with 
the specificity of functional metrics.  The main weaknesses of CADD scores include the inability 
to account for differences in local mutations rates and related phenomena, an inability to reflect 
the strength with which a site is being selected, difficulty with intergenic sites, and an inability to 
directly correlate CADD score with the likelihood that a variant is truly pathogenic (Kircher et al., 
2014; Rentzsch et al., 2019) 
To better identify and categorize curated phenotype terms that were related to the 
cardiovascular system, the International Classification of Diseases (ICD)-10 version 2016 code 
was obtained either directly from the WHO website ("ICD-10-CM the Complete Official 
Codebook," 2015), or from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database 
(Kanehisa, Sato, Furumichi, Morishima, & Tanabe, 2019), or Orphanet (Pavan et al., 2017).  
Google searches and Wikipedia were also occasionally used for terms whose codes could not be 
found elsewhere.  Cardiovascular system phenotypes received codes I00-I99 (Diseases of the 
Circulatory System) or Q20-Q28 (Congenital Malformations of the Circulatory System).  These 
were further subdivided into structural CHD terms which encompassed Q20-Q28 and a few from 
I00-I99, and non-structural terms which encompassed the bulk of I00-I99. 
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2.2.7 Data Analysis and Statistics 
Summary statistics were calculated in Microsoft Excel and a two-sample t-test assuming 
unequal variance was carried out using the Analysis ToolPak add-in to compare the mean number 
of calls between cases and controls.  Allele counts were obtained for each cohort at the variant, 
gene, and phenotype level and for overall number of alleles, number of highly damaging alleles, 
and number of pathogenic alleles.  Allele counts were then normalized to number of associated 
alleles per 100,000 alleles in the population.  Fold change (FC) was then calculated based on 
normalized allele counts and relative to the SCOOP cohort such that FC > 1 indicates more alleles 
in the CHD cases and FC < −1 indicates more alleles in the SCOOP controls.   
A binomial test was carried out to evaluate the probability of observing at least as many 
alleles as were present in the CHD cases by chance assuming the allele frequency in the SCOOP 
controls is representative of the population frequency.  This test was done at the variant, gene and 
phenotype level.  The test was carried out in Microsoft Excel (2016) using the binom.dist function 
in the form 1-binom.dist() to produce the upper tail probability.  The arguments for the binom.dist 
function are as follows. 
1) Number_s is the number of successes defined as the number of associated alleles in the 
CHD cases 
2) Trial is the number of trials defined as the number of possible associated alleles in the 
CHD cases equivalent to the number of samples times two alleles per locus times the 
number of associated variants. 
3) Probability_s is the probability of success defined as the allele frequency of associated 
alleles in the SCOOP controls. 
4) Cumulative when set to ‘TRUE performs the cumulative distribution function. 
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The Benjamini-Hochberg false discovery rate (BH FDR) was then calculated in Excel 
using the following method. 
1) Raw p-values as calculated by the binomial test were ordered from smallest to 
largest and ranked giving equal p-values the same rank 
2) The Benjamini-Hochberg critical value was calculated using the formula (i/m)Q 
where i is the rank of the raw p-value, m is the total number of tests, and Q is the 
desired false discovery rate equal to 0.05 in this case. 
Odds ratios, defined as the odds of having a minor allele in the CHD cases over the odds 
of having a minor allele in the SCOOP controls where “minor allele” refers to alleles in any variant 
present in the filtered dataset, were calculated at the variant, gene, and phenotype level using 
Microsoft Excel.  Fisher’s exact test and Benjamini-Hochberg FDR were then calculated using the 
R statistical package (R Development Core Team, 2013) and a slightly modified version of a freely 
available script found on an online discussion forum (Appendix D). 
2.2.8 Enrichment Analysis 
Gene lists were made of genes in each category (overall, pathogenic, highly damaging) 
with the largest absolute fold change (Appendix C.1) These lists were run through functional 
enrichment analysis on ToppGene (J. Chen, Bardes, Aronow, & Jegga, 2009) and Variant Effects 
Analysis on Ingenuity Pathway Analysis (IPA) (Kramer, Green, Pollard, & Tugendreich, 2014).  
ToppGene outputs lists of significant terms divided into multiple categories derived from various 
sources and calculates a p-values and a Benjamini-Hochberg false discovery rate (q-value) with 
the significance cutoff set at 0.05.  IPA Variant Effects Analysis produces a variety of different 
forms of data including a list of  “Canonical pathways” and a list of “Diseases and Bio Functions” 
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terms that are significantly enriched in the given gene set with significance reported in p-values.  
Lists of selected options and parameters for ToppGene and IPA analyses can be found in 
Appendixes C.2 and C.3, respectively.  Additionally, IPA has a “comparison analysis” feature that 
allows direct comparison of results from multiple analyses such that the analyses for CHD datasets 
(positive FC) could be compared to the lists from the SCOOP dataset (negative fold change).  For 
the comparison analysis IPA converts the p-values of significant terms to -log10(p-values).  
‘Deltas’ were calculated as the difference in –log10(p-value) with positive deltas indicating more 
significance in the CHD cases and negative deltas indicating more significance in the SCOOP 
controls. 
2.3 Results 
2.3.1 Summary Statistics 
Summary statistics for the CHD and SCOOP cohorts can be found in Table 1.  Overall 
there were a combined 36,913 variants in 12,711 genes between the two datasets with a great deal 
of overlap as 35,327 (95.55%) variants were present in both datasets leaving only 181 variants 
present in the CHD cases alone and 1405 variants present in the SCOOP controls alone.  It should 
be noted that non-CHD probands were only removed after processing and filtering and the degree 
of overlap between the CHD and SCOOP datasets was even greater in the original version that 
included data from all 651 study participants who have been sequenced with 199 and 299 variants 
unique to the CHD and SCOOP cohorts respectively. 
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The CHD cases consisted of 586 samples while the SCOOP controls consisted of 982 
samples, thus the total number of variants and calls is larger in the SCOOP controls.  While the 
average number of calls overall and for damaging and pathogenic calls is higher in the CHD cases, 
it should be noted that the cohorts are not stratified by race as the racial makeup of the SCOOP 
controls was not immediately available.  In looking at the CHD cases alone and stratifying by race 
as determined by PCA, Africans had far more calls than Whites while Asians had fewer calls than 
Whites and mixed-race patients had numbers intermediate between their component races 
(Appendix Figure 1).  CHD cases had a significantly higher mean number of calls overall and in 
calls in CHD-ome and Ciliome genes (Table 1).  Cases also had significantly more calls in 
damaging variants overall compared to controls while the excess in damaging calls in CHD-ome 
and Ciliome genes in cases compared to controls was trending toward significance.  The mean 
number of calls in variants curated at pathogenic were not significantly different between cases 
and controls overall or when restricting to CHD-ome or Ciliome genes.  Though all samples in 
both cases and controls had at least two calls in highly damaging variants, there were many case 
and control samples with zero or one calls in curated pathogenic variants. (Table 1). 
Table 1: Summary Statistics 
 
Overall Highly Damaging Pathogenic 
Variants CHD SCOOP CHD SCOOP CHD SCOOP 
Total 35508 36732 3515 3683 298 309 
Calls CHD SCOOP CHD SCOOP CHD SCOOP 
Total 125728 181074 10807 16484 906 1451 
Average per sample 214.5529 184.3931 18.4420 16.7862 1.5461 1.4776 
p = 6.74E-09 p = 1.11E-08 p = 0.2898 
CHD-ome 22.8481 19.8737 1.5375 1.4165 0.2389 0.2108 
p = 9.08E-08 p = 0.0578 p = 0.2694 
Ciliome 21.1297 18.2953 1.7918 1.6487 0.2201 0.2016 
p = 2.14E-06 p = 0.0526 p = 0.4587 
COSMIC CGC 10.3959 9.3391 0.6519 0.5448 0.0546 0.0550 
p = 8.72E-06 p == 0.0122 p = 0.9747 
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Minimum 53 79 5 3 0 0 
Maximum 804 962 46 48 7 6 
Standard Deviation 113.9552 65.2577 5.9050 4.7690 1.2885 1.1507 
Variance 12985.7827 4258.5691 34.8693 22.7432 1.6603 1.3242 
Samples with 0 calls 0 0 0 0 138 200 
Samples with 1 call 0 0 0 0 180 359 
Samples with 2+ calls 586 982 586 982 268 423 
p-values are the 2-tailed p-values for the 2-sample t-test assuming unequal variance 
2.3.2 Enrichment for Rare Variants 
Rare variants were those with a GnomAD allele frequency ≤ 0.01. Basic filtering had 
removed variants with a GnomAD allele frequency > 0.01 and with a CADD score < 10 leaving 
only rare (GnomAD allele frequency ≤ 0.01) damaging (CADD scores ≥ 10) variants.  Overall, 
there were 7029 genes with a normalized allele count FC > 1 including 19 genes with variants only 
present in CHD cases while 5682 genes had an FC < −1 including 159 with variants present only 
in SCOOP controls.  Of the genes with FC > 1, 37 were CHD100 genes, 539 were CHD-ome genes 
including two (AGTR2, NSHDL) with variants only present in CHD cases, and 504 Ciliome genes.  
Though a larger number of CHD100 genes had negative fold changes than positive fold changes 
(50 versus 37), fewer CHD-ome (468) and Ciliome (414) genes had negative FC than positive.  
However, all three gene sets had more genes that had variants present in SCOOP controls only 
than genes with variants present in CHD cases only.  Of the 87 CHD100 genes present in the 
dataset, eight had FC ≥ 2 and none had FC ≥ 5 while 143/1007 CHD-ome genes and 133/918 
Ciliome genes had FC ≥ 2.  There were 20 CHD-ome and 16 Ciliome genes with FC ≥ 5. 
Of the 1047 genes with an odds ratio greater than 1 and significant raw p-value, only 5 
(SMAD6, CCDC39, C50RF42, MEGF8, and EVL) were CHD100 genes, but none remained 
significant after adjustment.  For the CHD-ome 96 genes had significant p-values before 
Table 1 Continued 
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adjustment, but only five (PEPD, NCOR2, ABCC3, CASQ2, G6PD) remained significant after 
adjustment.  Of the 1223 genes with a significant excess of alleles in CHD cases overall, there 
were six CHD100 genes (SMAD6, CCDC39, C5ORF42, MEGF8, EVL, HECTD1) and 101 CHD-
ome genes with 21 of the latter group also being Ciliome genes (Appendix Table 2). 
2.3.2.1 ToppGene Analysis 
ToppGene enrichment analysis of the genes with FC ≥ 5 plus those with variants only in 
CHD cases returned few results, though there were multiple terms related to both G-protein-
coupled receptors and olfaction. (Appendix table 3) “GPCR downstream signaling” also came up 
as a significant term when looking at the set of genes with homozygous calls only in CHD cases.  
Among the genes associated with the GPCR-related terms were four CHD-ome genes (ACKR3, 
APLNR, HTR2B, S1PR1) of which ACKR3 has been reported as a candidate gene accounting for 
the TGA seen in patients with dup(2)(q37.3) (Costain et al., 2016).  A corresponding analysis of 
the genes with FC ≤ −5 plus those with variants present only in SCOOP controls did not produce 
any significant results. 
2.3.2.2 Ingenuity Pathway Analysis 
For IPA analyses, the largest –log10(p-value) tended to be cancer terms for both sets as 
were the terms with the largest deltas.  Though there were few bona fide structural CHD terms, 
significant terms related to the cardiovascular system tended to have positive deltas and 
encompassed a number of CHD-ome genes including AGTR2, CASQ2, CFLAR, DAG1, EGFR, 
G6PD, HTR2B, MYLK2, S1PR1, and ZIC3.  Additionally, there were a number of terms related to 
apoptosis (Appendix table 4). 
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2.3.2.3 Analysis by curated phenotype 
At the phenotype level, among the 13 phenotype terms with significant odds ratios after 
Benjamini-Hochberg FDR adjustment were four terms related to cardiomyopathy and one term 
related to catacholaminergic ventricular tachycardia.  Among the phenotype terms with a 
significant excess of alleles in CHD cases were two terms for different forms of Loeys-Dietz 
syndrome, Atrioventricular septal defect 2, left ventricular noncompaction, 2 terms for nonspecific 
heart defects and the very general term ‘cardiovascular phenotype’.  Additionally, ‘Hypoplastic 
left heart syndrome 2” (BH FDR = 0.0617) was close to significance.  Finally, there were six 
significant cilia-related phenotypes (Appendix Table 5) 
2.3.3 Enrichment for Rare Pathogenic Variants 
Pathogenic variants were defined as those being curated as “(likely) pathogenic” by 
ClinVar and “DM” by HGMD.  Only 231 genes had pathogenic variants in at least one of the 
cohorts, though this included 5 CHD100 genes, 35 CHD-ome genes, and 32 Ciliome genes of 
which zero, seven, and four had allele FC ≥ 2, respectively.  Only six genes had significant odds 
ratios before adjustment, two of which had OR < 1, and no genes remained significant after 
adjustment.  However, of the four genes with significant odds ratios > 1, three (G6PD, ZIC3, 
TTC7A) are CHD-ome genes.  Those three genes plus another CHD-ome gene, AIP, were among 
the eight genes with a significant excess of alleles in CHD cases after FDR adjustment (Table 2).  
The association between ZIC3 and heterotaxy spectrum CHD has been well documented 
(Andersen et al., 2014; Azhar & Ware, 2016; Cowan et al., 2014; De Luca et al., 2010; Deng, Xia, 
& Deng, 2015; Fahed et al., 2013; Finsterer, Stollberger, & Towbin, 2017; Hilger et al., 2015; 
Lalani & Belmont, 2014; Lebo & Baxter, 2014; A. H. Li et al., 2019; McCulley & Black, 2012; 
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Pierpont et al., 2007; Prendiville et al., 2014; Richards & Garg, 2010; Sutherland & Ware, 2009; 
Wessels & Willems, 2010; Xie et al., 2017).  Mutation in the mouse ortholog of Tetratricopeptide 
repeat domain 7A (TTC7A) gene (Ttc7) have been associated with an enlarged heart or decreased 
heart weight (Beamer, Pelsue, Shultz, Sundberg, & Barker, 1995; Takabayashi & Katoh, 2005).  
Male mice hemizygous for a G6pd (Glucose-6-phosphate dehydrogenase) mutation have 
developmental arrest with distended hearts by E7.5 while heterozygous females are either normal 
or die by E12.5 with an abnormal placenta depending on the parental origin of the mutant X 
chromosome (Longo et al., 2002). 
Table 2: Genes with significant enrichments for pathogenic variants 
 
Gene List Allele Count Odds Ratio 
Gene CHD100 CHD-ome Ciliome FC p-value BH FDR OR p-value BH FDR 
G6PD FALSE TRUE FALSE 14.4020 4.86E-11 5.61E-09 16.9706 0.0004 0.0809 
NOBOX FALSE FALSE FALSE 5.7608 5.81E-08 4.47E-06 6.7907 0.0009 0.0993 
ZIC3 FALSE TRUE TRUE 5.0407 3.5E-05 0.0020 5.9455 0.0160 0.9042 
TTC7A FALSE TRUE FALSE 2.3403 0.0004 0.0170 2.7564 0.0234 1.0000 
AIP FALSE TRUE FALSE 5.7608 0.0004 0.0177 6.7807 0.0669 1.0000 
ABCB4 FALSE FALSE FALSE 5.7608 0.0004 0.0177 6.7807 0.0669 1.0000 
CLCN1 FALSE FALSE FALSE 5.7608 0.0004 0.0177 6.7807 0.0669 1.0000 
CDHR1 FALSE FALSE FALSE 2.8804 0.0008 0.0269 3.3969 0.0671 1.0000 
Gene List indicates if the gene is present in either of the 3 focus gene lists.  For allele count, FC is based on 
normalized allele counts and the p-value is the upper tail probability of the binomial test.  For OR, the p-value 
was obtained from Fisher’s exact test 
 
2.3.3.1 ToppGene Analysis 
ToppGene analysis of the set of genes with pathogenic variants with allele FC ≥ 2 or with 
variants only present in CHD cases produced a number of significant terms related to  structural 
CHD that were not significant when carrying out a ToppGene analysis of the set of genes with 
pathogenic variants with allele FC ≤ −2 or with variants present only in SCOOP controls  (Table 
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3).  However, most of the significant structural CHD terms (BH FDR = 2.22E-03) were associated 
with ZIC3 alone.  Supporting the link between cilia and CHD, the term “9+0 nonmotile cilium” 
(BH FDR = 3.36E-05) was significant only in the enriched set.  Additionally, a number of terms 
related to pituitary adenoma, all associated with AIP (BH FDR = 2.22E-03) and multiple muscular 
dystrophy-related terms were also significant only in the enriched set.  The terms with the smallest 
Benjamini-Hochberg q-values encompassed four CHD-ome genes (AIP, C21ORF2, FKRP, ZIC3) 
and three ciliome genes (C21ORF2, FAM161A, ZIC3).  Mutations in AIP have been associated 
with DORV and other CHD in mice (B. C. Lin et al., 2007; Obler, Juraszek, Smoot, & Natowicz, 
2008).  In a mouse model of limb-girdle muscular dystrophy related to FKRP mutations, 
P144Lneo- mice were found to have left ventricular hypertrophy and dysfunction (Q. Yu et al., 
2018).  C21ORF2 (CFAP410) was reported to be a candidate CHD gene in patients with 
del(21)(q22.13-q22.3) in a chromosome microarray study that mentioned previous evidence based 
on a mouse knockout (Shanshen, Rosenberg, & Van Bergen, 2018), however the article did not 
provide a citation or source for the mouse knockout and no corroborating evidence could be found. 
Table 3: ToppGene analysis of genes enriched for pathogenic variants 
Name Genes in query p-value q-value FDR 
B&H 
Becker muscular dystrophy 4 (ANO5, CLCN1, 
FKRP, ALDH7A1) 
1.26E-06 5.14E-04 
9+0 non-motile cilium 4 (CERKL, FAM161A, 
CDHR1, CFAP410) 
8.36E-05 7.40E-03 
Photoreceptor cell cilium 4 (CERKL, FAM161A, 
CDHR1, CFAP410) 
7.88E-05 7.40E-03 
Congenital heart defects, multiple types, 1, 
x-linked 
1 (ZIC3) 2.22E-03 1.30E-02 
Heterotaxy, visceral, 1, x-linked 1 (ZIC3) 2.22E-03 1.30E-02 
Heterotaxy, visceral, 1, x-linked; htx1 1 (ZIC3) 2.22E-03 1.30E-02 
Heterotaxy, visceral, X-linked 1 (ZIC3) 2.22E-03 1.30E-02 
Multiple ventricular septal defects 1 (ZIC3) 2.22E-03 1.30E-02 
VACTERL association, x-linked, with or 
without hydrocephalus 
1 (ZIC3) 2.22E-03 1.30E-02 
Obscure African cardiomyopathy 1 (CLCN1) 2.22E-03 1.30E-02 
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Acromegaly due to pituitary adenoma 1 1 (AIP) 2.22E-03 1.30E-02 
Adenocarcinoma of liver 1 (CYP24A1) 2.22E-03 1.30E-02 
Pituitary adenoma 1, multiple types 1 (AIP) 2.22E-03 1.30E-02 
Pituitary adenoma, prolactin-secreting 1 (AIP) 2.22E-03 1.30E-02 
Prolactinoma, familial 1 (AIP) 2.22E-03 1.30E-02 
 
2.3.3.2 Ingenuity Pathway Analysis 
There were 24 significant cardiovascular system-related terms with positive deltas after 
IPA comparison analysis of the sets of genes with allele FC ≥ 2 and FC ≤ −2 for pathogenic 
variants, all of which were significant only in CHD cases (Table 4).  These terms encompassed 11 
genes of which four (AIP, FKRP, G6PD, ZIC3) are CHD-ome genes with ZIC3 also being a 
ciliome gene.  Additionally, IPA identified several significant disease and function networks of 
which the top two were “Cardiovascular System Development and Function, Cellular Assembly 
and Organization, Cellular Development” (Network 1) with 10 of 35 network molecules being in 
the enriched gene set and “Cardiovascular Disease, Inflammatory Response, Organismal Injury 
and Abnormalities” (Network 2) with 9 of 35 network molecules being in the enriched gene set 
(Figure 2).  In the figure Network 1 connections are shown in black while Network 2 connections 
are shown in pink with molecules in the query gene set being shaded gray.  There is a substantial 
amount of overlap between these two networks with a large number of connections appearing to 
converge on TP53, CCND1, TGFB1, and TGFBR2.  Though none of these genes were in the query 
list, only CCND1 is not a CHD-ome gene.  TGFB1 is associated with vascular anomalies in 
humans and valve defects in mice (Mattassi et al., 2018; D. Srivastava & Olson, 2000) while 
TGFBR2 has been associated with a variety of phenotypes involving the great vessels as well as 
heterotaxy and VSD (Azhar & Ware, 2016; Deng et al., 2015; LaHaye et al., 2014; Lalani & 
Belmont, 2014; Lebo & Baxter, 2014; C. J. Lin et al., 2012; Mattassi et al., 2018; Neeb, Lajiness, 
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Bolanis, & Conway, 2013; Pierpont et al., 2018; Richards & Garg, 2010; Zheng et al., 2018).  Mice 
with a TP53 knock-in allele (p5325,26,53,54/+) have atrioventricular cushion and outflow tract defects 
caused by inappropriately triggering cell cycle arrest or apoptosis (Van Nostrand et al., 2014).  
Overexpression of Ccnd1, encoding Cyclin D1, in mice has been shown to result in abnormal 
multinucleate cardiomyocytes (Soonpaa et al., 1997).  Pathogenic mutations to genes in the query 
list could thus alter the expression or transcriptional activity of these central genes leading to 
altered regulation of growth, proliferation, and apoptosis during heart development. 
Table 4: IPA analysis of genes enriched for pathogenic alleles 
Diseases and Bio Functions GS5 GS5b GS5b Genes 
Inflammation of vessel 4.251281 4.21414 ABCB4, ADA2, PCSK9 
Cardiac allograft vasculopathy 2.800796 2.788561 PCSK9 
Inferior vena cava thrombosis 2.800796 2.788561 VWF 
Quantity of trabecular myocardium 2.800796 2.788561 ZIC3 
VACTERL with hydrocephalus, X-linked 2.800796 2.788561 ZIC3 
X-linked multiple types congenital heart defects 
type 1 
2.800796 2.788561 ZIC3 
Inflammation of artery 2.738459 2.714131 ADA2, PCSK9 
Closure of ductus venosus 2.500099 2.487875 AIP 
Fragmentation of cardiac muscle 2.500099 2.487875 TRIM63 
Persistence of ductus venosus 2.500099 2.487875 AIP 
Structural integrity of m-bands 2.500099 2.487875 TRIM63 
Structural integrity of myosin filaments 2.500099 2.487875 TRIM63 
Rheumatic valvular heart disease 2.324342 2.312127 VWF 
Degeneration of cardiomyocytes 1.803798 1.791651 HADHA 
Abnormal morphology of myocardium 1.797615 1.774342 HADHA, TRIM63 
Abnormal morphology of dilated vasculature 1.762738 1.750602 G6PD 
Outgrowth of blood vessel 1.601675 1.589588 G6PD 
Abnormal morphology of dilated heart 1.551188 1.53912 G6PD 
Familial congenital heart disease 1.547929 1.525214 AIP, ZIC3 
Contractility of cardiomyocytes 1.506096 1.494047 TRIM63 
Dextrocardia 1.394146 1.382156 ZIC3 
Primary cardiomyopathy 1.39616 1.373886 FKRP, TRIM63 
Morphology of cardiovascular system 1.415838 1.369887 FKRP, G6PD, HADHA, TRIM63, 
VWF 
Terms related to the cardiovascular system that were significant only in the CHD gene sets. GS5 and GS5b are 





Figure 2: IPA network of genes enriched for alleles in pathogenic variants 
2.3.3.3 Analysis by curated phenotype 
At the phenotype level 32 phenotypes had significant raw p-values for odds ratio, but none 
remained significant after FDR adjustment, however 19 had a significant excess of pathogenic 
alleles in CHD cases after FDR adjustment.  There were only two significant structural CHD terms 
(Table 5), “Cardiac malformation” and “Congenital heart defects 1 nonsyndromic 1”, plus one 
cilia-related term that can include CHD, “Heterotaxy visceral X-linked”,  and two terms related to 
VATER/VACTERL association, all with a BH FDR  of 0.0059 and associated with ZIC3 alone.  
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The aforementioned two terms were the only terms out of 10 structural CHD terms to be 
significant, though “Noncompaction, left ventricular” had a significant excess of pathogenic alleles 
before adjustment and 8 of 10 terms had OR > 1.  In addition to the 10 structural CHD terms, there 
were 26 terms for non-structural heart disease (cardiomyopathies, channelopathies), though none 
were significant.  Overall, the two terms with the most significant excess of pathogenic alleles in 
CHD cases both related to glucose-6-phosphate dehydrogenase (G6PD) deficiency) (BH FDR = 
2.86E-08).  In fact, five of the 19 significant phenotypes related to G6PD with three additional 
phenotypes related to ovarian failure and associated with NOBOX. 
Table 5: Significant phenotypes with pathogenic alleles 
 
Allele Count Odds Ratio 
Phenotype (genes) FC p-value BH FDR OR p-value BH FDR 
Glucose-6-phosphate dehydrogenase 
deficiency (G6PD) 
14.4020 4.86E-11 2.86E-08 16.8251 0.0004 0.1880 
Cardiac malformation (ZIC3) 5.0407 3.5E-05 0.0059 5.8944 0.0160 0.8129 
Congenital heart defects 1, nonsyndromic, 
1 (ZIC3) 
5.0407 3.5E-05 0.0059 5.8944 0.0160 0.8129 
Heterotaxy, visceral, X-linked (ZIC3) 5..0407 3.50E-05 0.0059 5.8944 0.0160 0.8129 
VACTERL association with hydrocephaly, X-
linked (ZIC3) 
5..0407 3.50E-05 0.0059 5.8944 0.0160 0.8129 
VATER/VACTERL association (ZIC3) 5..0407 3.50E-05 0.0059 5.8944 0.0160 0.8129 
Noncompaction, left ventricular (HADHA) 2.8804 0.0228 0.9559 3.3556 0.5598 1.0000 
For allele count, FC is based on normalized allele counts and the p-value is the upper tail probability of the 
binomial test.  For OR, the p-value was obtained from Fisher’s exact test 
2.3.4 Enrichment for Rare Highly Damaging Variants 
Highly damaging variants were defined as those with a CADD score ≥ 30.  Of the 2864 
genes with highly damaging variants, 32 were CHD100 genes, 241 were CHD-ome genes, and 
258 were Ciliome genes.  There were 11 genes with highly damaging variants only in CHD cases, 
though none were CHD-ome genes and only one, DNALI1, is a Ciliome gene.  Of the 32 CHD100 
genes with highly damaging variants, 22 had allele count FC ≥ 2 compared to only seven with FC 
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≤ −2.  Additionally, 36/241 CHD-ome and 183/258 Ciliome genes with highly damaging variants 
had FC ≥ 2.  Though 64 genes had significant odds ratios before adjustment, none remained 
significant after FDR adjustment.  Of the 93 genes with significantly more highly damaging alleles 
in CHD cases, four (CCDC39, NRG1, SMAD6, TRIM32) are CHD-ome genes with CCDC39 and 
TRIM32 also being ciliome genes (Table 6).  A further nine Ciliome genes were also significant.  
Variants in SMAD6 have been associated with primarily left-sided obstructive lesions in humans 
while causing a variety of valvular and great artery defects in mice (Andersen et al., 2014; Chaix 
et al., 2016; Fahed et al., 2013; LaHaye et al., 2014; Y. Li et al., 2015; C. J. Lin et al., 2012; X. 
Liu et al., 2017; Prendiville et al., 2014; D. Srivastava & Olson, 2000).  Nrg1 mutations in mice 
cause hypoplastic endocardial cushions and absent myocardial trabeculation (C. J. Lin et al., 2012; 
D. Srivastava & Olson, 2000).  Mutations in CCDC39 are a cause of primary ciliary dyskinesia 
with situs inversus or heterotaxy in humans while mouse mutants display AVSD or complex CHD 
with heterotaxy (Burnicka-Turek et al., 2016; Deng et al., 2015; Y. Li et al., 2015).  Variants in 
TRIM32 cause Bardet-Biedl syndrome with VSD or dextrocardia in humans (Lalani & Belmont, 
2014). 
Table 6: Genes significantly enriched for alleles in variants with CADD ≥ 30 
 
Gene List Allele Count Odds Ratio 
Gene CHD100 CHD-ome Ciliome FC p-value BH FDR OR p-value BH FDR 
CCDC39 TRUE TRUE TRUE 8.6412 5.02E-10 3.59E-07 10.2365 0.0003 0.1969 
EFCAB6 FALSE FALSE TRUE 11.5216 1.51E-08 6.17E-06 13.6083 0.0022 0.4503 
MOGAT2 FALSE FALSE TRUE 6.4809 5.41E-07 0.0001 7.6315 0.0033 0.4503 
PKD1L2 FALSE FALSE TRUE 6.4809 5.41E-07 0.0001 7.6315 0.0033 0.4503 
SMAD6 TRUE TRUE FALSE 4.3206 1.39E-06 0.0003 5.1130 0.0029 0.4503 
ACAD10 FALSE FALSE TRUE 8.6412 3.13E-06 0.0006 10.1886 0.0125 0.8685 
TRIM32 FALSE TRUE TRUE 7.2010 3.73E-05 0.0045 8.4831 0.0293 1.0000 
KIF14 FALSE FALSE TRUE 7.2010 3.73E-05 0.0045 8.4831 0.0293 1.0000 
TARS FALSE FALSE TRUE 5.0407 3.5E-05 0.0046 5.9455 0.0160 0.8685 
NRG1 FALSE TRUE FALSE 3.8405 0.0001 0.0106 4.5315 0.0240 1.0000 
DNAH1 FALSE FALSE TRUE 2.2258 0.0002 0.0160 2.6180 0.0170 0.8785 
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LRRC48 FALSE FALSE TRUE 3.2405 0.0002 0.0174 3.8248 0.0214 1.0000 
CCDC170 FALSE FALSE TRUE 5.7608 0.0004 0.0296 6.7807 0.0669 1.0000 
Gene List indicates if the gene is present in either of the 3 focus gene lists. For allele count, FC is based on 
normalized allele counts and the p-value is the upper tail probability of the binomial test.  For OR, the p-value was 
obtained from Fisher’s exact test 
 
2.3.4.1 ToppGene Analysis 
ToppGene analysis of the set of genes with a highly damaging variant allele FC ≥ 2 or with 
highly damaging variants only in CHD cases produced few results, though three terms were related 
to fibronectin and two were related to EF-hand domains (Appendix Table 6). Genes encompassed 
by these terms included eight CHD-ome genes (ARHGEF4, FLT4, MYBPC3, NRG1, RYR2, 
TRIM32, TSC2, ZFYVE16) of which two (RYR2, TRIM32) are also Ciliome genes.    ARHGEF4 
has been identified as a candidate gene accounting for the TOF seen in del(2)(q22.1) patients 
(Silversides et al., 2012).  Mutations in FLT4 have been linked to TOF and vascular anomalies in 
humans with the gene also being a candidate CHD gene for copy number variants at 5q35.3 as 
well as being associated with vascular remodeling defects in mice (Dumont et al., 1998; Mattassi 
et al., 2018; Reuter et al., 2018; Xie et al., 2017).  MYBPC3 variants have been linked to left 
ventricular noncompaction as well as atrial and ventricular septal defects (Lebo & Baxter, 2014; 
van Waning et al., 2018; Wessels & Willems, 2010).  RYR2 has also been associated with left 
ventricular noncompaction (van Waning et al., 2018).  In addition to causing tuberous sclerosis, 
TSC2 variants have been associated with left ventricular obstruction defects (Jin et al., 2017).  
Finally, ZFYVE16 mutations have been potentially associated with situs anomalies (A. H. Li et al., 
2019)  These analyses were also done with an FC ≥ 3 to reduce the number of genes, but these 
analyses produced no results in ToppGene.  Additionally, an earlier analysis that did not include 
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genes with highly damaging variants only in CHD cases produced some additional results related 
to muscle fibers in the FC ≥ 2 set. 
2.3.4.2 Ingenuity Pathway Analysis 
Ingenuity Pathway Analysis of the FC ≥ 2 (GS9 and GS9c) and FC ≥ 3 (GS9b and GS9d) 
sets both produced many terms related to the cardiovascular system, though there was virtually no 
overlap between significant terms for each set (Table 7).  Significant terms for the FC ≥ 2 set 
tended to be more general or related to cardiomyopathies or channelopathies while significant 
terms for the FC ≥ 3 set tended to be more specific with terms related to the aortic valve and 
atrioventricular cushions.  There were also a large number of significant terms related to the 
cardiovascular system for the FC ≤ −2 and FC ≤ −3 sets, but these terms had no overlap with the 
positive FC sets.  The cardiovascular system-related terms with positive deltas encompassed 39 
genes of which 14 (ABI1, BCAR1, DTNA, FLT4, HAND1, HEYL, MYBPC3, NRG1, PKP2, 
PPARGC1B, RYR2, SMAD6, TNNI1, TSC2) were CHD-ome genes.  ABI1 variants have been 
associated with left ventricular outflow tract obstruction with extracardiac defects (Jin et al., 2017).  
Some cases of TOF have been linked with BCAR1 (Reuter et al., 2018).  Variants in DTNA have 
been associated with left ventricular noncompaction, persistent left superior vena cava, PDA, and 
HLHS (Lalani & Belmont, 2014; Lebo & Baxter, 2014).  HAND1 mutations have been associated 
with a variety of defects in both humans and mice including septal defects, DORV, and HLHS 
(Azhar & Ware, 2016; Firulli et al., 1998; L. Li et al., 2017; McCulley & Black, 2012; McFadden 
et al., 2005; Togi et al., 2004; Wessels & Willems, 2010).  Global deletion of Hey1 and HeyL in 
mice results in VSD as well as atrioventricular and semilunar valve defects (C. J. Lin et al., 2012).  
Pkp2-/- mice have hearts with thin-walled atria, reduced trabeculations, and blood leakage into the 
pericardium (Grossmann et al., 2004).  Ppargc1a-/-/Ppargc1b-/- double mutant mice have small 
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hearts with reduced output and arrest of mitochondrial biogenesis during the late fetal period (L. 
Lai et al., 2008).  Finally, TNNI1, which was curated as a CHD-ome gene through GO search, does 
not appear to have any structural phenotype but may be associated with sudden arrhythmic cardiac 
death or Sudden Infant Death Syndrome in humans (Shafaattalab et al., 2019).  Finally, the term 
“Apoptosis of endothelial progenitor cells”, associated with NRG1, was significant only the sets 
that included genes with highly damaging variants only in the CHD set (GS9b, GS9d).  “Apoptosis 
of microvascular endothelial cells”, associated with CD36, COMP, and ITSN1, none of which are 
CHD-ome genes, was significant in all 4 CHD genes sets but none of the SCOOP gene sets. 
Table 7: IPA analysis of genes with highly damaging variants 
Diseases and Bio Functions GS9 GS9b GS9c GS9d GS9c-9d genes 
Abnormal morphology of 
myocardium 
1.8009 0 1.7516 0 ABI1, BCAR1, HADHA, MYBPC3, 
PKP2, PPARGC1B, RYR2 
Morphology of myocardium 2.0519 0 1.9954 0 ABI1, BCAR1, HADHA, MYBPC3, 
PKP2, PPARGC1B, RYR2, TSC2 
Failure of heart 1.8435 0 1.7656 0 CACNA1S, CD36, CYP2C19, FLT4, 
GRIN3B, HAND1, MYBPC3, MYOM1, 
PDE4C, PPARGC1B, PTGIR, RASSF1, 
RYR2, XDH 
Dysfunction of heart 1.8527 0 1.7857 0 CACNA1S, CD36, DMD, DTNA, 
LAMA4, MYBPC3, PKP2, PTGIR, 
RYR2, SEMA3A, XDH 
Left heart disease 1.9157 0 1.8519 0 CACNA1S, DMD, DTNA, HAND1, 
LAMA4, MYBPC3, PKP2, PTGIR, 
RYR2, XDH 
Degeneration of heart 1.9544 0 1.9206 0 DTNA, HADHA, LAMA4, MYBPC3 
Abnormality of atrium 1.7360 0 1.6829 0 DTNA, HDAC7, LAMA4, MYBPC3, 
PDE4C, PKP2, SEMA3A, SIGMAR1 
Familial left ventricular 
noncompaction 
3.4085 0 3.3706 0 DTNA, MYBPC3, PKP2, RYR2 
Morphology of cardiovascular tissue 1.8770 0 1.8321 0 FLT4, HDAC7, NPHS2, S1PR3, 
SLC4A11, TKT 
Degeneration of cardiomyocytes 1.7388 0 1.7199 0 HADHA, LAMA4 
Morphogenesis of cardiac muscle 
tissue in heart ventricle 
2.5544 0 2.5184 0 HAND1, MYBPC3, PKP2, TNNI1 
Congenital heart defects, 
dysmorphic facial features and 
intellectual developmental disorder 
0 2.2113 0 2.1746 CDK13 
Morphogenesis of aortic valve 0 2.0594 0 1.9890 HEYL, SMAD6 
Apoptosis of endothelial progenitor 
cells 
0 1.9116 0 1.8750 NRG1 
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Expansion of atrioventricular canal 
cushion 
0 1.9116 0 1.8750 NRG1 
Expansion of ventricular compact 
zone 
0 1.9116 0 1.8750 NRG1 
Loeys-Dietz syndrome type 3 0 1.9116 0 1.8750 SMAD6 
Congenital heart disease with 
extracardiac congenital anomalies 
0 1.6634 0 1.5951 B4GALT7, CDK13 
Aortic valve disease type 2 0 1.9116 0 1.8750 SMAD6 
Bardet-Biedl syndrome type 11 0 2.2113 0 2.1746 TRIM32 
Meckel syndrome type 12 0 2.2113 0 2.1746 KIF14 
Primary ciliary dyskinesia type 14 0 1.9116 0 1.8750 CCDC39 
Terms related to the cardiovascular system that were significant only in the CHD gene sets. GS9-9d are the gene 
sets that were analyzed (Appendix C.1) and the numbers are -log10(p-values) generated from the IPA comparison 
analysis. 
 
An IPA analysis of the set of genes with highly damaging variants with homozygous calls 
only present in the CHD dataset produced a number of terms related to heart development that 
were only significant in CHD cases when compared to the set of genes with homozygous calls in 
highly damaging variants only present in SCOOP controls (Table 8).  Of the four genes associated 
with the terms in Table 8, two (DOCK6, NRG1) are CHD-ome genes while ANK3 is a ciliome 
gene.  Mutations in DOCK6 are a cause of Adams-Oliver syndrome which can include CHD 
(Hassed, Li, Mulvihill, Aston, & Palmer, 2017). 
This analysis also produced two overlapping disease and function networks related to the 
cardiovascular system (Figure 3). These were “Cardiovascular System Development and Function, 
Cell Death and Survival, Skeletal and Muscular Disorders” (Network 1, black lines) for which 16 
of 35 network molecules were in the input dataset and “Cardiovascular System Development and 
Function, Cell Death and Survival, Cell Morphology”  (Network 2, pink lines) for which one of 
two molecules in the network were in the input dataset (MRPL13).  These networks overlap and 
appear to converge on CTNNB1, CDKN1A, VEGFA, and the ERK1/2 complex.  CTNNB1 and 
VEGFA are integral components of the WNT/β-catenin and VEGF signaling pathways 
respectively and mutations in these genes are both known to cause a variety of heart defects in 
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humans and mice (Fahed et al., 2013; C. J. Lin et al., 2012; Lincoln & Garg, 2014; Neeb et al., 
2013; Prendiville et al., 2014; Reuter et al., 2018; Wessels & Willems, 2010).  Some patients with 
an ~1 Mb deletion in distal 22q11.2 that includes the ERK2 (MAPK1) gene show VSD, PTA, and 
RAA while conditional knockout in mouse neural crest causes conotruncal defects (Newbern et 
al., 2008).  Loss of ERK1 (MAPK3) has been proposed to underlie the TOF seen in patients with 
dup(16)(p11.2) (Silversides et al., 2012).  An MGI query for Cdkn1a, encoding cyclin dependent 
kinase inhibitor 1A, indicated that mutations in this gene are associated with “abnormal heart 
morphology” based on data uploaded from the International Mouse Phenotyping Consortium 
(IMPC) (Dickinson et al., 2016).  This points to a model in which homozygous damaging 
mutations in query list genes alter transcriptional activity of core genes to cause CHD. 
Table 8: IPA analysis of genes with homozygous calls in highly damaging variants only in the CHD cohort 
Diseases and Bio Functions GS11 GS11 genes 
Adams-Oliver syndrome type 2 2.6636 DOCK6 
Apoptosis of endothelial progenitor cells 2.3631 NRG1 
Adams-Oliver syndrome type 1 2.3631 DOCK6 
Expansion of atrioventricular canal cushion 2.3631 NRG1 
Expansion of ventricular compact zone 2.3631 NRG1 
Trabeculation of heart ventricle 2.1874 NRG1 
Dilated cardiomyopathy 3B 2.0629 DMD 
Differentiation of endocardial cells 1.8878 NRG1 
Apoptosis of ventricular myocytes 1.8213 NRG1 
Contraction of cardiac muscle 1.7509 ANK3, DMD 
Myocardial fibrosis 1.6678 DMD 
Terms significant only in the CHD gene set. G11 is the analyzed gene set (Appendix C.1) and the numbers are -




Figure 3: IPA network of genes with homozygous calls in highly damaging variants only in the CHD cohort 
2.3.4.3 Analysis by curated phenotype 
At the phenotype level, 40 phenotypes had a significant raw p-value for odds ratio 
including 31 with OR > 1, however none of them remained significant after FDR adjustment.  
There were 291 phenotypes with a significant excess of highly damaging alleles in CHD cases 
before adjustment which was reduced to 34 after adjustment.  The majority of the most significant 
terms were not bona fide disease terms, but rather terms indicating “susceptibility” or “association 
with”.  In fact, 12 of these terms were all associated with a single CD36 variant.  Though there 
were 35 structural CHD terms with highly damaging alleles, only 10 of these had an OR > 1 and 
there was a significant excess of highly damaging alleles in only 7 before adjustment (Table 9) 
and one, “Loeys-Dietz syndrome 3” (FDR = 0.0006) after adjustment.  This term was associated 
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with a single variant in SMAD6.  Additionally, there were two cilia-related terms with a significant 
excess of highly damaging alleles; “Bardet-Biedl syndrome 11” (FDR = 0.0074) associated with 
TRIM32 and “Ciliary dyskinesia, primary 37” (FDR = 0.0195) associated with DNAH1.  Of those 
two genes, TRIM32 is a CHD-ome gene.  Finally, ‘Zellweger syndrome’ associated with PEX6 
also showed an excess of highly damaging alleles.  Variants in PEX6 have also been associated 
with TOF (Grunert et al., 2014). 
Table 9: Phenotypes Enriched for Alleles in Highly Damaging Variants 
 
Alleles Odds Ratio 
Phenotype (genes) FC p-value BH FDR OR p-value BH FDR 
Loeys-Dietz syndrome 3 (SMAD6) 4.3206 1.39E-06 0.0006 5.0690 0.0030 0.3107 
Bardet-Biedl syndrome 11 (TRIM32) 7.2010 3.73E-05 0.0074 8.4105 0.0300 1.0000 
Ciliary dyskinesia, primary 37 (DNAH1) 2.2258 0.0002 0.0195 2.5956 0.0172 1.0000 
Zellweger syndrome (PEX6) 5.7608 0.0004 0.0380 6.7226 0.0682 1.0000 
Hypoplastic left heart syndrome 1 (HAND1) 2.8804 0.0075 0.3087 3.3596 0.2048 1.0000 
Left ventricular noncompaction 1 (DTNA)) 2.8804 0.0075 0.3087 3.3596 0.2048 1.0000 
Left ventricular noncompaction 10 (MYBPC3) 2.8804 0.0075 0.3087 3.3596 0.2048 1.0000 
Thoracic aortic aneurysm, phenotype 
modifier (ADCK4) 
1.9203 0.0112 0.3704 2.242 0.1654 1.0000 
Marfan/Thoracic aortic aneurysms and 
dissections (CBS) 
1.8003 0.0347 0.7555 2.0994 0.3080 1.0000 
Noncompaction, left ventricular (ACADVL, 
HADHA, LAMA4) 
1.9203 0.0357 0.6895 2.2358 0.4362 1.0000 
For allele count, FC is based on normalized allele counts and the p-value is the upper tail probability of the 
binomial test.  For OR, the p-value was obtained from Fisher’s exact test 
 
2.4 Discussion 
Though a variety of CHD-ome genes showed significant excesses of alleles for different 
analyses, there were several genes that seemed to pop up frequently.  As previously mentioned, 
SMAD6 and ZIC3 are already well-known causes of CHD.  SMAD6 is one of two inhibitory SMAD 
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(I-SMAD) proteins along with SMAD7 that act as inhibitors of TGF-β signaling through a variety 
of mechanisms (Reviewed in Miyazawa & Miyazono, 2017).  It acts to repress BMP signaling 
during normal development of the heart valves and outflow tract.  ZIC3 encodes a multifunctional 
zinc finger transcription factor that can interact with components of multiple developmental 
signaling pathways including Hedgehog, Wnt, Planar Cell Polarity, and TGF-β (Reviewed in 
Bellchambers & Ware, 2018). 
Mutations in C21ORF2, also known as CFAP410 (Cilia and flagella associated protein 
410), have been linked with several ciliopathy phenotypes including cone/rod dystrophy, axial 
spondylometaphyseal dysplasia, and Jeune asphyxiating thoracic dystrophy (McInerney-Leo et al., 
2017; Reiter & Leroux, 2017).  Shanshen et al. (2018) identified this gene as a CHD candidate 
gene in patients with del(21)(q22.13-q22.3) based on genetic analysis of patients and cross-
referencing with the Online Mendelian Inheritance in Man (OMIM) database which they say 
indicted a mouse knockout model.  However, they did not explicitly cite the source and I was 
unable to find any evidence for a mouse knockout model with a cardiac phenotype through 
multiple searches, so this genes inclusion in the CHD-ome may be dubious.  Data suggests this 
gene plays a role in cilia formation and/or maintenance (C. K. Lai et al., 2011).  Like ZIC3 and 
C21ORF2, CCDC39 (Coiled-coil domain containing 39) is a ciliome as well and CHD-ome gene 
but is also present in the CHD100 set and has been associated with PCD, situs inversus, and 
heterotaxy in humans while mouse mutants have displayed AVSD, complex CHD, and heterotaxy 
(Burnicka-Turek et al., 2016; Deng et al., 2015; Y. Li et al., 2015).  CCDC39 is necessary for 
proper motion of motile cilia as it plays an essential role in the construction of inner dynein arms 
and dynein regulatory complexes (Merveille et al., 2011).  FKRP (Fukutin related protein) 
mutations cause dystroglycanopathy/muscular dystrophy in humans with left ventricular 
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noncompaction and ventricular dysfunction observed in a mouse model (Q. Yu et al., 2018).  The 
FKRP protein in involved in glycosylation of alpha-dystroglycan which is essential for proper 
sarcolemma function (Brockington et al., 2001).  Neuregulin 1 (NRG1) encodes an epidermal 
growth factor (EGF) family ligand and when mutated in mice results in absent ventricular 
trabeculation and endocardial cushion defects with deficient mesenchymal cells (Lee et al., 1995; 
C. J. Lin et al., 2012; Meyer & Birchmeier, 1995; D. Srivastava & Olson, 2000).  Its Erb-b2 
receptor tyrosine kinase binding partners, ERBB2, ERBB3, and ERBB4, are themselves CHD-ome 
genes which similarly cause absent trabeculation or cushion hypoplasia when mutated in mice 
(Lee et al., 1995; Meyer & Birchmeier, 1995) 
The significant enrichment for G6PD variants is interesting.  There are conflicting reports 
on whether deficiency of G6PD, which catalyzes the rate-determining step in the pentose 
phosphate pathway and synthesizes NADH, increase the risk for cardiovascular disease or have a 
protective effect (Reviewed in Hecker, Leopold, Gupte, Recchia, & Stanley, 2013).  Some mouse 
studies have indicated a protective effect through decreases in cholesterol synthesis, superoxide 
production, and reductive stress while other studies have indicated that mutant mice are more 
susceptible to ventricular dilation post-myocardial infarct or pressure overload and that they have 
a poorer recovery from ischemia-reperfusion injury. In mice, hemizygous male embryos 
developmentally arrest by E7.5 and have distended hearts while heterozygous females are either 
normal or die by E12.5 with a placentation defect depending on parental inheritance of the mutant 
X chromosome.  It could be interesting to investigate whether patients harboring a G6PD mutation 
had a higher incidence of adverse outcome than patients without a mutation.  At the very least, 
G6PD status could potentially be used as a prognostic factor to identify patients at higher risk of 
adverse outcome. 
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ToppGene analyses produced several terms related to G-protein coupled receptor (GPCR) 
activity and signaling and though the majority of genes associated with those terms tended to be 
related to olfaction, they did include four CHD-ome genes.  ACKR3 (Atypical chemokine receptor 
3) has been identified as a candidate gene for the dextro-transposition of the great arteries seen in 
patients with dup(2)(q37.3) (Costain et al., 2016).  This gene, also known as Cxcr7, encodes a 
chemokine receptor that plays a key role in valve development and has been shown to cause 
semilunar valve defects with occasional malalignment of the aorta when mutated in mice (Sierro 
et al., 2007; S. Yu, Crawford, Tsuchihashi, Behrens, & Srivastava, 2011).  Mutations in Aplnr, 
encoding the Apelin receptor, have been associated with a variety of vasculogenesis and cardiac 
defects in mouse mutants (Charo et al., 2009; Freyer et al., 2017; Kang et al., 2013).  Htr2b, 
encoding the 5-hydroxytryptamine (serotonin) receptor 2B, has been linked to reduced ventricular 
trabeculation and weight and disorganized sarcomeres when mutated in mice while overexpression 
results in cardiac hypertrophy (Nebigil et al., 2000; Nebigil et al., 2003).  In mice, mutations in the 
sphingosine-1-phophate receptor 1 (S1pr1) gene result in defective formation and patterning of the 
aorta (Allende, Yamashita, & Proia, 2003; Gaengel et al., 2012).  A recent review (Nebigil & 
Desaubry, 2019) discusses the importance of GPCRs in epicardial epithelial-to-mesenchymal and 
mesenchymal-to-epithelial transformations as well as noting that these pathways could be 
therapeutic targets.  Additionally, GPCRs have a major role in cilia signaling including the 
modulation of Hedgehog signaling (Reviewed in Mykytyn & Askwith, 2017). 
That the genes and pathways that came up frequently included such a wide range of 
functions including multiple signaling pathways, cilia formation and maintenance, and sarcomere 
stability is in agreement with the highly complex nature of heart development (Bruneau, 2013; 
Klena et al., 2017; Sylva et al., 2014; Williams et al., 2019).  The fact that a large number of CHD-
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ome and Ciliome genes were both enriched and depleted in CHD cases could be interpreted 
multiple ways.  First, it could be that the genes that are enriched in our cases are playing more of 
a role in the etiology of CHD, at least among our cohort.  Second, it could be that the lack of rare 
pathogenic or damaging variants in the genes that are depleted in CHD cases could have a 
protective effect with wildtype alleles of the depleted genes acting to offset some of the deleterious 
effects of the variants in the enriched genes.  Though only eight genes showed a significant excess 
of pathogenic alleles in CHD cases, the fact that four of those genes were CHD-ome genes seems 
significant.  Additionally, eight of the 37 genes with a significant excess of alleles in CHD cases 
before adjustment were CHD-ome genes.  This agrees with the hypothesis that CHD patients are 
enriched for pathogenic variants in genes associated with heart development. 
Though there were far more genes with highly damaging variants than with pathogenic 
variants, only two CHD100 and an additional two CHD-ome genes had a significant excess of 
highly damaging alleles in CHD cases after adjustment.  The small proportion of significant CHD-
ome genes compared to the total number of significant genes could indicate that highly damaging 
variants in genes involved in heart development are not well tolerated.  Though very few structural 
CHD phenotypes were significant, 8/10 structural phenotypes with pathogenic allele had odds 
ratios > 1 compared to only 10/32 with highly damaging variants.  This again suggests variants 
associated with CHD tend to be less damaging in CHD patients.  Overall, these observations may 
suggest a complex genetic model with multiple components.  CHD patients may carry moderately 
damaging variants in multiple genes affecting multiple pathways involved in heart development.  
Individually, these variants may not cause disease, but together they can significantly perturb 
critical signaling pathways to the point of causing abnormal development.  If even one of these 
moderately damaging variants were to be replaced with a highly damaging variant, then this would 
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amplify the disruptions in key developmental pathways to the point they would no longer be 
compatible with life.  Conversely, healthy controls with highly damaging variants would have 
fewer damaging variants in other genes involved in heart development such that other partially 
redundant pathways would be able to sufficiently compensate for the single highly damaging 
variant and allow normal development.  Protective alleles in other genes that lessen the impact of 
damaging variants may also play a role on both sides of this model. 
That CHD patients showed significant difference in the mean number of calls in damaging 
variants overall and a difference in the mean number of calls in damaging variants in CHD-ome 
and Ciliome genes that was trending towards significance compared to SCOOP controls while the 
means number of calls in curated pathogenic variants between cases and controls were not 
significant across the board seems to add another wrinkle to this model.  It would be necessary to 
conduct a more detailed analysis to determine if certain genes are driving the significance at the 
global level.  As there was a large number of genes with highly damaging variants, even if very 
few genes showed a significant excess of alleles in CHD patients at the gene level, the cumulative 
effect of many genes with a non-significant excess of alleles may be enough to drive the global 
difference in the mean number of calls toward significance.  The small number of genes with 
curated pathogenic variants may have prevented such a phenomenon from occurring in this 
category. 
This study has several limitations.  Firstly, our study population is not a random sample of 
consecutive CHD patients but shows a bias towards heterotaxy spectrum CHD and HLHS.  This 
may lead to overrepresentation of variants associated with these conditions and 
underrepresentation of variants associated with other types of CHD.  Additionally, our study 
population contains a mix of isolated and syndromic CHD cases which may have different genetic 
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etiologies as has previously been demonstrated (Sifrim et al., 2016).  Specifically, our study 
population contained several patients each with Down syndrome and DiGeorge syndrome.  This 
study is also limited by the fact that the exome data is not controlled for population stratification.  
Though the racial makeup of the CHD cases is known, the racial makeup of the SCOOP controls 
was not immediately available and, based on the distribution of calls by range, there appears to be 
a significantly higher percentage of non-whites among the CHD cases than the SCOOP controls.  
This would result in inflating the apparent enrichment for variants that have a higher allele 
frequency in non-whites.  In the absence of control for race, it would be beneficial to perform a 
statistical test to estimate to what extent data from non-white cases is influencing the results. 
It is also possible that my definition of pathogenicity was too stringent as indicated by the 
fact that there were so few genes with “pathogenic” alleles defined as those curated as both 
“(Likely) pathogenic” by ClinVar and “DM” by HGMD.  There were a large number of variants 
that were curated as either “(Likely) pathogenic” or “DM”, but not both, and these were left out of 
this part of the analysis.  Using an “or” definition of pathogenicity such that variants that were 
curated as “(Likely) pathogenic” by ClinVar” or “DM” by HGMD would have included a much 
larger number of variants in the analysis (Appendix Table 2).  Another issue in this area is that the 
phenotypes were only those that have been associated with the variants in our dataset.  There are 
certainly other phenotypes associated with variants that were not present in the dataset.  For 
example, though some CHD100 and CHD-ome genes were not associated with any cardiac 
phenotypes in our dataset, they could very well be known to cause heart defects in humans, but no 
variants curated as such were present in our dataset. 
There were also issues with the data analysis methods.  The initial analysis only calculated 
fold changes in normalized allele counts and the cutoffs for generating the gene lists to be run in 
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ToppGene and IPA were chosen arbitrarily to obtain lists that were not too long or too short.  It 
might have made more sense to have calculated odds ratios and then generated the lists for 
enrichment analysis based on those genes with significant odds ratios.  However, though many 
genes had significant raw p-values after carrying out Fisher’s exact test, implementing a 
Benjamini-Hochberg false discovery rate eliminated virtually all of them.  This was likely due to 
the very large difference in number of mutant alleles vs. reference alleles in the study cohorts.  
This method also could not take zygosity into account.  No adjustment was made for hemizygosity 
of X chromosome genes in males so that hemizygous males were treated as homozygous with two 
alleles.  Additionally, our study cohort had several patients each with trisomy 21 and monosomy 
X which were also not taken into account. 
Ingenuity Pathway Analysis also produced some difficulties.  Though this software can be 
used for enrichment analysis, it is more designed to look at expression data.  Though there are a 
large number of data sources that gene sets are queried against which are all selected by default, 
when they are left selected the “Disease and Function” output will be almost entirely cancer-related 
terms.  Leaving the “Cell Lines” option selected in the “Tissues and Cell Lines Activated” section 
will probably also contribute to the excess of cancer-related terms as the cell lines are almost 
exclusively cancer cell lines.  Further compounding this issue is that outputs seem to be limited to 
500 terms.  The parameters for these analyses would thus have to be carefully selected so as not to 
overload the output with cancer-related terms.  Despite these limitations, this research provides 
additional support for the complex genetic etiology of congenital heart disease as well as a 
framework on which to base future research. 
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3.0 Cancer Genes in CHD Patients 
3.1 Introduction 
Down syndrome is not only the condition most frequently associated with CHD which is 
present in about 50% of cases (Reviewed in Versacci et al., 2018), but also has a well-documented 
association with leukemia (Botto et al., 2013; Fisher et al., 2012; Mili, Khoury, Flanders, & 
Greenberg, 1993; Mili, Lynch, Khoury, Flanders, & Edmonds, 1993; Nishi et al., 2000; Windham, 
Bjerkedal, & Langmark, 1985).  The links between developmental genes and cancer have also 
been reviewed (Bellacosa, 2013; Moore, 2009).  Some of the same complex regulatory networks 
critical for embryogenesis may also play roles in the later development of cancer, and their role 
may exceed that of genes involved in later fetal growth and maturation (Moore, 2009).  Among 
these developmental pathways and regulators are the Hedgehog and Wnt/β-catenin signaling 
pathways, the Polycomb repressive complex, and other chromatin modifiers and epigenetic factors.  
Additionally, multiple classes of disease have been associated with both developmental defects 
and increased cancer risk (Bellacosa, 2013).  Among these disease classes are the cohesinopathies 
such as Cornelia-de Lange syndrome, the RASopathies such as Noonan syndrome, the 
phakomatoses such as Neurofibromatosis, and the overgrowth syndromes such as Beckwith-
Wiedemann syndrome.  It has been hypothesized that childhood cancers could arise from 
perturbations of the same developmental pathways that result in birth defects (Botto et al., 2013). 
Similarly, it is thought that pediatric solid tumors arise from mutations in early development genes 
while hematopoietic malignancies result from mutations in genes active later in development 
(Narod, Hawkins, Robertson, & Stiller, 1997).  Fisher et al. (2012) proposed a similar hypothesis 
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while also theorizing that leukemias mainly arise from single gene defects that alter clonal 
leukocyte proliferation. 
Numerous studies have documented the relationship between birth defects and childhood 
cancer. A statistically significant relationship was first recognized at least 35 years ago with 
children with birth defects also noted to develop cancer at a younger age than those without birth 
defects (Windham et al., 1985). A large-scale literature review has documented a general positive 
relationship between birth defects and cancer as well as relationships between specific birth defects 
and cancer types (K. J. Johnson et al., 2017).  Additional studies noted that patients with 
malformations tended to develop cancer more frequently as a whole (Nishi et al., 2000; Norwood 
et al., 2017).  A pair of related studies found that children with birth defects are significantly more 
likely to develop cancer before the age of 15 (Mili, Khoury, et al., 1993; Mili, Lynch, et al., 1993).  
These studies found an excess of leukemia, brain tumors, neuroblastoma, Wilms tumor, and 
retinoblastoma.  Another study found that children with minor birth defects are more likely to have 
cancer and, conversely, that children with cancer are more likely to have minor birth defects 
(Durmaz et al., 2011).  Botto, Flood, et al. (2013) reported that children with birth defects had a 
2.9-fold increased risk of cancer compared to a control population without birth defects.  Finally, 
it has been reported that children with non-chromosomal birth defects are at increased risk for solid 
tumors including lymphomas, central nervous system tumors, neuroblastoma,  and non-central 
nervous system germ cell tumors, but not leukemias (Fisher et al., 2012). 
A Canadian study reported a 1.6-2 times higher prevalence of cancer in CHD patients 
compared to the general population while a study from Western Australia reported a cancer hazard 
ratio of 1.74 among children with cardiovascular defects (Dawson, Charles, Bower, de Klerk, & 
Milne, 2015; Gurvitz et al., 2016).  It has been reported that children with Wilms tumor have a 
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higher incidence of TGA, aortic stenosis, and VSD than the general population while an excess of 
cardiac septal defects has also been reported in children with several types of cancer (Botto et al., 
2013; Narod et al., 1997).  CHD patients have been reported to develop brain tumors and Wilms 
tumor more frequently than expected (Nishi et al., 2000).  A study examining late causes of death 
in CHD patients reported a greater likelihood of dying from neoplastic disorders than the general 
population mainly attributed to genetic factors and interventional exposures (Raissadati, Nieminen, 
Haukka, Sairanen, & Jokinen, 2016).  Another study reported that children with CHD had an 
elevated cancer hazard risk and seemed at particular risk for lymphoma (Fisher et al., 2012).  
Children with defects of the great arteries, valves, and atrioventricular septum were found to have 
a higher cancer risk, especially for lymphatic and hematopoietic cancers (Sun, Overvad, & Olsen, 
2014).  Finally, heart anomalies have been associated with hepatoblastoma, neuroblastoma and 
other unspecified malignancies (Norwood et al., 2017). 
The RASopathies are a group of related disorders caused by dysregulation of the 
RAS/MAPK pathway and characterized by a variety of birth defects including CHD such as 
pulmonary stenosis and septal defects as well as an increased risk of certain cancers (Kratz et al., 
2015; Kratz, Rapisuwon, Reed, Hasle, & Rosenberg, 2011; Rauen, 2013).  Among the 
RASopathies, Noonan syndrome is the most common single gene cause of CHD with over 80% 
of patients having a cardiovascular malformation, particularly pulmonary stenosis, while patients 
are also at increased risk of developing neuroblastoma, acute leukemia, low-grade glioma, and 
rhabdomyosarcoma (Kratz et al., 2011; Romano et al., 2010).  Costello syndrome is associated 
with an increased risk of neuroblastoma, rhabdomyosarcoma, and bladder cancer while the cancer 
types associated with cardiofaciocutaneous syndrome and Noonan syndrome with multiple 
lentigines overlap those of Noonan syndrome and Costello syndrome respectively (Kratz et al., 
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2011).  Finally, neurofibromatosis can include atrioventricular valve regurgitation, mitral valve 
prolapse, aortic valve regurgitation, pulmonary valve stenosis, and ASD, or VSD in addition to the 
eponymous neurofibromas and other tumors (Incecik, Herguner, Alinc Erdem, & Altunbasak, 
2015). 
Several extrinsic factors have also been proposed to contribute to the increased risk of 
cancer in CHD patients.  Raissadati et al. (2016) had noted that CHD patients have an increased 
rate of neoplasia in radiation-sensitive tissues.  It has been hypothesized that adult CHD patients 
are at an increased risk for cancer due to interventional radiation exposure, genetics, and other 
environmental factors (Gurvitz et al., 2016).  One study found that the risk of developing cancer 
among CHD patients undergoing catheterization was elevated but not to a statistically significant 
level while another study reported that young CHD patients incur a small but significant risk of 
developing radiation-induced cancers following interventional catheterization (Olsen et al., 2014; 
Yakoumakis et al., 2013).  Finally, it has been observed that CHD patients who develop cancer 
had a higher rate of undergoing procedures that involved low-dose exposure to ionizing radiation 
than did CHD patients who did not develop cancer (Cohen et al., 2018).  Another hypothesis 
involves chronic activation of the hypoxia pathway in patients with cyanotic CHD leading to an 
increased risk for cancer such as pheochromocytoma or paraganglioma (Opotowsky et al., 2015).  
Finally, it has been noted that CHD patients undergoing univentricular palliation leading to the 
Fontan procedure can develop hepatic dysfunction secondary to chronic pulmonary hypertension 
or vascular congestion and right heart failure which can in turn lead to an increased risk of 
hepatocellular carcinoma as soon as two years post-Fontan (Asrani, Warnes, & Kamath, 2013; 
Augustyn, Peng, Singal, & Yopp, 2015; A. C. Egbe et al., 2018). 
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Over the course of reviewing WES data from study participants, it was noticed that these 
patients appeared to have a large number of rare variants in genes known to be associated with 
cancer (Lo, 2016-2019).  To this end, I investigated if there is a real excess of rare variants in genes 
known to be associated with cancer in our CHD patients compared to a control cohort. 
3.2 Materials and Methods 
3.2.1 Gene Sets 
Two partially overlapping gene sets were used in this analysis.  The first set was the set of 
genes with variants present in CHD cases and/or SCOOP controls that are associated with a cancer 
phenotype as curated by ClinVar or HGMD.  Cancer phenotypes were defined as those with the 
ICD-10 version 2016 codes C00-C97 (Malignant neoplasms), D00-D09 (In situ neoplasms), D10-
D36 (Benign neoplasms), D37-D48 (Neoplasms of uncertain or unknown behavior), and Q85 
(Phakomatoses not elsewhere classified) as well as Z15.09 (Genetic susceptibility to other 
malignant neoplasms) which was found through a Google search for ICD-10 codes related to 
cancer susceptibility. 
The second gene set was obtained from the Catalogue Of Somatic Mutations In Cancer 
(COSMIC) Cancer Gene Census (CGC) (Forbes et al., 2015; Sondka et al., 2018; Tate et al., 2019) 
which is a list of genes for which germline and/or somatic mutations have been linked to cancer.  
The CGC contains 717 genes and six loci of which 680 genes have somatic mutations associated 
with cancer, 107 have germline mutations, and 64 have both somatic and germline mutations.  
Figure 2 illustrates the degree of overlap between the two cancer gene sets and the CHD-ome and 
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Ciliome gene sets including only genes present in our dataset.  The darkest gray indicates the area 
where all four lists intersect, the medium gray indicates the intersection of three lists, the light gray 
indicates the intersection of two lists, and the white indicates no intersection. 
 
Figure 4 Overlap of CHD-ome, Ciliome, and cancer gene sets 
3.2.2 Data Analysis and Statistics 
Data analysis was carried out in the same manner as described earlier except restricted to 
genes with variants in CHD cases and/or SCOOP controls associated with a cancer phenotype or 
genes in the COSMIC CGC. 
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3.3 Results 
3.3.1 Enrichment for Genes with Cancer Phenotypes 
3.3.1.1 Overall enrichment 
Overall, variants in 187 genes had at least one cancer phenotype as curated by ClinVar or 
HGMD.  Of those genes, 13 had significant odds ratios before adjustment, seven with OR > 1 and 
six with OR < 1, but none remained significant after adjustment.  There were 10 genes with a 
significant excess of alleles in CHD cases after adjustment of which five (AIP, ACKR3, EGFR, 
ENG, PTCH1) are CHD-ome genes (Table 10).  In mice, global deletion of EGFR, encoding the 
epidermal growth factor receptor gene, results in hypoplastic outflow valves (C. J. Lin et al., 2012).  
Endoglin (ENG) variants have been associated with vascular anomalies in humans (Mattassi et al., 
2018).  PTCH1 (Patched 1) mutations have been associated with CHD including BAV with or 
without coarctation of the aorta in humans (Bonachea et al., 2014; Zaidi & Brueckner, 2017). 
Table 10: Significant genes with cancer phenotypes overall 
 Gene List Allele Count Odds Ratio 
Gene CHD100 CHD-ome Ciliome FC p-value BH FDR OR p-value BH FDR 
AIP FALSE TRUE FALSE 4.0326 6.09E-07 6.56E-05 4.7552 0.0015 0.0996 
SPINK1 FALSE FALSE FALSE 4.8007 2.92E-06 0.0002 5.6540 0.0065 0.2224 
CD27 FALSE FALSE FALSE 5.7608 4.55E-06 0.0004 6.8007 0.0073 0.2236 
ACKR3 FALSE TRUE FALSE 5.0507 3.53E-05 0.0019 5.9305 0.0161 0.3177 
WWOX FALSE FALSE FALSE 1.6386 0.0002 0.0089 1.9266 0.0118 0.2836 
EGFR FALSE TRUE FALSE 5.7608 0.0004 0.0127 6.7807 0.0669 0.5869 
CHEK2 FALSE FALSE FALSE 5.7608 0.0004 0.0127 6.7807 0.0669 0.5869 
ENG FALSE TRUE FALSE 1.6907 0.0005 0.0143 1.9918 0.0181 0.3296 
MSH2 FALSE FALSE FALSE 2.5924 0.0011 0.0271 3.0463 0.0501 0.5267 
PTCH1 FALSE TRUE TRUE 2.0803 0.0013 0.0321 2.4446 0.0451 0.5146 
Gene List indicates if the gene is present in either of the 3 focus gene lists. For allele count, FC is based on 
normalized allele counts and the p-value is the upper tail probability of the binomial test.  For OR, the p-value 
was obtained from Fisher’s exact test 
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There was a total of 361 curated cancer phenotypes with 21 having a significant odds ratio 
before adjustment, nine with OR > 1 and 12 with OR < 1, though none remained significant after 
adjustment.  There were 80 cancer phenotypes with an excess of alleles in CHD cases before 
adjustment with 35 remaining significant after adjustment (Appendix Table 7). 
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3.3.1.1.1 ToppGene analysis 
ToppGene analysis of the set of genes with cancer phenotype allele FC ≥ 2 overall 
produced multiple significant structural CHD phenotype terms that were significant only in that 
set and not in the set of genes with cancer phenotype allele FC ≤ −2 (Appendix Table 8). However, 
there were a number of structural CHD terms as well as terms related to heart development and 
morphogenesis that were significant only in the set of genes with cancer phenotype allele FC ≤ −2.   
Additionally, there were also a number of significant terms related to cardiac neoplasms. There 
was little overlap in significant terms between sets with only two terms related to the 
cardiovascular system, “Neoplasm of the heart” and “Angiofibromas” out of 104 being significant 
in both sets.  There were also a number of terms related to apoptosis, nitric oxide signaling, and 
cilia/hedgehog signaling that were significant in the set of genes with allele FC ≥ 2 for variants 
associated with cancer phenotypes, though there were also a number of such significant terms in 
the set of genes with allele FC ≤ −2. 
Of particular interest were the results of a ToppGene analysis of the genes appearing in 
Table 10 which produced multiple terms related to apoptosis, nitric oxide synthesis, ERBB4 
signaling, and transcriptional regulation by AP-2 (TFAP2) family transcription factors (Table 11).  
Many of these or similar terms were also significant in ToppGene analysis of the set of genes with 
curated cancer phenotype allele FC ≥ 2 overall.  Apoptosis has been shown to play a pivotal role 
in heart development, particularly with respect to the endocardial cushions and atrioventricular 
canal (Abdelwahid, Pelliniemi, & Jokinen, 2002; Grunert et al., 2014; Jerse & Zidar, 2011; 
Poelmann, Molin, Wisse, & Gittenberger-de Groot, 2000; Sanchis, Llovera, Ballester, & Comella, 
2008; Vicente Steijn et al., 2018; D. Yang et al., 2012; Z. Zhao & Rivkees, 2000).  The AP-2 
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(TFAP2) signaling pathway has been shown to play a critical role in neural crest and outflow tract 
development in mice as well as being linked with familial isolated patent ductus arteriosus in 
humans (Brewer, Feng, Huang, Sullivan, & Williams, 2004; Brewer, Jiang, Donaldson, Williams, 
& Sucov, 2002; Ji et al., 2014).  Evidence has suggested that defective nitric oxide synthesis and 
signaling play a role in the etiology of a variety of cardiac defects including abnormal cardiac situs, 
septal defects, BAV, and HLHS (Hrstka, Li, Nelson, & Pipeline, 2017; Y. Liu & Feng, 2012; 
Siamwala et al., 2019).  ERBB4 signaling plays an important role in valve development and 
myocardial trabeculation (Iwamoto & Mekada, 2006; D. Srivastava & Olson, 2000). 
Table 11: ToppGene analysis of genes in Table 10 
Name Genes in Query p-value q-value 
FDR B&H 
apoptotic signaling pathway 5 (CHEK2, MSH2, CD27, WWOX, ACKR3) 8.73E-06 1.88E-03 
intrinsic apoptotic signaling pathway 4 (CHEK2, MSH2, WWOX, ACKR3) 1.17E-05 2.16E-03 
intrinsic apoptotic signaling pathway by 
p53 class mediator 
3 (CHEK2, MSH2, WWOX) 7.93E-06 1.88E-03 
intrinsic apoptotic signaling pathway in 
response to DNA damage 
3 (CHEK2, MSH2, ACKR3) 2.11E-05 3.00E-03 
negative regulation of response to stimulus 7 (CHEK2, SPINK1, EGFR, ENG, WWOX, 
ACKR3, PTCH1) 
6.73E-06 1.88E-03 
nitric-oxide synthase activity 2 (EGFR, ENG) 4.23E-04 1.90E-02 
regulation of apoptotic process 7 (CHEK2, EGFR, MSH2, ENG, CD27, 
WWOX, ACKR3) 
3.91E-06 1.88E-03 
regulation of cell death 7 (CHEK2, EGFR, MSH2, ENG, CD27, 
WWOX, ACKR3) 
7.75E-06 1.88E-03 
regulation of nitric oxide mediated signal 
transduction 
2 (SPINK1, EGFR) 1.46E-05 2.36E-03 
regulation of programmed cell death 7 (CHEK2, EGFR, MSH2, ENG, CD27, 
WWOX, ACKR3) 
4.41E-06 1.88E-03 
Signaling by ERBB4 2 (EGFR, WWOX) 4.13E-04 4.85E-02 
Transcriptional regulation by the AP-2 
(TFAP2) family of transcription factors 
2 (EGFR, WWOX) 3.57E-04 4.85E-02 
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3.3.1.1.2 Ingenuity Pathway Analysis 
IPA comparison analysis of the sets of genes with allele FC ≥ 2 and FC ≤ −2 for variants 
with cancer phenotypes overall produced only seven structural CHD terms of which six were 
present only in the set with FC ≥ 2 and having positive deltas while the seventh term, 
“cardiogenesis” was present in both sets and had a negative delta (−1.7107).  The six terms with 
positive deltas encompassed only five genes (ACKR3, AIP, CDK4, EGFR, PTCH1).  Overall, the 
set of genes with FC ≤ −2 for variants with cancer phenotypes produced a number of significant 
cardiovascular terms, many of which related to formation of the heart.  Additionally, there were 
several terms related to apoptosis significant only in the CHD set, however most of them were not 
relevant to the heart (Table 12).  There were also multiple apoptosis-related terms significant only 
the in the SCOOP set and one term, “apoptosis” significant in both sets (delta = 0.0743).   
Table 12: IPA analysis of genes with allele FC ≥ 2 for variants with cancer phenotypes 
Diseases and Bio Functions GS19 Genes 
Exit from apoptosis of B lymphocytes 2.7430 MSH2 
Closure of ductus venosus 2.7430 AIP 
Persistence of ductus venosus 2.7430 AIP 
Abnormal morphology of cardiac valve 2.8200 ACKR3, CDK4 
Apoptosis of germinal center 3.0438 MSH2 
Apoptosis of pleural cells 3.0438 EGFR 
Cardiogenesis 3.5356 ACKR3, CASP10, CDK4, EGFR, PTCH1 
Formation of semilunar valve 3.6037 ACKR3, EGFR 
Ventricular septal defect 3.6389 ACKR3, AIP, CDK4 
Congenital heart disease 3.6459 ACKR3, AIP, CDK4, PTCH1 
Apoptosis of T lymphocytes 3.8467 CASP10, CD27, CHEK2, ITK 
Apoptosis 4.1573 AIP, CASP10, CD27, CHEK2, EGFR, ITK, LIG4, MITF, MSH2, 
PTCH1 
Apoptosis of lymphocytes 4.6845 CASP10, CD27, CHEK2, ITK, MSH2 
Apoptosis of blood cells 5.0994 AIP, CASP10, CD27, CHEK2, ITK, MSH2 
Terms significant only in the CHD gene set. G19 is the analyzed gene set (Appendix C.1) and the numbers are -
log10(p-values) generated from the IPA comparison analysis. 
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3.3.1.2 Enrichment for pathogenic and highly damaging variants 
Pathogenic variants are those curated as “(likely) pathogenic” by ClinVar and “DM” by 
HGMD while highly damaging variants are those with a CADD score ≥ 30. Only 19 genes had 
variants curated as pathogenic by both ClinVar and HGMD that were associated with cancer 
phenotypes with none having a significant unadjusted odds ratio p-value.  Only five genes had a 
significant excess of curated pathogenic alleles in CHD cases unadjusted of which only one, AIP, 
remained significant after adjustment (BH FDR = 0.0177).  There were 71 genes with cancer 
phenotypes with highly damaging variants though, as with pathogenic variants, none had a 
significant unadjusted odds ratio p-value.  There were 15 genes with a significant excess of highly 
damaging alleles in CHD cases unadjusted, but none remained significant after adjustment. 
Of the 93 cancer phenotypes with pathogenic alleles, none had significant odds ratios 
unadjusted and only 13 had a significant excess of alleles in CHD cases before adjustment with 
none remaining significant after adjustment.  However, six terms related to pituitary or parathyroid 
adenoma were trending towards significance (BH FDR = 0.0562), though all these terms were 
associated with a single variant in the AIP gene. There were 107 cancer phenotypes with highly 
damaging variants, but only one had a significant OR before adjustment and 29 had a significant 
excess of alleles in CHD cases, but nothing remained significant after adjustment.  The term closest 
to significance after adjustment was “Hereditary cancer predisposition syndrome” (BH FDR = 
0.0728) associated with variants in APC, ATM, BLM, BMPR1A, BRCA2, BRIP1, CDH1, NBN, 
POLD1, POLE, SUFU, and TSC2. 
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3.3.1.2.1 ToppGene Analysis 
Because the sets of genes with cancer phenotypes enriched for pathogenic and highly 
damaging variants were individually so small, they were combined and run through enrichment 
analysis as a single set.  No structural CHD phenotype terms were significant in the set of genes 
with pathogenic or highly damaging allele FC ≥ 2, though there were several terms related to 
vascular anomalies (Table 13).  The most significant term related to the cardiovascular system for 
this analysis was “Atrial fibrillation (BH FDR = 5.93E-03) associated with ROS1, CYP2C19, and 
ATM while there were also three significant terms related to response to oxygen levels all of which 
were associated with TSC2, BRIP1, and ATM.  Also, there were again a number of terms related 
to apoptosis.  Finally, there were multiple structural CHD terms that were significant in the sets of 
genes with allele FC ≤ −2 both overall and when restricting to pathogenic or highly damaging 
variants. 
Table 13: ToppGene analysis of genes with pathogenic/highly damaging variants associated with cancer 
phenotypes 
Name Hit in Query List p-value q-value 
FDR B&H 
increased sensitivity to induced cell 
death 
4 (TYR, BRIP1, ATM, ERCC6) 3.98E-05 3.07E-03 
Cardiac rhabdomyoma 1 (TSC2) 7.37E-04 6.93E-03 
Abnormal induced cell death 4 (TYR, BRIP1, ATM, ERCC6) 1.50E-04 7.36E-03 
Abnormality of the vasculature 8 (FANCM, CDH1, POLD1, TSC2, BRIP1, ATM, 
AIP, ERCC6) 
9.41E-04 1.18E-02 
response to hypoxia 3 (TSC2, BRIP1, ATM) 1.37E-03 2.51E-02 
Abnormal cell death 7 (TYR, CDH1, TSC2, BRIP1, ATM, AIP, ERCC6) 1.27E-03 2.58E-02 
response to decreased oxygen levels 3 (TSC2, BRIP1, ATM) 1.50E-03 2.59E-02 
response to oxygen levels 3 (TSC2, BRIP1, ATM) 1.78E-03 2.59E-02 
intrinsic apoptotic signaling pathway 
in response to DNA damage 
2 (ATM, ERCC6) 2.05E-03 2.81E-02 
Mitochondrial cardiomyopathy 1 (ROS1) 1.17E-02 3.02E-02 
Abnormal carotid artery morphology 2 (FANCM, BRIP1) 5.43E-03 3.50E-02 
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Abnormal vascular morphology 6 (FANCM, CDH1, TSC2, BRIP1, AIP, ERCC6) 5.42E-03 3.50E-02 
Angiofibroma 1 (TSC2) 1.54E-02 3.51E-02 
Cardiovascular Diseases 3 (ROS1, CYP2C19, ATM) 1.53E-02 3.51E-02 
Aortic Diseases 1 (TSC2) 1.61E-02 3.59E-02 
Ventricular Dysfunction, Left 1 (ATM) 1.61E-02 3.59E-02 
Abnormal apoptosis 6 (TYR, CDH1, TSC2, BRIP1, ATM, AIP) 2.62E-03 3.66E-02 
abnormal vascular development 4 (TYR, CDH1, TSC2, AIP) 3.34E-03 4.02E-02 
patent ductus venosus 1 (AIP) 3.36E-03 4.02E-02 
Angiomyolipoma 1 (TSC2) 1.97E-02 4.09E-02 
Coronary Stenosis 1 (ATM) 2.55E-02 4.71E-02 
Increased trophectoderm apoptosis 1 (CHD1) 5.59E-03 4.93E-02 
 
Table 13 Continued 
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3.3.1.2.2 Ingenuity Pathway Analysis 
When restricting to variants with pathogenic or highly damaging alleles, “Hypoxia 
signaling in the cardiovascular system” was one of the Canonical Pathway terms that was 
significant only in the set with FC ≥ 2 (Table 14).  This analysis produced only 15 total significant 
‘Disease and Bio Function’ terms related to the cardiovascular system of which four were 
significant in the set with FC ≥ 2 (Table 14) and 11 were significant in the set with FC ≤ −2 with 
no terms being significant in both sets.  The significant cardiovascular terms for the set with 
pathogenic or highly damaging allele FC ≥ 2 encompassed only four genes (AIP, ATM, CYP2C19, 
TSC2).  These results seem to suggest that pathogenic and highly damaging variants in genes with 
curated cancer phenotypes do not play a major role in the etiology of CHD though rare variants 
overall may play a role, especially those in genes in the apoptosis pathway.  Additionally, they 
suggest that variants in genes related to hypoxia signaling or response to oxygen levels may serve 
as a prognostic indicator.  As for the term “Major adverse cardiovascular event”, variants in 
CYP2C19 have been associated with a higher incidence of coronary heart disease and adverse 
outcomes following treatment (Zhang et al., 2019). 
Table 14: IPA analysis of genes with pathogenic or highly damaging variants with cancer phenotypes 
Canonical Pathways GS21 
 
Hypoxia Signaling in the Cardiovascular System 1.3703 
 
Diseases and Bio Functions GS21 Genes 
Familial cardiovascular disease 3.3493 AIP, ATM, CYP2C19, 
TSC2 
Apoptosis of epithelial cell lines 3.2570 CDH1, TSC2 
Dysfunction of vascular endothelial cells 3.2309 ATM 
Apoptosis of squamous epithelial cells 3.2309 CHD1 
Persistence of ductus venosus 2.9300 AIP 
Major adverse cardiovascular event 2.6292 CYP2C19 
Terms significant only in the CHD gene set. G21 is the analyzed gene set (Appendix C.1) 
and the numbers are -log10(p-values) generated from the IPA comparison analysis. 
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3.3.2 Enrichment for COSMIC Cancer Gene Census Genes 
3.3.2.1 Overall Enrichment 
Overall, 487 COSMIC CGC genes were present in our dataset including eight CHD100, 
133 CHD-ome, 48 Ciliome, and 77 with variants curated as being associated with cancer 
phenotypes.  CHD patients had significantly more calls in CGC genes overall and in calls in highly 
damaging CGC gene variants but the average number of calls per sample in CGC gene variants 
curated as pathogenic were nearly identical and not significantly different (Table 1).  There were 
34 CGC genes with a significant odds ratio before adjustment including 26 with OR > 1, but only 
one (NCOR2) remained significant after adjustment.  There were 35 CGC genes with significantly 
more alleles in CHD cases after adjustment including 13 CHD-ome genes (NCOR2, ACKR3, 
USP44, FSTL3, NRG1, EGFR, PIK3CB, ARID1A, SPEN, PTCH1, USP8) (Table 14). In mice 
Arid1a (AT-rich interaction domain 1A) has been shown to be required for cardiac neural crest 
development with mutants showing outflow tract and pharyngeal arch artery defects as well as 
VSD and absent myocardial trabeculation (Chandler et al., 2013; Chandler & Magnuson, 2016). 
FSTL3 (Follistatin-like 3) has been identified as a candidate gene accounting for the TOF seen in 
patients with del(19)(p13.3) (Silversides et al., 2012).  Ncor2 (Nuclear receptor corepressor 2) null 
mice exhibit hypoplastic ventricle walls and VSD (Jepsen, Gleiberman, Shi, Simon, & Rosenfeld, 
2008). PIK3CB, encoding Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta, 
has been identified as a candidate gene accounting for the CHD seen in patients with del(3)(q22.3) 
(Xie et al., 2017). SPEN family transcriptional repressor (SPEN) variants have been associated 
with HLHS in humans while mouse mutants exhibit defects in septation and myocardium 
formation (Kuroda et al., 2003; X. Liu et al., 2017). Variants in ubiquitin-specific peptidase 44 
(USP4) have been associated with CHD in humans (Zaidi et al., 2013). Finally, mice with 
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mutations in Usp8 (Ubiquitin-specific peptidase 8) show abnormal heart development (Niendorf 
et al., 2007). 
Table 15: Significant CHD-ome genes in the CGC 
 Gene List Allele Count Odds Ratio 
Gene CHD100 CHD-ome Ciliome FC p-value BH FDR OR p-value BH FDR 
NCOR2 FALSE TRUE FALSE 1.0110 5.96E-09 1.46E-06 1.2026 2.84E-06 0.0029 
ACKR3 FALSE TRUE FALSE 5.0407 3.53E-05 0.0019 5.9305 0.0161 0.3177 
USP44 FALSE TRUE FALSE 2.8805 9.38E-05 0.0042 3.3886 0.0133 0.2905 
FSTL3 FALSE TRUE FALSE 3.8405 0.0001 0.0046 4.5315 0.0240 0.3688 
NRG1 FALSE TRUE FALSE 1.7831 0.0003 0.0092 2.0967 0.0147 0.3092 
EGFR FALSE TRUE FALSE 5.7608 0.0004 0.0127 6.7807 0.0669 0.5869 
PIK3CB FALSE TRUE FALSE 2.8804 0.0008 0.0227 3.3886 0.0674 0.5869 
ARID1A FALSE TRUE FALSE 1.8833 0.0011 0.0289 2.2132 0.0361 0.4534 
SPEN FALSE TRUE FALSE 2.1603 0.0014 0.0320 2.5376 0.0392 0.4820 
PTCH1 FALSE TRUE TRUE 2.0803 0.0013 0.0321 2.4446 0.0451 0.5146 
USP8 FALSE TRUE FALSE 3.6005 0.0015 0.0340 4.2324 0.1099 0.7091 
Gene List indicates if the gene is present in either of the 3 focus gene lists. For allele count, FC is based on 
normalized allele counts and the p-value is the upper tail probability of the binomial test.  For OR, the p-value 
was obtained from Fisher’s exact test 
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3.3.2.1.1 ToppGene Analysis 
ToppGene analysis of the sets of CGC genes with FC ≥ 2 and FC ≤ −2 overall produced 
107 terms potentially related to the cardiovascular system of which 39 were significant in the 
enriched set and 71 in the depleted set with three terms being significant in both.  Aside from 
several terms related to valvular dysplasia, all associated with FLNA alone (Table 16), most bona-
fide structural CHD terms were significant only in SCOOP controls.  Though there were few bona-
fide structural CHD terms significant in CHD cases, there were several syndromes that can include 
CHD including Noonan syndrome 10 (LZTR1) (BH FDR = 1.48E-02) and Cornelia-de Lange 
syndrome (MYC, AFF4) (BH FDR = 1.48E-02).  Other significant terms of interest included 
“abnormal oxygen level” (BH FDR = 1.03E-02) associated with MYC, FLNA, PRRX1, EGFR, 
NFIB, ACKR3, RSPO2, and SDHB as well as several terms related to apoptosis.  Overall, the terms 
significant in CHD cases only encompassed one CHD100 gene (DNM2) and a further nine CHD-
ome genes (ACKR3, AFF4, EGFR, FLNA, LZTR1, MYOD1, PIK3CB, PTCH1, SOX2). 
Table 16: ToppGene Analysis of COSMC CGC genes with FC ≥ 2 overall 
Name Hit in Query List p-value q-value 
FDR B&H 
canonical Wnt signaling 
pathway involved in negative 
regulation of apoptotic process 
2 (MYC, MITF) 8.38E-05 4.58E-03 
abnormal oxygen level 8 (MYC, FLNA, PRRX1, EGFR, NFIB, ACKR3, RSPO2, 
SDHB) 
1.59E-04 1.03E-02 
Neoplasms, Radiation-Induced 2 (MYC, PTCH1) 2.35E-03 1.48E-02 
Cornelia De Lange Syndrome 2 (MYC, AFF4) 3.11E-03 1.48E-02 
Cardiac Paraganglioma 1 (SDHB) 3.64E-03 1.48E-02 
NOONAN SYNDROME 10 1 (LZTR1) 3.64E-03 1.48E-02 
Congenital dysplasia of cardiac 
valve 
1 (FLNA) 3.64E-03 1.48E-02 
abnormal response to radiation 4 (ERCC2, CHEK2, MSH2, PTCH1) 3.37E-04 1.62E-02 
Costello syndrome (disorder) 2 (PIK3CB, CDK4) 4.59E-03 1.78E-02 




9 (RSPO3, FLNA, CYSLTR2, PRRX1, PIK3CB, ACKR3, 
TNFAIP3, DDIT3, DNM2) 
1.12E-03 2.06E-02 
Radiation-Related Angiosarcoma 1 (MYC) 7.23E-03 2.32E-02 
Abnormal heart morphology 19 (SOX2, MYC, TPM3, CNBP, FLNA, USP8, PRRX1, 
LZTR1, WAS, CANT1, PAX8, CHEK2, MSH2, ATIC, 
PTCH1, AFF4, SDHB, DNM2, CDK4) 
1.97E-03 3.21E-02 
Abnormality of cardiovascular 
system morphology 
22 (SOX2, MYC, TPM3, CNBP, FLNA, USP8, PRRX1, 
ERCC2, LZTR1, WAS, SH2B3, CANT1, PAX8, CD28, 





3 (MYOD1, NCOA1, SPEN) 1.10E-03 3.43E-02 
Notch signaling pathway 4 (SOX2, MYC, EGFR, SPEN) 3.28E-03 3.57E-02 
nitric-oxide synthase binding 2 (EGFR, DNM2) 3.21E-03 3.63E-02 
canonical Wnt signaling 
pathway involved in positive 
regulation of apoptotic process 
1 (MYC) 5.85E-03 4.37E-02 
 
Table 16 Continued 
105 
3.3.2.1.2 Ingenuity Pathway Analysis 
An IPA analysis of the sets of CGC genes with FC ≥ 2 and FC ≤ −2 overall produced 18 
terms related to the cardiovascular system of which only six were significant in CHD cases with 
only two of those terms, “Enlargement of heart” (-log10 p-value = 4.3330) and “Congenital 
anomaly of the cardiovascular system” (-log10 p-value = 4.0832) being significant only in CHD 
cases.  The six terms significant in CHD cases encompassed 24 genes including one CHD100 gene 
(DNM4) and an additional 11 CHD-ome genes (ABI1, ACKR3, EGFR, FLNA, FSTL3, MYOD1, 
PIK3CB, PTCH1, SPEN, USP44, USP8).  There were 16 terms significant in the set of genes with 
FC ≤ −2 with many of them related to heart morphology/morphogenesis and a few related to 
conduction. 
3.3.2.2 Enrichment for pathogenic and highly damaging variants 
Only nine CGC genes had curated pathogenic variants with none having significant raw 
odds ratio p-values and only one (ZEB1) having a significant excess of alleles in CHD cases before 
adjustment but losing significance after adjustment.  None of the nine genes were CHD100 or 
CHD-ome genes, though three (VHL, TSHR, NBN) were Ciliome genes.  There were only three 
genes whose odds ratios for highly damaging alleles were significant before adjustment, but none 
remained significant after adjustment.  Alleles in highly damaging variants were significantly more 
frequent in 29 genes before adjustment, however only two genes, RNF213, (BH FDR = 0.0001) 
and NRG1 (BH FDR = 0.0106), remained significant after adjustment.  An additional 10 CHD-
ome genes (ABI1, SETBP1, SPEN, ATM, PER1, ATIC, ARID1B, FLT4, MYOD1, TSC2) had 
significant raw p-values. 
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3.3.2.2.1 ToppGene analysis 
ToppGene analysis of the set of CGC genes with highly damaging alleles FC ≥ 2 did not 
produce any significant bona-fide structural CHD terms, though two significant terms were 
“Abnormal cardiovascular development” associated with RNF213, NRG1, TSC2, FLT4, ABI1, 
SPEN and CDH1 and “Fenestration (morphologic abnormality)” associated with FLT4, a CHD-
ome gene (Table 16).  Additionally, there were four significant terms related to VEGF signaling, 
a term related to WNT signaling, as well as two terms with potential prognostic value for CHD 
patients, “Radiation-Related Angiosarcoma” associated with FLT4 and “response to oxygen 
levels” associated with TSC2, BRIP1, ATM, and MYOD1.  ToppGene analysis of the set of CGC 
genes with highly damaging allele FC ≤ −2 produced a number of terms related to cardiovascular 
system morphogenesis and development. 
Table 17: ToppGene analysis of CGC genes with highly damaging variants 
Name Hit Count in Query List p-value FDR B&H 
Cardiac rhabdomyoma 1 (TSC2) 1.48E-03 1.51E-02 
MOYAMOYA DISEASE 2 1 (RNF213) 1.48E-03 1.51E-02 
Moyamoya disease 2 1 (RNF213) 1.48E-03 1.51E-02 
Radiation-Related Angiosarcoma 1 (FLT4) 2.95E-03 2.14E-02 
Fenestration (morphologic 
abnormality) 
1 (FLT4) 8.81E-03 3.48E-02 
abnormal cardiovascular development 7 (RNF213, NRG1, TSC2, FLT4, ABI1, 
SPEN, CDH1) 
6.26E-04 3.81E-02 
negative regulation of Wnt signaling 
pathway 
3 (RNF213, TSC2, CDH1) 2.20E-03 3.86E-02 
response to oxygen levels 4 (TSC2, BRIP1, ATM, MYOD1) 1.49E-03 3.86E-02 
abnormal endocardium morphology 2 (TSC2, ABI1) 1.49E-03 4.04E-02 
Nuclear signaling by ERBB4 2 (NCOR1, NRG1) 6.48E-04 4.09E-02 
Signaling by VEGF 4 (JAK1, NRG1, FLT4, ABI1) 1.55E-03 4.09E-02 
altered vascular endothelial growth 
factor signaling 
1 (FLT4) 1.53E-03 4.09E-02 
Signaling by ERBB4 2 (NCOR1, NRG1) 1.92E-03 4.27E-02 
vascular endothelial growth factor-
activated receptor activity 
1 (FLT4) 1.12E-02 4.28E-02 
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vascular endothelial growth factor 
binding 
1 (FLT4) 1.24E-02 4.53E-02 
dihydrofolate metabolic process 1 (ATIC) 4.76E-03 4.84E-02 
Table 17 Continued 
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3.3.2.2.2 Ingenuity Pathway Analysis 
An IPA analysis of the sets of CGC genes with highly damaging allele FC ≥ 2 or FC ≤ −2 
showed that significant terms related to the cardiovascular system were only present in SCOOP 
controls.  There were also no significant terms related to apoptosis in the FC ≥ 2 set.  It is possible 
that the analysis settings for this set were incorrect as most of the results were cancer-related terms 
and over 400 of the 500 total significant terms in the FC ≥ 2 set were not significant in the FC ≤ 
−2 set 
3.4 Discussion 
Only a small proportion of the total gene set had variants associated with a cancer 
phenotype by ClinVar or HGMD within our study population.  There are certainly other genes in 
our dataset that have variants associated with cancer, however cancer-associated variants in those 
genes were not represented in our dataset.  This small sample size of genes probably makes it 
difficult to arrive at any solid conclusions.  However, it is worth noting that five of the 10 genes 
with cancer phenotypes having a significant excess of alleles in CHD cases after adjustment were 
CHD-ome genes (AIP, ACKR3, EGFR, ENG, PTCH1).  This observation is in agreement with the 
hypothesis that genes associated with cancer are playing a role in the etiology of CHD.  
Additionally, the finding of several terms related to apoptosis in a ToppGene analysis of these 10 
genes is significant as this process plays several key roles in heart development.  Only one gene, 
AIP, had a significant excess of pathogenic alleles associated with a cancer phenotype after 
adjustment while there were no significant genes with highly damaging variants associated with a 
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cancer phenotype after adjustment.  No genes had a significant raw odds ratio p-value either overall 
or for genes with pathogenic or highly damaging variants associated with a cancer phenotype. 
Similarly, though there were a large number of cancer phenotypes overall, none had a 
significant odds ratio unadjusted while few had a significant excess of overall alleles in CHD cases 
and nothing remained significant after adjustment for either pathogenic or highly damaging alleles.  
Though there were five terms approaching significance for pathogenic alleles, these were all 
associated with the same variant in AIP.  This illustrates a common problem when performing an 
analysis based on curated phenotypes in that many variants have multiple curated phenotypes and, 
in many cases, that variant may be the only variant associated with many of those phenotypes. 
ToppGene analysis of the sets of genes with overall allele FC ≥ 2 or FC ≤ −2 produced a 
variety of significant terms related to CHD or heart/cardiovascular system morphology and 
development in each set with little overlap.  IPA comparison analysis of the gene sets revealed 
several terms related to structural CHD that were significant only in the CHD set, however multiple 
terms related to cardiovascular system morphology and development were also significant in the 
SCOOP set.  This could suggest that variants in these genes are providing a protective effect in the 
SCOOP controls.  The small number of genes with cancer phenotypes that had an allele FC ≥ 2 or 
FC ≤ −2 for pathogenic or highly damaging variants necessitated combining them into a single set 
for enrichment analysis.  ToppGene analysis of the set with allele FC ≥ 2 did not produce any 
significant structural CHD terms but did produce a number of terms related to response to hypoxia 
all associated with ATM, BRIP1, and TSC2.  Variants in these genes could thus provide a 
prognostic indicator of how well patients with cyanotic CHD will tolerate long-term decreased 
oxygen saturation, though the terms do not indicate in what direction the response is modified.  
These terms could also bear significance in relation to the possible increased cancer risk secondary 
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to chronic activation of the hypoxia pathway (Oleaga-Alday, Goni-Goicoechea, Calles-Romero, 
Perez de Ciriza-Cordeu, & Paja-Fano, 2015; Opotowsky et al., 2015).  There were also multiple 
terms related to tumors originating in the heart or vascular tissue for which variants in the 
associated genes may influence cancer risk in CHD patients.  A number of terms related to 
cardiovascular system morphology and development were significant only in the SCOOP set.  This 
could suggest that pathogenic or highly damaging variants in these genes that are associated with 
cancer phenotypes do not play a major role in the etiology of CHD in our study population.  
Another possibility is that these damaging variants are actually playing a protective role in the 
SCOOP population, perhaps by counterbalancing perturbations in developmental pathways caused 
by variants in other genes.  Both scenarios are consistent with a multigenic model in which mildly 
damaging variants in multiple genes affecting multiple pathways act synergistically to cause CHD 
in the first scenario or variants in some genes acting to counteract the variants in other genes in the 
second scenario. 
IPA analysis of these gene sets revealed “Hypoxia Signaling in the Cardiovascular System” 
as a canonical pathway term that was significant only in CHD cases.  This again suggests that 
variants in genes involved in hypoxia signaling and response to oxygen levels could be used as a 
prognostic indicator.  There were few significant ‘Disease and Bio Function’ terms related to the 
cardiovascular system including just four that were significant in CHD cases.  However, two of 
these terms, “Dysfunction of vascular endothelial cells” associated with ATM and “Major adverse 
cardiovascular event” associated with CYP2C19 may suggest variants in these genes may serve as 
prognostic indicators of patient outcome. 
Though NCOR2 was the only CGC gene with a significant odds ratio, its true significance 
may be questionable as the numbers were driven by a single common variant present in the 
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majority of samples from both cohorts that was inadvertently left in the data after filtering.  The 
allele frequency for this variant was however much higher in CHD cases (99.6%) compared to 
SCOOP controls (85.1%).  Additionally, there are 13 NCOR2 variants in our dataset with 12 of 
them being enriched in CHD cases.  NCOR2, (nuclear receptor corepressor 2) encodes a 
corepressor protein that interacts with FOXP1, itself a CHD-ome gene, to drive cardiac growth 
and mutant mice were shown to have hypoplastic ventricles and VSD (Jepsen et al., 2008).  With 
this in mind, this gene may still be worth investigating further for potential modifier effects.  With 
the exception of several terms related to valvular dysplasia, all associated with FLNA, ToppGene 
analysis of the genes with overall allele FC ≥ 2 produced no bona fide structural CHD terms.  
Mutations in FLNA (filamin A) have been associated with isolated valve defects, particularly 
involving the mitral valve, as well as Melnick-Needles syndrome, the most severe of the 
otopalatodigital syndromes (Azhar & Ware, 2016; LaHaye et al., 2014; Lalani & Belmont, 2014; 
Prendiville et al., 2014; Wessels & Willems, 2010).  This analysis did produce several significant 
terms for which investigation of the associated genes and variants could provide prognostic 
information.  Among these terms, “Cyanosis” and “Abnormal oxygen level” could indicate genes 
in which variants may provide information as to how well chronic hypoxia will be tolerated in 
cyanotic CHD patients.  Variants in MYC and PTCH1 associated with “Neoplasms, Radiation-
Induced” may identify patients at higher risk for developing cancers secondary to interventional 
radiation exposure (Cohen et al., 2018; Yakoumakis et al., 2013).  Most significant terms related 
to the cardiovascular system produced from an IPA analysis were significant only in SCOOP 
controls including several terms related to cardiovascular system development and morphology.  
This could suggest that variants in the associated genes primarily play a modifier role such that 
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they only cause CHD when combined with variants in other genes or that these genes are exerting 
a protective effect on subjects in the SCOOP cohort who carry them. 
Only nine CGC genes have variants curated as “(Likely) pathogenic” by ClinVar and 
“DM” by HGMD with none being significant.  This could suggest that pathogenic variants in these 
genes do not play a role in CHD.  As there were only nine CGC genes with pathogenic variants 
with only one of those genes having an allele FC ≥ 2 or ≤ −2, enrichment analysis was not carried 
out for this set.  MUTYH was the lone gene with a large fold change (-2.0830). 
Though many more CGC genes had highly damaging variants than pathogenic variants, 
NRG1 was the only CHD-ome gene with a significant excess of such alleles after correction.  In 
mice, mutations in Nrg1 have been associated with hypoplastic endocardial cushions and defective 
trabeculation (C. J. Lin et al., 2012; D. Srivastava & Olson, 2000).  It may however be worth noting 
that 10 of 29 (34.5%) CGC genes with significantly more alleles in CHD cases before adjustment 
were CHD-ome genes when considering that only 27.3% (133/487) of the CGC genes in the entire 
dataset were CHD-ome genes.  ToppGene analysis of the set of genes with allele FC ≥ 2 for highly 
damaging variants did not produce any significant bona fide structural CHD terms however, two 
terms, “Radiation-Related Angiosarcoma” associated with FLT4 and “response to oxygen levels” 
associated with TSC2, BRIP1, ATM, and MYOD1, could provide possible prognostic factors.  
Additionally, there were four significant terms related to VEGF signaling.  Damaging variants in 
genes in this pathway have been linked to TOF as well as Down syndrome-related AVSD 
(Ackerman et al., 2012; Reuter et al., 2018).  Multiple terms related to structural CHD were only 
significant in ToppGene analysis of genes with an allele FC ≤ −2 for highly damaging variants.  
Similarly, IPA analyses of the genes sets with allele FC ≥ 2 or FC ≤ −2 for highly damaging 
variants produced significant terms related to the cardiovascular system only in SCOOP controls.  
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Overall, these results suggest that pathogenic and/or highly damaging variants in genes associated 
with cancer are not playing a major role in the etiology of CHD in our study population at least in 
terms of direct causation, but that they may have modifier effects.  However, it did identify genes 
associated with response to low oxygen levels and with radiation-induced neoplasms as possible 
prognostic and risk factors. 
One question that arises when considering this data is how the focus on and pre-selection 
of cancer genes impacts the null model of no enrichment for cancer-related genes.  Though this 
analysis was specifically looking at genes with curated cancer phenotypes and genes in the CGC, 
the p-values obtained were still the same as those obtained from the analysis in Chapter 2.  In this 
sense, the p-values show which cancer-related genes are significant among the entire set of genes 
overall or the entire set of genes with highly damaging variants or the entire set of genes with 
curated pathogenic variants.  However, the gene sets used for enrichment analysis were those with 
large fold changes and with associated cancer phenotypes or those with large fold changes and 
present in the CGC.  This may have had the effect of artificially increasing the significance of 
terms related to inherent properties of cancer cells such as invasiveness, proliferation, apoptosis, 
and angiogenesis.  However, as many of these properties are also inherent to cells in the developing 
embryo, these terms could still be relevant.  Additionally, many of these terms could also be found 
as significant terms in the un-focused genes sets based on the entire set of genes in our study 
population. 
As this study was a subset of the larger study discussed in Chapter 2, it suffers from the 
same weaknesses including a non-random sample population and failure to correct for population 
stratification.  In addition to these, there is the issue of somatic versus germline mutations in cancer 
genes.  Though the CGC does indicate whether identified mutations in each gene are somatic, 
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germline, or both, the type of mutation was not taken into consideration and all genes were used 
in the analysis.  Ideally, it would have been better to use only those genes for which germline 
mutations have been identified as it is entirely possible that somatic mutations found only in cancer 
cells could be so deleterious as to be incompatible with embryonic development if they were to 
occur as a germline mutations present in all cells of a developing embryo.  However, neither 
ClinVar nor HGMD annotations indicate whether variants associated with cancer are found in a 
germline or somatic state so it is quite possible that the analysis based on genes associated with 
cancer phenotypes also contains a mix of genes with somatic and germline mutations.  In this 
respect, the inclusion of genes with only somatic mutations in the CGC analysis may not have 
mattered and may have in fact been the correct approach.  It was also interesting to note that of the 
187 genes with variants associated with a cancer phenotype in our dataset, only 77 of these genes 
were present in the CGC.  This could reflect differences in the criteria used to identify a gene as 
being associated with cancer.  Finally, the use of ICD-10 codes to identify cancer phenotypes may 
have missed some syndromic conditions that include increased risk of developing cancer if the 
cancer susceptibility is not the primary phenotype.  For instance, xeroderma pigmentosum which 
is well known to confer an increased risk of skin cancer has the ICD-10 code Q82.1 placing it in 
the subsection “Other congenital malformations of the skin”.  Ultimately, despite its limitations, 
this study provides possible insights into genes and variants that may modify risk of cancer 
secondary to interventional radiation exposure or to chronic activation of the hypoxia pathway. 
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4.0 Correlating Patient Phenotypes 
4.1 Introduction 
Over the course of the preceding analyses, there were multiple genes that came up 
frequently.  The purpose of this section is to summarize some of these genes and examine the 
phenotypes of patients carrying variants in these genes to determine if any patterns are present. 
4.2 Materials and Methods 
This section will mainly just focus on reporting the phenotypes of patients who carry 
variants in genes of interest to determine if there are any malformation patterns in patients carrying 
these variants. 
4.3 Results and Discussion 
4.3.1 AIP 
AIP (Aryl hydrocarbon receptor interacting protein) showed an excess of alleles in the 
CHD cohort both overall (BH FDR = 6.56E-05) and when restricting to variants curated as 
pathogenic (BH FDR = 0.0176).  Our dataset contained two missense variants; a c.47G>A 
p.Arg16His variant present in 10 CHD and four SCOOP samples as well as a C.911G>A 
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p.Arg304Gln variant present in four CHD  and one SCOOP sample.  Neither variant is highly 
damaging by the definition used in this dissertation (CADD scores of 25 and 25.4 respectively) 
(table 18).  Though the Arg16His variant showed a significant excess of alleles in CHD controls, 
the Arg304Gln variant did not.  However it was the Arg304Gln variant that stood out as three out 
of four of our patients carrying this variant had DORV while only two out of 10 patients with the 
Arg16His variant had DORV.  Preliminary data has shown a significant odds of having DORV 
among patients with an AIP variant in our study population (OR = 3.6631, χ2 p-value = 0.0245).  
Aip null mice have been shown to present DORV while mice harboring a hypomorphic allele have 
shown a patent ductus venosus (B. C. Lin et al., 2007; Obler et al., 2008).  The authors 
hypothesized that this protein may act as a chaperone that plays a role in folding and localization 
of other proteins and that the loss of AIP causes DORV through the aberrant function of one of 
these “client” proteins. 
Table 18: Summary of patients with AIP variants 
Variant 11:67250676:G:A 11:67258382:G:A 
HGVS c.47G>A, p.Arg16His c.911G>A, p.Arg304Gln 
CADD PHRED 25 24.4 
GnomAD AF 0.0020 0.0017 
ClinVar Conflicting interpretations, Likely benign, 
Uncertain significance): Hereditary cancer-
predisposing syndrome, Somatotroph 
adenoma, Familial Isolated Pituitary 
Adenomas 
Conflicting interpretations (Drug response, 
Likely benign, Pathogenic, Uncertain 
significance): Dopamine agonist response, 
Hereditary cancer-predisposing syndrome, 
Pituitary dependent hypercortisolism, 
Somatotroph adenoma, Familial Isolated 
Pituitary Adenomas 
HGMD DM?: Pituitary adenoma|Cushing's disease DM: Pituitary adenoma, Macroadenoma, 
Parathyroid adenoma, Acromegaly & 
somatotroph adenoma 
Samples (HOM) 10 (0) 4 (0) 
OR (raw/adj. p) 4.2169 (0.0115/0.4496) 6.7226 (0.0682/0.8192) 
Binomial p (adj.) 3.98E-05 (0.0249) 0.0004 (0.1787) 




7238: DORV, VSD, persistent LSVC 
7517: ASD-secundum, hypoplastic 
ascending aorta, PDA 
7528: DORV, HRV, CoA 
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7105: DORV, VSD-subpulmonic, HRV, HAA 
7106: DORV, mitral atresia, VSD, HLHS 
7277: ASD-secundum 
7539: CoA, BAV 
7557: TOF with pulmonary atresia, Possible 
compound heterozygote 
7659: DILV, TGA, VSD 
7748: TOF 
7765: BAV, CoA 
7557: TOF with pulmonary atresia, possible 
compound heterozygote 
4.3.2 ACKR3 
Atypical chemokine receptor 3 (ACKR3) was one of four CHD-ome genes along with 
APLNR, HTR2B, and S1PR1 that were among the multiple terms associated with GPCR signaling 
that came up in a ToppGene analysis of genes with an overall allele FC ≥ 5.  Though variants in 
the other 3 genes did not show any clear phenotype pattern, three of six patients harboring a 
c.892C>T p.His298Tyr variant had PTA with two of them also having persistent left superior vena 
cava (Table 19).  However, one of these three patients has extracardiac abnormalities and could 
thus represent an undiagnosed syndromic condition.  There was an additional c.1007C>T 
p.Ala336Val variant present in a single CHD patient with TOF.  Neither variant had a significant 
OR, but the His292Tyr variant showed a significant excess of alleles in the CHD cases (BH FDR 
= 0.0029).  This gene is significantly enriched in the CHD cases overall (BH FDR = 0.0019) and 
preliminary data indicated an odds ratio of 47.5 for having PTA given an ACKR3 variant (χ2 p-
value = 1.73E-14).  ACKR3 has been identified as a candidate gene for the dextro-transposition of 
the great arteries seen in patients with dup(2)(q37.3) (Costain et al., 2016).  This gene, also known 
as Cxcr7, encodes a chemokine receptor that plays a key role in valve development and has been 
shown to cause semilunar valve defects with occasional malalignment of the aorta when mutated 
in mice, though defects in aortopulmonary septation were not seen (Sierro et al., 2007; S. Yu et 
al., 2011) 
Table 18 Continued 
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Table 19: Summary of patients with ACKR3 variants 
Variant 2:237490000:C:T 2:237490115:C:T 
HGVS c.892C>T; p.His298Tyr c.1007C>T; p.Ala336Val 
CADD PRED 27.5 23.4 
GnomAD AF 0.00223276 0.0005329 
ClinVar Not curated Not curated 
HGMD DM? (Renal cell carcinoma, susceptibility) Not curated 
Samples (HOM) 6 (0) 1 (0) 
OR (raw/adj. p) 10.10 (0.0129/0.4496) 1.6763 (1/1) 
Binomal p (adj.) 3.13E-06 (0.0029) 0.1208 (1) 
Patients 7266 (White F): PTA, persistent left SVC, 
ASD-secundum, product of diabetic mother 
7288 (White M): PTA, persistent left SVC, 
genitourinary defects 
7320 (White M): c-TGA, ASD-secundum 
7535 (White F): Ebstein’s malformation 
7587 (White M): VSD, PDA, multiple 
extracardiac malformations 
7740 (White F): Truncus arteriosus, S/P 
heart transplant 
7231 (White F): TOF 
4.3.3 ZFYVE16 
ToppGene analysis of the set of genes with allele FC ≥ 2 in highly damaging variants 
produced terms that encompassed eight CHD-ome genes including ZFYVE16 which was 
associated with the term “Protein phosphatase 1 regulatory subunits”.  Of the four patients 
harboring a c.4055C>T p.Thr1352Ile variant in ZFYVE16 (Zinc finger FYVE-type containing 16), 
three have TGA (Table 20).  There was a significant excess of ZFYVE16 alleles in CHD cases 
overall (BH FDR = 0.0157) and a significant excess of highly damaging alleles before adjustment 
(p = 0.0075).  At the variant level, neither variant had a significant odds ratio, nor did they have a 
significant excess of allele in CHD cases after adjustment.  Preliminarily, a χ2 test indicated that 
the odds of having TGA given a ZFYVE16 variant were not significant (p = 0.1315). Additionally, 
one of the three patients with c.127G>A p.Val43Ile has heterotaxy.  Variants in this gene have 
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been associated with situs abnormalities in humans (A. H. Li et al., 2019).  The FYVE-type domain 
containing zinc finger proteins have been implicated in the regulation of TGF-β signaling through 
SMADs (Moustakas & Heldin, 2002). 
Table 20: Summary of patients with  ZFYVE16 variants 
Variant 5:79732631:G:A 5:79768610:C:T 
HGVS c.127G>A, p.Val43Ile c.4055C>T, p.Thr1352Ile 
CADD PHRED 23.5 32 
GnomAD AF 0.0014 0.0010 
ClinVar Not curated Not curated 
HGMD Not curated Not curated 
Samples (HOM) 3 (0) 4 (0) 
OR (raw/adj. p) 5.0376 (0.1501/1) 3.3596 (0.2048/1) 
Binomial p (adj.) 0.0033 (1) 0.0075 (1) 
Patients 6014: AVSD-complete, PAPVR, Interrupted 
IVC, Hemiazygous continuation, Heterotaxy 
7758: AVSD, Down syndrome 
7766: DILV, Pulmonary stenosis, HRV, VSD 
7364: c-TGA, VSD-muscular, right-sided 
aortic arch 
7482: VSD-perimembranous, pulmonary 
stenosis, ASD-secundum 
7593: TGA, VSD-muscular 
7660: AVSD-unbalanced, DORV, c-TGA, 
PAPVR 
4.3.4 ABI1 
Variants in ABI1 (Abl interactor 1) have been associated with LVOTO defects with 
extracardiac anomalies in a large study (Jin et al., 2017).  There were three patients in our study 
cohort each heterozygous for the same highly damaging ABI1 variant of whom two had LVOTO 
defects (Table 21).  This variant showed a significant excess of highly damaging alleles overall (p 
= 0.0033), but lost significance after adjustment.  For IPA enrichment analysis of genes with allele 
FC ≥ 2 for genes with highly damaging analysis, this gene came up associated with the terms 
“Abnormal morphology of myocardium” and “Morphology of myocardium”.  In mice, Abi1 has 
been shown to play a critical role in reorganization of the actin cytoskeleton and cell migration 
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through the WAVE2 complex with null embryos displaying cardiac and other defects (Dubielecka 
et al., 2011). 
Table 21: Summary of patients with ABI1 variant 
Variant 10:27066073:G:A 
HGVS c.383C>T; p.Ala128Val 
CADD PHRED 30 
GnomAD AF 0.000354 
ClinVar Not curated 
HGMD Not curated 
Samples (HOM) 3 (0) 
OR (raw/adj. p) 5.0376 (0.1501, 1) 
Binomial p (adj.) 0.0033 (1) 
Patients 3003: Single ventricle, TAPVR, AVSD-complete, PCD, 
heterotaxy 
7351: HLHS, Shone’s complex 
7428: Parachute mitral valve, hypoplastic aortic arch, aortic 
stenosis with BAV, ASD-secundum, Shone’s complex 
4.3.5 ARHGEF4 
Rho guanine nucleotide exchange factor 4 (ARHGEF4) showed a significant enrichment 
for highly damaging alleles before adjustment (p = 0.0228), but lost significance after adjustment.  
This gene also came up in a ToppGene analysis of genes with allele FC ≥ 2 for highly damaging 
variants associated with the term “Rho guanine nucleotide exchange factors”.  Overall, there were 
five variants in the combined CHD and SCOOP exome data, but one of these variants was only 
present in SCOOP controls.  Though this gene has been identified as a candidate gene accounting 
for the TOF seen in patients with del(2)(q22.1) (Silversides et al., 2012), none of the five patients 
with ARHGEF4 variants had TOF, though they all have left-sided lesions (Table 22).  Though not 
associated with structural heart defects in mice, Arhgef4 (also known as Asef) has been shown to 
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be required for vascular endothelial cell migration mediated by FGF and VEGF signaling 
(Kawasaki et al., 2010). 
Table 22: Summary of patients with ARHGEF4 variants 











11.24 14.06 12.77 34 
GnomAD AF 0.0015 0.0005 0.0003 0.0007 
ClinVar Not curated Not curated Not curated Not curated 
HGMD Not curated Not curated Not curated Not curated 
Samples 
(HOM) 
1 (0) 1 (0) 1 (0) 1 (0) 
OR (raw/adj. 
p) 
0.8377 (1/1) 0.3346 (0.4208/1) 0.8377 (1/1) 3.3556 (0.5600/1) 
Binomial p 
(adj.) 
0.3351 (1) 0.7988 (1) 0.3351 (1) 0.0228 (1) 










Mutations in the BCAR1 scaffold protein, Cas family member gene have been linked to 
some cases of TOF (Reuter et al., 2018).  In our study cohort, there were 11 total BCAR1 variants 
with one of those being highly damaging.  One of the three patients carrying this highly damaging 
variant had TOF as did one patient each carrying one of two other variants (Table 23).  BCAR1 
showed a significant enrichment for alleles overall (BH FDR = 0.0005), but only unadjusted for 
alleles in highly damaging variants (p = 0.0331).  Similar to the previously mentioned ABI1, this 
gene came up in an IPA enrichment analysis of genes with allele FC ≥ 2 for genes with highly 
damaging analysis, this gene came up associated with the terms “Abnormal morphology of 
myocardium” and “Morphology of myocardium”.  Bcar1 (also known as Crkas) encodes the 
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p130Cas protein and plays a role in actin filament assembly with mutant mice displaying poorly 
developed hearts with disorganized myofibrils and disrupted Z-disks (Honda et al., 1998) 
Table 23: Summary of patients with BCAR1 variants 
Variant 16:75268977:C:T 16:75269046:C:T 16:75269697:G:A 
HGVS c.1958G>A; p.Arg653Gln c.1889G>A; p.Arg630Gln c.1238C>T; p.Pro413Leu 
CADD 
PHRED 
27.3 34 23.4 
GnomAD 
AF 
0.0053 0.0009 0.0029 
ClinVar Not curated Not curated Not curated 
HGMD Not curated Not curated Not curated 
Samples 
(HOM) 




1.1535 (0.6951/1) 2.5175 (0.3691, 1) 1.6792 (0.3822 (1) 
Binomial p 
(adj.) 
0.2525 (1) 0.0331 (1) 0.0714 (1) 
Patients 6016: Tricuspid atresia, VSD, 
HRV, pulmonary stenosis, 
persistent left SVC 
7130: VSD, aortic stenosis 
with BAV, CoA 
7219: TOF 
7244: TGA, tricuspid atresia, 
VSD, ASD-secundum 









subpulmonic, Double orifice 
mitral valve, IAA 
7661: Dextrocardia, AVSD-
unbalanced, Right-sided 
aortic arch, Pulmonary 
atresia, Right atrial isomerism 




7275:  Aortic stenosis with 
BAV 
7083: DILV, aortopulmonary 
collaterals 
7264: TOF 
7386: HLHS, CoA, ASD-
secundum 
7400: HLHS, ASD-secundum 
7544: Superior sinus venosus 
defect, PAPVR 
7708: Dextrocardia, TGA, 
HRV, Pulmonary atresia 
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4.3.7 C21ORF2 
A study by Shanshen et al. (2018) reported that C21ORF2, also known as CFAP410 (Cilia 
and flagella associated protein 410) was a candidate gene to explain the CHD seen in patients with 
del(21)(q22.13-q22.3) based on a review and the presence of a mouse knockout model, however 
my own search was unable to turn up any evidence of a mouse knockout that displayed any 
structural CHD phenotypes.  Still, in looking over our patient data, there seems to be a high 
prevalence of aortic valve and aortic arch phenotypes among patients carrying one of the three 
variants present in our dataset (Table 24).  Though the function of C21ORF2 is not fully 
understood, a small study suggested possible roles in ciliogenesis and hedgehog signaling 
(Wheway et al., 2015). In our patient population, there is a significant excess of C21ORF2 alleles 
overall (BH FDR = 0.0008), however significance for an excess of pathogenic alleles is lost after 
adjustment (p = 0.0228).  This gene came up associated with a variety of significant terms 
including several non-motile cilia-related terms in a ToppGene analysis of genes with an allele FC 
≥ 2 for variants curated as pathogenic. 
Table 24: Summary of patients with C21ORF2 variants 
Variant 21:45750380:G:A 21:45751814:C:T 21:45753071:C:G 
HGVS c.965C>T; p.Ala322Val c.457G>A: p.Gly153Ser c.218G>C; p.Arg73Pro 
CADD 
PHRED 
16.71 21.8 23.9 
GnomAD 
AF 
0.0040 0.0062 0.0003 





HGMD Not curated Not curated DM: Jeune syndrome; 
Spondylometaphyseal 
dysplasia, axial; Retinitis 
pigmentosa, simplex; Cone 








6.7226 (0.0682, 0.8192) 2.3541 (0.1449, 1) 3.3556 (0.5600 (1) 
Binomial 
p (adj.) 
0.0004 (0.1787) 0.0114 (1) 0.0228 (1) 
Patients 7002: TGA, VSD, ASD-
secundum 
7198: aortic stenosis with 
BAV, CoA, Short stature, 
Turner syndrome 
*7380: VSD-inlet, aortic 
stenosis, CoA, PDA 
7405: TAPVR, hypoplastic 
aortic arch 
6065: AVSD-unbalanced, 
interrupted IVC, ASD 
7091: TOF, pulmonary 
atresia, right-sided aortic arch 
7113: DORV, AVSD-
unbalanced, parachute mitral 
valve, HLV 
7446: HRV (PA/IVS), Scoliosis 
7504: AVSD-partial 
7672: CoA 
7766: DILV, Pulmonary 
stenosis, HRV, VSD 
7505: Aortic stenosis with 
BAV 
*Possible compound heterozygote with 21:45753117:C:A (c.172G>T; p.Val58Leu) present in 23 total samples 
4.3.8 FLNA 
Mutations in filamin A (FLNA) have been associated with X-linked valvular dysplasia, 
mitral valve disease, and Melnick-Needles syndrome, the most severe form of the otopalatodigital 
syndromes which can include TOF (Azhar & Ware, 2016; LaHaye et al., 2014; Lalani & Belmont, 
2014; Prendiville et al., 2014; Wessels & Willems, 2010).  There were two variants in this gene 
present in our dataset, both present as possible compound heterozygotes in three female patients 
as well as two SCOOP samples.  The variants are located about 15 kb apart and could represent 
either a haplogroup or some sort of linkage.  This along with the variants being present in both 
cases and controls suggests it may be benign, though it is noteworthy that all three CHD patients 
have valve defects as well as extracardiac defects that may represent subtle features of the 
otopalatodigital syndromes (Table 25).  Overall, there was a significant excess of alleles in CHD 
cases before adjustment (p = 0.0112), however this significance was lost after adjustment.  This 
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gene had initially shown up in a ToppGene analysis of CGC genes associated with several terms 
related to valvular dysplasia as well as the term “abnormal oxygen level”.  This latter association 
likely refers to its regulation and modification by the oxygen sensor PHD2 as it relates to the 
control of dendritic spines and synapses (Segura et al., 2016). 
Table 25: Summary of patients with FLNA variants 
Variant X:153578465:G:A X:153593616:G:A 







ClinVar Benign/likely benign - Connective tissue 
disorder; Melnick-Needles syndrome; Oto-
palato-digital syndrome, type II; 
Periventricular nodular heterotopia 1; 
Frontometaphyseal dysplasia; Cardiovascular 
phenotype 
Conflicting interpretations: Benign; Likely 
benign; Uncertain significance - Connective 
tissue disorder; Melnick-Needles syndrome; 
Oto-palato-digital syndrome, type II; 
Periventricular nodular heterotopia 1; 
Frontometaphyseal dysplasia; Cardiovascular 
phenotype 
HGMD Not curated Not curated 
Samples 
(HOM) 




2.5175 (0.3691/1) 2.5175 (0.3691/1) 
Binomial 
p (adj.) 
0.0331 (1) 0.0331 (1) 
Patients 7146: HLHS, aortic atresia, mitral atresia, hypoplastic aortic arch, ankyloglossia, hip dysplasia 
7223: VSD, pulmonary stenosis, Dysmorphic features 
7744: VSD, Subpulmonic stenosis, Genitourinary defect, underdeveloped thumbs 
4.3.9 SMAD6 
Our patient cohort showed an excess of highly damaging variants in SMAD6 (BH FDR = 
0.0003) as well as an excess of highly damaging alleles associated with the phenotype “Loeys-
Dietz syndrome 3” caused by SMAD6 mutations.  Variants in SMAD6 (SMAD family member 6) 
have been associated with a variety of mainly left-sided lesions in both humans and mice 
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(Andersen et al., 2014; Chaix et al., 2016; Fahed et al., 2013; LaHaye et al., 2014; Y. Li et al., 
2015; C. J. Lin et al., 2012; X. Liu et al., 2017; Prendiville et al., 2014; D. Srivastava & Olson, 
2000).  Contruncal defects (TOF, DORV, TGA) were common among the 12 patients in our study 
cohort carrying a SMAD6 variant (Table 26).  SMAD6 is one of two inhibitory SMAD (I-SMAD) 
proteins along with SMAD7 that act as inhibitors of TGF-β signaling through a variety of 
mechanisms (Reviewed in Miyazawa & Miyazono, 2017).  It acts to repress BMP signaling during 
normal development of the heart valves and outflow tract. 
Table 26: Summary of patients with SMAD6 variants 
Variant 15:66995657:G:A 
HGVS c.61G>A; p.Asp21Asn 
CADD PHRED 30 
GnomAD AF 0.005063 
ClinVar Benign: Loeys-Dietz syndrome 3 
HGMD Not curated 
Samples (HOM) 12 (0) 
OR (raw/adj. p) 5.0690 (0.0030, 0.3073) 
Binomial p (adj.) 1.39E-06 (0.0014) 
Patients 7086: TOF, RAA 
7226: TOF with pulmonary atresia, aortopulmonary collateral, DiGeorge 
syndrome 
7323: TGA 
7378: TOF with pulmonary atresia 
7435: TGA 
7442: TGA 
7453: HLHS, coronary artery fistula, ASD-secundum 
7513: DORV, pulmonary stenosis, right-sided aortic arch, Goldenhar 
syndrome 
7539: CoA, BAV 
7559: DORV, mitral atresia, VSD-perimembranous, HLV, Dysmorphic 
features 
7562: TGA 
7675: IAA, VSD, subaortic stenosis 
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4.3.10 TRIM32 
CHD patients had a significant excess of alleles in rare highly damaging variants (BH FDR 
= 0.00045) in the Tripartite motif-containing 32 (TRIM32) gene.  It also came up in a ToppGene 
analysis of genes with an allele FC ≥ 2 for rare damaging variants associated with the term “striated 
muscle myosin thick filament”.  Variants in this gene have been associated with the ciliopathy, 
Bardeet-Biedl syndrome, which can occasionally include VSD or dextrocardia (Lalani & Belmont, 
2014).  TRIM32 has also been shown to be involved in cardiomyocyte hypertrophy as well as being 
implicated as a key regulator of cardiomyocyte viability and apoptosis (Borlepawar et al., 2017).  
Of the four variants present in our dataset, only the damaging Arg408Cys variant was significant 
though one patient with this variant and one with the Gln186His variant had dextrocardia (Table 
27). 
Table 27: Summary of patients with TRIM32 variants 










21.3 25.9 23.2 33 
GnomAD AF 1.25E-05 0.0002 0.0019 0.0015 








Likely benign; Likely 
pathogenic; Uncertain 
significance – Bardet-Biedl 
syndrome; Bardet-Biedl 
syndrome 11 
HGMD Not curated Not curated Not curated DM?: Usher syndrome 
Samples 
(HOM) 
1 (0) 1 (0) 2 (0) 5 (0) 
OR (raw/adj. 
p) 
0.8377 (1, 1) 1.6763 (1, 1) 0.8376 (1, 1) 8.4105 (0.0300, 0.6083) 
Binomial p 
(adj.) 
0.3350 (1) 0.1208 (1) 0.4270 (1) 3.73E-05 (0.0242) 













7384:  Hypoplastic right 
ventricle (pulmonary atresia 
with intact ventricular 
septum) 
7563: TOF, VSD, Right aortic 
arch 
7661: Dextrocardia, AVSD-
unbalanced, Right aortic 
arch, Pulmonary atresia, 
Right atrial isomerism, 
Heterotaxy-asplenia 
4.3.11 ZIC3 
The association between ZIC3 (Zinc finger protein of cerebellum 3) and heterotaxy 
spectrum CHD has been well documented (Andersen et al., 2014; Azhar & Ware, 2016; Cowan et 
al., 2014; De Luca et al., 2010; Deng et al., 2015; Fahed et al., 2013; Finsterer et al., 2017; Hilger 
et al., 2015; Lalani & Belmont, 2014; Lebo & Baxter, 2014; A. H. Li et al., 2019; McCulley & 
Black, 2012; Pierpont et al., 2007; Prendiville et al., 2014; Richards & Garg, 2010; Sutherland & 
Ware, 2009; Wessels & Willems, 2010; Xie et al., 2017).  This gene encodes a multifunctional 
zinc finger transcription factor that can interact with components of multiple developmental 
signaling pathways including Hedgehog, Wnt, Planar Cell Polarity, and TGF-β (Reviewed in 
Bellchambers & Ware, 2018).  There was a significant excess of curated pathogenic ZIC3 alleles 
among CHD patients (BH FDR = 0.0020) while also being associated with several phenotypes and 
enrichment analysis terms related to cardiac malformations, heterotaxy, and VATER/VACTERL 
association.  Of the five patients carrying the single ZIC3 variant in our dataset, three had 
diagnosed syndromic conditions that could account for their CHD while the other two had 
heterotaxy consistent with variants in this gene (Table 28).  Of the two male patients, the one with 
Down syndrome was reported as being homozygous in the exome data, though the other male 
patient was reported as being heterozygous.  As the exome data did not consider hemizygosity for 
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X chromosome loci in males and instead treated them as homozygous calls, it would have been 
expected that all male patients would have been homozygous for all X chromosome loci.  This 
could perhaps be explained by low quality sites in some male patients with different reads reporting 
different nucleotides. 
Table 28: Summary of patients with ZIC3 variants 
Variant X:136648899:G:T 
HGVS c.49G>T; p.Gly17Cys 
CADD PHRED 24.9 
GnomAD AF 0.0026 
ClinVar Conflicting interpretations: Benign; Likely benign; Pathogenic - VACTERL 
association with hydrocephaly, X-linked; Heterotaxy, visceral, X-linked; 
Congenital heart defects 1, nonsyndromic, 1 
HGMD DM: Cardiac malformation; VATER/VACTERL association 
Samples (HOM) 5 (2)* 
OR (raw/adj. p) 5.8944 (0.0165, 0.4893) 
Binomial p (adj.) 3.5E-05 (0.0231) 
Patients 2007 (M):: TOF, AVSD, Down syndrome 
7007 (M): DORV, AVSD-unbalanced, Azygous continuation, Bilateral SVC, 
Left atrial isomerism, Heterotaxy-polysplenia 
7198 (F): Aortic stenosis with BAV, CoA, Short stature, Turner syndrome 
7283 (F): AVSD-unbalanced, Dextrocardia, Heterotaxy-asplenia 
7719 (F): Hypoplastic right ventricle, CHARGE syndrome 
*The 2 homozygous calls were a presumably hemizygous male with Down syndrome and a female with 




5.0 Final Summary and Conclusions 
The goal of this study was to investigate whether patients with congenital heart disease 
have an increased burden of rare pathogenic or highly damaging variants in genes known to be 
associated with heart development and genes known to be associated with cancer.  To this end, 
there were a number of CHD-ome genes that came up frequently including ACKR3, AIP, 
C21ORF2, CCDC39, FKRP, FLT4, G6PD, NRG1, SMAD6, and ZIC3.  Of these genes, SMAD6 
and ZIC3 are well-described causes of congenital heart disease in humans while most of the other 
genes have been linked with human CHD or heart defects in mouse models.  While only eight 
genes showed a significant excess of alleles in pathogenic variants in CHD cases, four of those 
genes were CHD-ome genes whereas while 93 genes have a significant excess of alleles in highly 
damaging variants in CHD cases, only six of them were CHD-ome genes.  This seems to suggest 
that highly damaging variants in genes associated with heart development are not well tolerated in 
the CHD population. 
These results hint at a complex model where multiple variants of low to moderate 
damaging impact combine to cause CHD in patients.  In these cases, multiple variants of low to 
moderate impact may be sufficient to disturb the complex developmental pathway involved in 
heart development to the point of causing CHD.  If just one of those variants were to be replaced 
by a highly damaging variant, this could then disrupt these developmental pathways to such an 
extent as to be incompatible with life.  Highly damaging variants in CHD-ome genes may be more 
tolerated in a control population due to a lack of additional variants in other CHD-ome genes such 
that other pathways could compensate for the effect of a single highly damaging variant.  
Alternatively, the presence of significant terms related to heart development in the SCOOP gene 
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sets could indicate that variants in these genes are somehow exerting a protective effect perhaps 
by counterbalancing the effects of variants in other developmental genes.  It would thus be 
interesting to investigate whether there is a difference in the number of variants in CHD-ome genes 
between cases and controls and if there is a difference in the average functional impact of the 
variants present.  It may also be worthwhile to further subdivide the cases into mild CHD and 
complex/severe CHD groups. 
A next logical step would have been to investigate whether or not any of the genes that 
came up repeatedly seem to be associated with any particular type or class of CHD in the study 
cohort.  Preliminary work did in fact suggest links between AIP and DORV, ACKR3 and PTA, and 
ZFYVE16 and TGA.  These variants would first need to be validated by Sanger sequencing in our 
patients and then tested against a replication cohort to investigate if the same relationships occur.  
If validated and replicated, these variants could be generated in the orthologous mouse genes 
through CRISPR-Cas9 gene editing to determine if they cause the same or similar defects in mice.  
A dataset was obtained from the Pediatric Cardiac Genomics Consortium (Jin et al., 2017) to use 
as a replication cohort, however processing of the data was not completed in time to carry out the 
analysis for this dissertation. 
Though only 10 genes with curated cancer phenotypes in our dataset had a significant 
excess of alleles in CHD cases, five of those genes were CHD-ome genes which agrees with the 
hypothesis that genes associated with cancer play a significant role in heart development. 
Furthermore, ToppGene analysis of these 10 genes suggests that genes involved in the apoptosis 
pathway in particular are playing a role. Of the 35 CGC genes with an overall excess of alleles in 
CHD cases, 11 were CHD-ome genes which again suggests genes involved in cancer are playing 
a role in heart development.  Results pointed toward those cancer genes involved with apoptosis 
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as playing a significant role in the etiology of CHD.  However, despite the overall significance, 
there were very few genes with variants with curated cancer phenotypes or CGC genes that showed 
an excess of pathogenic or highly damaging alleles.  I feel these results again hint at the previously 
described complex etiology of CHD.  Pathway enrichment analysis of these cancer genes produced 
several terms related to oxygen levels and radiation-related neoplasms which could both be of 
interest as chronic hypoxia and radiation exposure during interventional treatments have both been 
linked to cancer (Cohen et al., 2018; Oleaga-Alday et al., 2015; Opotowsky et al., 2015; 
Yakoumakis et al., 2013). 
This study was limited by several factors, the most notable of which were a non-random 
study population and a lack of control for population stratification.  Due to the selection criteria 
for study participants, there is a bias toward heterotaxy spectrum CHD and HLHS which in turn 
could skew results to show enrichment for variants in genes associated with these classes of CHD 
and not for other classes.  Because the demographic information for the SCOOP controls was not 
immediately available, this was not controlled for.  However, the distribution of average number 
of calls per subject between cohorts suggests that there is a much larger proportion of non-whites 
among the CHD cases than the SCOOP controls.  The SCOOP cohort itself is not an ideal control 
cohort because the subjects all have severe obesity and are thus not ‘normal’.  Furthermore, the 
presence of subclinical CHD such as BAV or small septal defects cannot be excluded from these 
subjects.  Data was obtained from the Framingham Heart Study (Eicher et al., 2017; Tsao & Vasan, 
2015) to use as a control, however this data was acquired too late in the process to redo the analysis. 
There were also a number of limitations to the data analysis methods used beyond the lack 
of control for population stratification.  Enrichment analysis was done based on fold change of 
normalized allele counts with the cutoff chosen somewhat arbitrarily to obtain lists that were not 
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too long or too short.  It might have made more sense to create these lists based on significant odds 
ratios, however these calculations were not carried out until after the enrichment analysis had been 
done based on fold changes.  It would have been necessary to perform these analyses using raw p-
values as adjusted p-values essentially eliminated all significance.  This loss of significance was 
likely related to very large difference between number of mutant and wild type alleles in the 
cohorts.  Though the tests for significance for pathogenic and highly damaging alleles were limited 
to the set of genes with such alleles, the analysis of different subsets was not restricted in this way.  
For instance, the analysis of genes with pathogenic variants curated as causing cancer phenotypes 
was based on the analysis of the entire set of genes with curated pathogenic variants regardless of 
phenotypes.  This may have artificially reduced the number of significant genes; however, it could 
also suggest that genes associated with cancer phenotypes are not particularly enriched in our study 
population relative to all genes with curated phenotypes.  Finally, the exact and binomial tests 
cannot adequately control for population stratification and other covariates inherent in genetic 
analysis and it would have been preferable to use a more advanced methodology such as the 
sequence kernel association test (Ionita-Laza, Lee, Makarov, Buxbaum, & Lin, 2013; M. C. Wu 
et al., 2011; Yan et al., 2014) for these analyses. 
Despite these limitations, this research still provides a foundation on which to guide future 
research.  This research has provided more evidence of a complex, multigenic etiology for at least 
some CHD as well as preliminarily identifying some disease-gene associations.  Furthermore, 
genes associated with response to oxygen levels and radiation-induced cancers were identified as 
possible prognostic factors.  Variants in genes related to response to oxygen levels could provide 
information as to how well patients with cyanotic CHD will tolerate prolonged cyanosis as well as 
to their increased risk of cancer due to chronic activation of the hypoxia pathway.  Variants in 
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genes associated with radiation-induced cancers could serve as risk factors to identify patients at 
increased risk of such cancers from repeated interventional exposures.  Together, these results are 
of public health significance as they provide a basis for the further understanding of the etiology 
of CHD, for the development of novel treatment strategies, and for the assessment of risks of late 
complications. 
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Appendix A Tables 
Appendix Table 1 Structural Cardiac Defects in Our Study Population 
Structural Cardiac Defect Number of Patients 
Transposition of the great arteries 84 
VSD (unspecified) 76 
Secundum ASD 75 
Coarctation of the aorta 73 
Hypoplastic left heart syndrome 70 
Double outlet right ventricle 65 
Pulmonary stenosis 64 
Tetralogy of Fallot 60 
Bicuspid aortic valve 47 
Aortic stenosis with bicuspid aortic valve 36 
Right-sided aortic arch 31 
Congenitally corrected transposition of the great arteries 30 
Ebstein's malformation of the tricuspid valve 28 
Hypoplastic aortic arch 25 
Pulmonary atresia 25 
AVSD-unbalanced 24 
Aortic stenosis 22 
Tricuspid atresia 19 
VSD-perimembranous 19 
Hypoplastic right ventricle (Pulmonary atresia with intact septum) 18 
TOF with pulmonary atresia 18 
Double inlet left ventricle 17 
Patent ductus arteriosus 17 
Hypoplastic right ventricle 16 
Total anomalous pulmonary venous return 16 
Mitral atresia 15 
Hypoplastic left ventricle 14 
Aortopulmonary collaterals 13 
AVSD (unspecified) 13 
Dextrocardia 13 
Partial anomalous pulmonary venous return 12 
Persistent left superior vena cava 12 
Subaortic stenosis 12 
Truncus arteriosus (common arterial trunk) 12 
VSD-muscular 11 
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Aortic atresia 10 
Interrupted aorta 10 
Mitral stenosis 10 
ASD (unspecified) 8 
AVSD-partial 8 
Interrupted inferior vena cava 8 
Multiple unspecified VSDs 8 
Azygous continuation 7 
Coronary artery anomaly 7 
Coronary artery fistula 7 
Parachute mitral valve 7 
AVSD-balanced 6 
AVSD-complete 6 
Tricuspid stenosis 6 
Bilateral superior vena cava 5 
Left isomerism of the atrial appendages 5 
Hemiazygous continuation 4 
Juxtaposition of the atrial appendages to the right 4 
Mitral hypoplasia 4 
Subpulmonic VSD 4 
Mesocardia 3 
Shone's complex 3 
Single ventricle 3 
Bicuspid pulmonary valve 2 
Dilated left ventricle 2 
Hypertrophy of the right ventricle 2 
Pulmonary atresia with intact ventricular septum 2 
Subpulmonic stenosis 2 
Doubly committed VSD 2 
Inlet VSD 2 
Outlet VSD 2 
Ssubaortic VSD 2 
Sinus venosus ASD 1 
Criss-cross atrioventricular valves 1 
Dextroversion 1 
Dilated aortic root 1 
Distal origin of the right subclavian artery 1 
Double orifice mitral valve 1 
Double orifice tricuspid valve 1 
Hypoplastic right heart syndrome 1 
Hypertrophy of the left ventricle 1 
Hypoplastic ascending aorta 1 
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Malposition of great vessels 1 
Overriding and straddling tricuspid valve 1 
Overriding tricuspid valve 1 
Right isomerism of the atrial appendages 1 
Straddling tricuspid valve 1 
Superior sinus venosus defect 1 
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Appendix Table 2: Significant CHD-ome and Ciliome genes overall 
  Gene Set Allele Count Odds Ratio 
SYMBOL CHD100 CHD-ome Ciliome FC p-value BH FDR OR p-value BH FDR 
PEPD FALSE TRUE FALSE 4.1766 2.15E-12 3.04E-09 4.9178 2.85E-06 0.0029 
G6PD FALSE TRUE FALSE 14.4020 4.86E-11 4.11E-08 16.9706 0.0004 0.0489 
CASQ2 FALSE TRUE FALSE 6.1209 1E-10 5.8E-08 7.2136 5.18E-05 0.0151 
NCOR2 FALSE TRUE FALSE 1.0110 5.96E-09 1.46E-06 1.2026 2.84E-06 0.0029 
ABCC3 FALSE TRUE FALSE 1.7471 1.37E-08 3.05E-06 2.0560 3.44E-05 0.0151 
HTR2B FALSE TRUE FALSE 7.2010 5.68E-08 9.03E-06 8.5156 0.0014 0.0996 
MYLK2 FALSE TRUE FALSE 10.0814 2.3E-07 3.02E-05 11.8970 0.0052 0.2003 
UQCRC2 FALSE TRUE FALSE 10.0814 2.3E-07 3.02E-05 11.8970 0.0052 0.2003 
AIP FALSE TRUE FALSE 4.0326 6.09E-07 6.56E-05 4.7552 0.0015 0.0996 
SHANK3 FALSE TRUE FALSE 3.6005 1.21E-06 0.0001 4.2359 0.0023 0.1328 
SMAD6 TRUE TRUE FALSE 4.3206 1.39E-06 0.0001 5.1130 0.0029 0.1540 
RYR2 FALSE TRUE TRUE 1.9941 2.48E-06 0.0002 2.3449 0.0009 0.0768 
WNK3 FALSE TRUE FALSE 8.6412 3.16E-06 0.0002 10.1648 0.0125 0.2836 
DAG1 FALSE TRUE FALSE 5.7608 4.55E-06 0.0004 6.8007 0.0073 0.2236 
PEX6 FALSE TRUE FALSE 2.7364 4.73E-06 0.0004 3.2174 0.0031 0.1565 
PPARD FALSE TRUE FALSE 2.3043 7.1E-06 0.0005 2.7402 0.0023 0.1344 
BCAR1 FALSE TRUE FALSE 1.6802 7.25E-06 0.0005 1.9756 0.0015 0.0996 
ECE2 FALSE TRUE FALSE 2.2503 8.01E-06 0.0005 2.6460 0.0030 0.1565 
CCNH FALSE TRUE FALSE 3.9606 7.87E-06 0.0005 4.6654 0.0058 0.2103 
UBR2 FALSE TRUE FALSE 3.9606 7.92E-06 0.0005 4.6596 0.0058 0.2103 
C21orf2 FALSE TRUE TRUE 1.8517 1.2E-05 0.0008 2.1823 0.0026 0.1443 
PCDHA9 FALSE TRUE FALSE 4.3206 1.8E-05 0.0011 5.1023 0.0125 0.2836 
MTHFD1 FALSE TRUE TRUE 2.0163 2E-05 0.0012 2.3729 0.0040 0.1719 
MYBPC3 FALSE TRUE FALSE 2.0466 2.11E-05 0.0012 2.4051 0.0034 0.1585 
BBS2 FALSE TRUE TRUE 3.1204 2.32E-05 0.0013 3.6771 0.0074 0.2236 
CASP5 FALSE TRUE FALSE 3.1204 2.34E-05 0.0013 3.6720 0.0074 0.2239 
IFT88 FALSE TRUE TRUE 2.8804 3.22E-05 0.0018 3.3852 0.0108 0.2836 
ZIC3 FALSE TRUE TRUE 5.0407 3.5E-05 0.0019 5.9455 0.0160 0.3177 
NR0B1 FALSE TRUE FALSE 5.0407 3.5E-05 0.0019 5.9455 0.0160 0.3177 
CFLAR FALSE TRUE FALSE 5.0407 3.5E-05 0.0019 5.9455 0.0160 0.3177 
ACKR3 FALSE TRUE FALSE 5.0407 3.53E-05 0.0019 5.9305 0.0161 0.3177 
VANGL1 FALSE TRUE FALSE 5.0407 3.53E-05 0.0019 5.9305 0.0161 0.3177 
ALG13 FALSE TRUE FALSE 7.2010 3.73E-05 0.0020 8.4831 0.0293 0.3929 
BVES FALSE TRUE FALSE 7.2010 3.73E-05 0.0020 8.4831 0.0293 0.3929 
S1PR1 FALSE TRUE FALSE 7.2010 3.73E-05 0.0020 8.4831 0.0293 0.3929 
ACE FALSE TRUE FALSE 1.4638 3.9E-05 0.0021 1.7203 0.0027 0.1540 
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PRKAG2 FALSE TRUE FALSE 3.6005 4.04E-05 0.0021 4.2394 0.0112 0.2836 
PRKDC FALSE TRUE FALSE 1.8785 4.15E-05 0.0022 2.2077 0.0042 0.1762 
CCDC39 TRUE TRUE TRUE 1.5711 4.55E-05 0.0023 1.8482 0.0034 0.1585 
ALPK3 FALSE TRUE FALSE 2.3567 5.68E-05 0.0028 2.7703 0.0069 0.2236 
SLC25A46 FALSE TRUE FALSE 2.0332 5.76E-05 0.0028 2.3919 0.0057 0.2103 
BBS12 FALSE TRUE TRUE 2.1123 6.05E-05 0.0029 2.4860 0.0062 0.2203 
SPAG1 FALSE TRUE TRUE 3.1684 6.68E-05 0.0031 3.7313 0.0164 0.3177 
PCDHA2 FALSE TRUE FALSE 3.1684 6.71E-05 0.0031 3.7270 0.0165 0.3177 
C5orf42 TRUE TRUE TRUE 1.5362 7.79E-05 0.0035 1.8056 0.0050 0.2003 
USP44 FALSE TRUE FALSE 2.8804 9.38E-05 0.0042 3.3886 0.0133 0.2905 
FSTL3 FALSE TRUE FALSE 3.8405 0.0001 0.0046 4.5315 0.0240 0.3688 
PDLIM3 FALSE TRUE FALSE 3.8405 0.0001 0.0046 4.5315 0.0240 0.3688 
KCNAB1 FALSE TRUE FALSE 3.8405 0.0001 0.0046 4.5193 0.0241 0.3688 
FPR1 FALSE TRUE FALSE 2.5204 0.0001 0.0058 2.9657 0.0139 0.2980 
MEGF8 TRUE TRUE TRUE 1.5510 0.0002 0.0063 1.8235 0.0078 0.2328 
SOX4 FALSE TRUE FALSE 1.7282 0.0002 0.0066 2.0372 0.0110 0.2836 
CRELD1 FALSE TRUE TRUE 3.2405 0.0002 0.0072 3.8102 0.0216 0.3682 
ETV2 FALSE TRUE FALSE 3.2405 0.0002 0.0072 3.8138 0.0216 0.3682 
ADAMTS10 FALSE TRUE FALSE 1.5637 0.0002 0.0089 1.8396 0.0105 0.2824 
NRG1 FALSE TRUE FALSE 1.7831 0.0003 0.0092 2.0967 0.0147 0.3092 
PTBP1 FALSE TRUE FALSE 1.8903 0.0004 0.0125 2.2295 0.0165 0.3177 
ZNF423 FALSE TRUE TRUE 1.6706 0.0004 0.0126 1.9646 0.0158 0.3177 
EGFR FALSE TRUE FALSE 5.7608 0.0004 0.0127 6.7807 0.0669 0.5869 
ABCC6 FALSE TRUE FALSE 5.7608 0.0004 0.0127 6.7807 0.0669 0.5869 
GP1BB FALSE TRUE FALSE 5.7608 0.0004 0.0127 6.7807 0.0669 0.5869 
EDNRA FALSE TRUE FALSE 2.4689 0.0004 0.0131 2.9173 0.0293 0.3929 
PCDHA12 FALSE TRUE FALSE 1.9203 0.0004 0.0132 2.2567 0.0214 0.3682 
EVC2 FALSE TRUE TRUE 1.5202 0.0004 0.0138 1.7867 0.0154 0.3177 
TXNRD2 FALSE TRUE FALSE 1.9546 0.0004 0.0138 2.2991 0.0186 0.3362 
CHRNA1 FALSE TRUE FALSE 2.2403 0.0005 0.0142 2.6331 0.0285 0.3929 
DOT1L FALSE TRUE FALSE 2.2403 0.0005 0.0142 2.6331 0.0285 0.3929 
ENG FALSE TRUE FALSE 1.6907 0.0005 0.0143 1.9918 0.0181 0.3296 
TCOF1 FALSE TRUE FALSE 1.3168 0.0005 0.0150 1.5496 0.0120 0.2836 
EVL TRUE TRUE FALSE 3.3605 0.0005 0.0157 3.9616 0.0458 0.5146 
GJC1 FALSE TRUE FALSE 3.3605 0.0005 0.0157 3.9616 0.0458 0.5146 
RIPPLY3 FALSE TRUE FALSE 3.3605 0.0005 0.0157 3.9527 0.0460 0.5146 
ZFYVE16 FALSE TRUE FALSE 3.3605 0.0005 0.0157 3.9527 0.0460 0.5146 
MYO18B FALSE TRUE FALSE 1.3859 0.0005 0.0157 1.6287 0.0145 0.3075 
GPR126 FALSE TRUE FALSE 1.7145 0.0006 0.0165 2.0153 0.0211 0.3682 
XIRP2 FALSE TRUE FALSE 1.7282 0.0006 0.0179 2.0313 0.0193 0.3465 
PIK3CB FALSE TRUE FALSE 2.8804 0.0008 0.0227 3.3886 0.0674 0.5869 
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CCDC40 FALSE TRUE TRUE 1.7791 0.0008 0.0227 2.0912 0.0278 0.3929 
TP53BP2 FALSE TRUE FALSE 1.2624 0.0008 0.0228 1.4875 0.0179 0.3279 
CNTN3 FALSE TRUE TRUE 1.5362 0.0009 0.0237 1.8060 0.0245 0.3728 
TLDC1 FALSE TRUE FALSE 1.5395 0.0010 0.0259 1.8098 0.0229 0.3688 
SGCZ FALSE TRUE FALSE 2.5924 0.0011 0.0271 3.0463 0.0501 0.5267 
HECTD1 TRUE TRUE TRUE 2.5924 0.0011 0.0271 3.0476 0.0501 0.5267 
PTPRJ FALSE TRUE FALSE 1.8833 0.0011 0.0288 2.2125 0.0361 0.4534 
ARID1A FALSE TRUE FALSE 1.8833 0.0011 0.0289 2.2132 0.0361 0.4534 
TTN FALSE TRUE FALSE -1.0209 0.0011 0.0290 1.1500 0.0118 0.2836 
CCDC148 FALSE TRUE FALSE 2.4003 0.0012 0.0302 2.8222 0.0659 0.5869 
TRPS1 FALSE TRUE FALSE 2.4003 0.0012 0.0302 2.8222 0.0659 0.5869 
NEK2 FALSE TRUE TRUE 2.2632 0.0013 0.0317 2.6639 0.0485 0.5266 
BASP1 FALSE TRUE FALSE 2.0163 0.0013 0.0318 2.3718 0.0358 0.4521 
SPEN FALSE TRUE FALSE 2.1603 0.0014 0.0320 2.5376 0.0392 0.4820 
PTCH1 FALSE TRUE TRUE 2.0803 0.0013 0.0321 2.4446 0.0451 0.5146 
SIRT1 FALSE TRUE FALSE 2.0803 0.0013 0.0321 2.4495 0.0449 0.5146 
CLUAP1 FALSE TRUE TRUE 2.0803 0.0013 0.0321 2.4468 0.0450 0.5146 
TNFSF11 FALSE TRUE FALSE 2.0803 0.0013 0.0321 2.4468 0.0450 0.5146 
MYOCD FALSE TRUE FALSE 2.1603 0.0013 0.0321 2.5393 0.0391 0.4818 
SETDB2 FALSE TRUE FALSE 3.6005 0.0014 0.0340 4.2394 0.1097 0.7091 
SIN3B FALSE TRUE FALSE 3.6005 0.0014 0.0340 4.2394 0.1097 0.7091 
USP8 FALSE TRUE FALSE 3.6005 0.0015 0.0340 4.2324 0.1099 0.7091 
FLNB FALSE TRUE FALSE 1.2268 0.0020 0.0447 1.4414 0.0277 0.3929 
NPHP4 FALSE TRUE TRUE 1.4023 0.0020 0.0450 1.6474 0.0316 0.4157 
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Appendix Table 3: ToppGene analysis of genes with allele FC ≥ 5 overall 





33 (PDE7A, OR6K2, MCF2, CCL27, F2, CXCR5, OR8A1, OR10A4, 
ACKR3, AGTR2, OR1G1, TAAR9, OR8G5, OR10G8, OR6C6, OR8D4, 
OR7G2, GNGT2, OR9A2, OR2AG1, OR5P2, HTR2B, HTR4, OR5L1, 





38 (PDE7A, OR6K2, PSMA5, MCF2, PSMC6, CCL27, F2, CXCR5, 
OR8A1, OR10A4, ACKR3, AGTR2, OR1G1, TAAR9, OR8G5, OR10G8, 
OR6C6, OR8D4, OR7G2, GNGT2, OR9A2, OR2AG1, OR5P2, HTR2B, 
HTR4, OR5L1, OR5AS1, WNT8B, OR5K3, OR5H14, CNKSR2, S1PR1, 




18 (OR6K2, OR8A1, OR10A4, OR1G1, OR8G5, OR10G8, OR6C6, 
OR8D4, OR7G2, OR9A2, OR2AG1, OR5P2, OR5L1, OR5AS1, OR5K3, 





18 (OR6K2, OR8A1, OR10A4, OR1G1, OR8G5, OR10G8, OR6C6, 
OR8D4, OR7G2, OR9A2, OR2AG1, OR5P2, OR5L1, OR5AS1, OR5K3, 





28 (DCAF1, IL10RB, IL12A, NAT2, PDE7A, PSMA5, DAG1, TNIP1, NCL, 
F2, SOCS2, CXCR5, OR10A4, ACKR3, BANK1, PNP, OR2AG1, 
HNRNPDL, PLXNA3, TIMD4, S1PR1, ABCC6, TNFRSF11B, EGFR, EBI3, 







41 (KLK6, PDE7A, OR6K2, MCF2, CCL27, F2, CXCR5, OR8A1, DEFB1, 
OR10A4, ACKR3, AGTR2, OR1G1, GPSM2, TAAR9, CCL17, OR8G5, 
OR10G8, OR6C6, OR8D4, OR7G2, GNGT2, OR9A2, CA2, OR2AG1, 
OR5P2, GPR3, HTR2B, HTR4, OR5L1, OR5AS1, OR5K3, OR5H14, 





18 (OR6K2, OR8A1, OR10A4, OR1G1, OR8G5, OR10G8, OR6C6, 
OR8D4, OR7G2, OR9A2, OR2AG1, OR5P2, OR5L1, OR5AS1, OR5K3, 






38 (IL10RB, CRLF1, OR6K2, TNFRSF10A, CXCR5, OR8A1, OR10A4, 
ACKR3, AGTR2, OR1G1, TAAR9, OR8G5, OR10G8, OR6C6, OR8D4, 
OR7G2, OR9A2, GP1BB, OR2AG1, OR5P2, PLXNA3, GPR3, HTR2B, 
HTR4, OR5L1, OR5AS1, OR5K3, GRIA3, OR5H14, CLDN3, S1PR1, 
EGFR, EBI3, CD27, OR2Y1, MRGPRX3, TNFRSF1A, OR51V1) 
1.22E-04 2.76E-02 






43 (IL10RB, CRLF1, OR6K2, TNFRSF10A, F2, CXCR5, OR8A1, OR10A4, 
AMOT, ACKR3, AGTR2, NR0B1, OR1G1, TAAR9, OR8G5, OR10G8, 
OR6C6, OR8D4, OR7G2, OR9A2, GP1BB, OR2AG1, OR5P2, PLXNA3, 
GPR3, HTR2B, HTR4, OR5L1, OR5AS1, OR5K3, GRIA3, OR5H14, 
CLDN3, S1PR1, TNFRSF11B, EGFR, EBI3, CD27, CD36, OR2Y1, 






27 (OR6K2, CXCR5, OR8A1, OR10A4, ACKR3, AGTR2, OR1G1, TAAR9, 
OR8G5, OR10G8, OR6C6, OR8D4, OR7G2, OR9A2, OR2AG1, OR5P2, 
GPR3, HTR2B, HTR4, OR5L1, OR5AS1, OR5K3, OR5H14, S1PR1, 






4 (TNFRSF10A, TNFRSF11B, CD27, TNFRSF1A) 2.71E-04 4.23E-02 
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Appendix Table 4: IPA analysis of genes with allele FC ≥ 5 overall 
Diseases and Bio Functions GS1 GS1b Molecules 
Apoptosis of dermal cells 3.55061 3.398593 CFLAR, EGFR, PIAS4, PRDX6, TNFRSF10A, TNFRSF1A 
Apoptosis of synovial cells 3.203127 3.096519 CFLAR, S1PR1, TNFRSF10A, TNFRSF11B 
Apoptosis of keratinocytes 2.931953 2.806023 EGFR, PIAS4, PRDX6, TNFRSF10A, TNFRSF1A 
Apoptosis of fibroblast-like 
synoviocytes 
2.91593 2.833972 S1PR1, TNFRSF10A, TNFRSF11B 
Beat of cells 2.855215 2.798741 CA2, CASQ2 
Progressive cardiomyopathy 2.855215 2.798741 DAG1, MED30 
Apoptosis of microvascular 
endothelial cells 
2.598588 2.517939 CD36, TNFRSF10A, TNFRSF1A 
Apoptosis of epithelial cells 2.439064 2.241002 CFLAR, EGFR, F2, NCL, PIAS4, PRDX6, S1PR1, 
TNFRSF10A, TNFRSF1A, TNIP1 
Apoptosis of connective tissue 
cells 
2.301996 2.108166 CD36, CFLAR, CRADD, DCAF1, EGFR, S1PR1, 
TNFRSF10A, TNFRSF11B, TNFRSF1A, TNIP1 
Survival of vascular endothelial 
cells 
2.224656 2.146084 CFLAR, PRDX6, S1PR1 
Abnormal morphology of dilated 
vasculature 
2.135477 2.080411 AMOT, G6PD 
Apoptosis of bladder cancer cell 
lines 
2.111823 2.034024 CFLAR, DCAF1, EGFR 
Apoptosis of endothelial cells 2.061799 1.930709 CD36, CFLAR, PRDX6, TNFRSF10A, TNFRSF11B, 
TNFRSF1A 
Apoptosis of CD8+ T lymphocyte 2.059721 2.004888 CD27, CFLAR 
Apoptosis of peripheral B 
lymphocytes 
1.921618 1.893077 CFLAR 
Apoptosis of pleural cells 1.921618 1.893077 EGFR 
Lipoapoptosis of hepatocytes 1.921618 1.893077 TNFRSF10A 
Quantity of trabecular 
myocardium 
1.921618 1.893077 ZIC3 
Vacterl with hydrocephalus, X-
linked 
1.921618 1.893077 ZIC3 
X-linked multiple types 
congenital heart defects type 1 
1.921618 1.893077 ZIC3 
X-linked visceral heterotaxy 1 1.921618 1.893077 ZIC3 
Hypertrophy of heart 1.886004 2.562005 AGTR2, CASQ2, CCDC134, CD36, EGFR, HTR2B, 
KCNJ11, MYLK2, PFKFB1, RRAD, TCF15, TNFRSF1A 
Cardiac death 1.880552 0 CA2, F2, KCNJ11, SCNN1A 




Appendix Table 5: Significant cardiovascular and cilia phenotypes overall 
    Allele count Odds ratio 
Phenotype Variants FC p-value BH FDR OR p-value BH FDR 
Cardiomyopathy, non-
compaction, left ventricular 




3 6.1209 1E-10 5.02E-08 7.2136 5.18E-05 0.0380 
Dilated cardiomyopathy 1JJ 5 3.4565 5.14E-09 1.78E-06 4.0691 0.0001 0.0487 
Hypertrophic cardiomyopathy 126 1.1275 1.07E-08 3.02E-06 1.3243 8.03E-06 0.0132 
Dilated Cardiomyopathy, 
Dominant 
139 1.0677 8.13E-07 0.0001 1.2539 0.0001 0.0487 
Loeys-Dietz syndrome 3 1 4.3206 1.39E-06 0.0002 5.1130 0.0029 0.1547 
Loeys-Dietz syndrome 2 6 2.3043 7.77E-06 0.0008 2.7102 0.0024 0.1370 
Joubert syndrome 17 8 1.7367 1.6E-05 0.0013 2.0428 0.0025 0.1394 
Cardiac malformation 1 5.0407 3.5E-05 0.0023 5.9455 0.0160 0.3555 
Congenital heart defects 1, 
nonsyndromic, 1 
1 5.0407 3.5E-05 0.0023 5.9455 0.0160 0.3555 
Heterotaxy, visceral, X-linked 1 5.0407 3.5E-05 0.0023 5.9455 0.0160 0.3555 
Bardet-Biedl syndrome 11 1 7.2010 3.73E-05 0.0024 8.4831 0.0293 0.4791 
Ciliary dyskinesia 119 1.0416 4.05E-05 0.0025 1.2231 0.0015 0.1204 
Ciliary dyskinesia, primary, 28 2 3.1684 6.68E-05 0.0036 3.7313 0.0164 0.3572 
Cardiovascular phenotype 383 -1.0546 0.0002 0.0072 1.1131 0.0022 0.1253 
Atrioventricular septal defect 
2 
3 3.2405 0.0002 0.0084 3.8102 0.0216 0.4284 
Noncompaction, left 
ventricular 
17 1.3157 0.0002 0.0097 1.5462 0.0076 0.2591 
Ciliary dyskinesia, primary, 37 23 1.2326 0.0003 0.0131 1.4482 0.0092 0.2883 
Ciliary dyskinesia, primary, 33 7 1.5302 0.0007 0.0224 1.7992 0.0210 0.4284 
Hypoplastic left heart 
syndrome 1 




Appendix Table 6: ToppGene analysis of genes with allele FC ≥ 2 for highly damaging variants 




Solute carriers 18 (SLC8B1, SLC30A10, SLC25A24, SLC7A14, 
SLC2A2, SLC6A13, SLC25A10, SLC4A4, SLC16A13, 
SLC17A7, SLC35E4, SLC27A3, SLC7A8, SLC16A3, 




EF-hand domain containing 11 (CABP5, MCC, RYR2, RYR3, SLC25A24, EFCAB6, 




Protein phosphatase 1 regulatory 
subunits 
10 (TSC2, SH3RF2, CAMSAP3, SLC7A14, NCOR1, 









10 (NRG1, ROBO4, FLT4, MYBPC2, MYBPC3, 









12 (ROBO4, FANK1, MYBPC2, MYBPC3, MYOM1, 





Rho guanine nucleotide exchange 
factors 





Keratins, type I 4 (KRT26, KRT24, KRT36, KRT28) 1.58E-
03 
4.17E-02 
DNA polymerases 4 (POLD1, POLL, DNTT, POLM) 7.33E-
04 
3.37E-02 
ATP binding cassette subfamily A 3 (ABCA7, ABCA10, ABCA8) 1.89E-
03 
4.17E-02 
Fibronectin type III domain 
containing|I-set domain 
containing|Myosin binding proteins 
3 (MYBPC2, MYBPC3, MYOM1) 3.15E-
04 
2.70E-02 
striated muscle myosin thick 
filament 











Appendix Table 7: Significant caner phenotypes overall 
    Allele Count Odds Ratio 
Phenotype Variants FC p-value BH FDR OR p-value BH FDR 
Familial Isolated Pituitary 
Adenomas 
2 4.0326 6.09E-07 9.45E-05 4.7552 0.0015 0.1204 
Pituitary adenoma 2 4.0326 6.09E-07 9.45E-05 4.7552 0.0015 0.1204 
Somatotroph adenoma 2 4.0326 6.09E-07 9.45E-05 4.7552 0.0015 0.1204 
Renal cell carcinoma, 
susceptibility 
1 8.6412 3.13E-06 0.0004 10.1886 0.0125 0.3159 
Lymphoproliferative syndrome 2 1 5.7608 4.55E-06 0.0005 6.8007 0.0073 0.2543 
Adenomatous polyposis coli, 
attenuated 
1 7.2010 3.73E-05 0.0024 8.4831 0.0293 0.4791 
Hereditary nonpolyposis 
colorectal cancer type 8 
1 7.2010 3.73E-05 0.0024 8.4831 0.0293 0.4791 
Subcutaneous panniculitis-like T 
cell lymphomas with 
haemophagocytic 
lymphohistiocytic syndrome 
2 2.2258 0.0002 0.0077 2.6240 0.0169 0.3586 
Acromegaly & somatotroph 
adenoma 
1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Adrenocortical carcinoma 1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Bladder, breast, colon, 
endometrial, male breast, 
ovarian, pilocytic astrocytoma & 
renal cancer, melanoma & colon 
polyps 
1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Breast and colorectal cancer, 
susceptibility to 
1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Breast cancer, and colorectal 
cancer association with 
1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Cancer in pancreatic cancer 
syndrome, association with 
1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Cancer of multiple types, 
susceptibility to 





and other cancers 
1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Cowden/Cowden-like syndrome 1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Differentiated thyroid 
carcinoma, increased risk 
1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Gastric cancer, association with 1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Gastric cancer, increased risk, 
association with 
1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Gastrointestinal carcinoma 1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
HNPCC-related colorectal 
cancer, association with 
1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
147 
Leukemia risk 1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Li-Fraumeni syndrome 2 1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Li-Fraumeni syndrome, 
increased risk 
1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Lung cancer squamous, reduced 
risk 
1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Macroadenoma 1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Multi-organ cancers 1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Papillary thyroid carcinoma, 
association with 
1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Papillary thyroid carcinoma, 
increased risk 
1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Polycythaemia vera, increased 
risk 
1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Prostate cancer and additional 
primary cancers 
1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Thrombocythaemia, increased 
risk, association with 
1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Thyroid cancer, increased risk 1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
Uterine serous carcinoma 1 5.7608 0.0004 0.0140 6.7807 0.0669 0.6802 
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Appendix Table 8: ToppGene analysis of genes with allele FC ≥ 2 in variants with cancer phenotypes 
Name Genes in Query List p-value q-value 
FDR B&H 
Neoplasm of the heart 6 (CHEK2, CASP10, LIG4, SDHB, CDK4, 
PTCH1) 
3.18E-06 1.26E-04 
regulation of apoptotic process 9 (CHEK2, EGFR, CD27, CASP10, LIG4, 
ACKR3, MSH2, CDK4, MITF) 
2.18E-05 4.89E-03 
regulation of programmed cell death 9 (CHEK2, EGFR, CD27, CASP10, LIG4, 
ACKR3, MSH2, CDK4, MITF) 
2.52E-05 4.89E-03 
regulation of cell death 9 (CHEK2, EGFR, CD27, CASP10, LIG4, 
ACKR3, MSH2, CDK4, MITF) 
4.93E-05 5.48E-03 
regulation of nitric oxide mediated signal 
transduction 
2 (SPINK1, EGFR) 6.14E-05 5.92E-03 
Cardiac fibroma 1 (PTCH1) 1.17E-03 6.10E-03 
Cardiac Paraganglioma 1 (SDHB) 1.17E-03 6.10E-03 
calcified aortic valve 2 (EGFR, ACKR3) 1.19E-04 6.31E-03 
Heart Neoplasm 1 (SDHB) 2.33E-03 9.24E-03 
intrinsic apoptotic signaling pathway in 
response to DNA damage 
3 (CHEK2, ACKR3, MSH2) 1.92E-04 9.86E-03 
apoptotic signaling pathway 5 (CHEK2, CD27, CASP10, ACKR3, 
MSH2) 
4.07E-04 1.44E-02 
nitric oxide mediated signal transduction 2 (SPINK1, EGFR) 4.28E-04 1.44E-02 
negative regulation of apoptotic process 6 (EGFR, CD27, LIG4, ACKR3, MSH2, 
MITF) 
4.03E-04 1.44E-02 
negative regulation of programmed cell 
death 
6 (EGFR, CD27, LIG4, ACKR3, MSH2, 
MITF) 
4.53E-04 1.44E-02 
Atrial myxoma 1 (MSH2) 5.82E-03 1.62E-02 
aortic valve stenosis 2 (EGFR, ACKR3) 6.04E-04 1.62E-02 
heart left ventricle outflow tract stenosis 2 (EGFR, ACKR3) 6.04E-04 1.62E-02 
Abnormal venous morphology 5 (CHEK2, SPINK1, LIG4, UGT1A10, 
CDK4) 
3.00E-03 1.65E-02 
abnormal induced cell death 4 (CHEK2, TYR, LIG4, MSH2) 8.27E-04 1.79E-02 
thick pulmonary valve 2 (EGFR, ACKR3) 8.46E-04 1.79E-02 
Angiofibromas 2 (MSH2, SDHB) 3.51E-03 1.85E-02 
abnormal cell death 9 (CHEK2, TYR, CD27, FANCB, LIG4, 
MSH2, ITK, AIP, PTCH1) 
1.11E-03 1.94E-02 
thick aortic valve 2 (EGFR, ACKR3) 1.13E-03 1.94E-02 
negative regulation of cell death 6 (EGFR, CD27, LIG4, ACKR3, MSH2, 
MITF) 
8.00E-04 1.99E-02 
intrinsic apoptotic signaling pathway in 
response to DNA damage by p53 class 
mediator 
2 (CHEK2, MSH2) 1.03E-03 2.08E-02 
abnormal apoptosis 8 (TYR, CD27, FANCB, LIG4, MSH2, ITK, 
AIP, PTCH1) 
1.31E-03 2.15E-02 
Abnormal vascular morphology 9 (CHEK2, SPINK1, CASP10, FANCB, 
LIG4, UGT1A10, SDHB, AIP, CDK4) 
5.52E-03 2.55E-02 
Myxoma of heart 1 (EGFR) 1.51E-02 2.99E-02 
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Myxoma of the Endocardium 1 (EGFR) 1.74E-02 3.27E-02 
increased sensitivity to induced cell death 3 (TYR, LIG4, MSH2) 3.52E-03 3.63E-02 
negative regulation of nitric oxide mediated 
signal transduction 
1 (SPINK1) 2.98E-03 3.67E-02 
intrinsic apoptotic signaling pathway by p53 
class mediator 
2 (CHEK2, MSH2) 3.04E-03 3.71E-02 
hedgehog receptor activity 1 (PTCH1) 3.12E-03 3.84E-02 
smoothened binding 1 (PTCH1) 3.12E-03 3.84E-02 
Neoplasms, Radiation-Induced 1 (PTCH1) 2.31E-02 3.92E-02 
intrinsic apoptotic signaling pathway 3 (CHEK2, ACKR3, MSH2) 3.61E-03 3.98E-02 
abnormal heart valve morphology 3 (EGFR, ACKR3, CDK4) 4.43E-03 4.25E-02 
hedgehog family protein binding 1 (PTCH1) 5.19E-03 4.28E-02 
canonical Wnt signaling pathway involved in 
negative regulation of apoptotic process 
1 (MITF) 4.95E-03 4.31E-02 
positive regulation of nitric oxide mediated 
signal transduction 
1 (EGFR) 4.95E-03 4.31E-02 
Abnormal heart morphology 10 (CHEK2, CASP10, FANCB, LIG4, 
UGT1A10, MSH2, SDHB, AIP, CDK4, 
PTCH1) 
1.16E-02 4.35E-02 
patent ductus venosus 1 (AIP) 5.03E-03 4.42E-02 
Endocardial Cushion Defects 1 (EGFR) 2.88E-02 4.55E-02 
patched binding 1 (PTCH1) 8.29E-03 4.80E-02 
Bicuspid aortic valve 1 (EGFR) 3.11E-02 4.80E-02 
Cardiac Lymphoma 1 (CD27) 3.22E-02 4.91E-02 
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Appendix Table 9: Breakdown of variants by ClinVar and HGMD pathogenicity 
ClinVar Clinical Significance 
HGMD Pathogenicity 
DM DM|DM? DM? DP DFP FP NA 
Pathogenic 311 0 95 8 7 6 58 
Pathogenic/Likely pathogenic 43 0 4 0 0 0 4 
Likely pathogenic 126 0 42 4 6 1 29 
Benign 318 1 806 58 28 33 3109 
Benign/Likely benign 65 0 228 24 7 2 728 
Likely benign 293 1 655 48 22 17 2267 
Conflicting interpretations 229 1 342 16 10 6 868 
Affects 2 0 0 0 0 4 2 
association 0 0 1 0 1 0 0 
drug response 6 0 0 0 3 4 0 
protective 2 0 1 1 1 0 0 
risk factor 17 0 10 4 8 0 0 
other 4 0 3 0 0 3 0 
Uncertain significance 369 1 482 21 13 14 2230 
not provided 9 0 11 1 2 2 78 
NA 180 0 468 122 37 123 29476 
Orange cells are variants that were included using the “and” definition of pathogenicity while yellow cells are 
variants that would have been considered pathogenic using the “or” definition.  Note that many variants had 
multiple significance assertions in ClinVar so the numbers are not exclusive.  DM = Disease-associated mutation, 
DM? = Disease associated mutation without strong evidence, DP = Disease-associated polymorphism, DFP = 
Disease-associated functional polymorphism, FP = Functional polymorphism, NA = Not applicable. 
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Appendix B Figures 
 
Appendix Figure 1: Average number of calls by race for the CHD cohort 
 
Breaking down the number of calls by sample by race as determined by principal 
component analysis of exome data showed that Africans had far more calls than Whites and Asians 
with the mixed races being intermediate between their component races.  The cutoff for assigning 
one race exclusively was 85% and the one sample marked ‘other’ was found to be 84% white and 





Appendix C Lists 
Appendix C.1 Gene Sets for Enrichment Analysis 
The following is a list of gene sets (GS) used for enrichment analysis in ToppGene and 
IPA.  Initially, these analyses were done only with genes for which a numeric fold change could 
be calculated, i.e. those with alleles in both the CHD and SCOOP cohorts.  The analyses were then 
redone to include “unique” genes that only had variants in that category (overall, pathogenic, 
CADD ≥ 30) in one cohort such that for the sets with FC ≥, “unique” refers to the CHD cohort and 
for sets with FC ≤, “unique” refers to the SCOOP cohort.  Also listed are the total number of genes 
in each set.  Gene sets 7 and 8 were to be genes with FC ≥ 1 or FC ≤ −1 for pathogenic alleles, but 
these sets were not looked at.  For the Cosmic Gene Census (CGC) gene sets there were no genes 
with variants only in the CHD cohort, so gene sets 15, 17, and 19 did not have “b” sets.  
Additionally, only nine CGC genes had pathogenic alleles so no enrichment analyses were done 
for these. 
• GS1: Set of genes with FC ≥ 5 (n = 278) 
o GS1b: Set of genes with FC ≥ 5 plus unique (n = 297) 
• GS2: Set of genes with FC ≤ −5 overall (n = 58) 
o GS2b: Set of genes with FC ≤ −5 overall plus unique (n = 217) 
• GS3: Genes with FC ≥ 2 and homozygous calls only in CHD (n = 247) 
• GS4: Genes with FC ≤ −2 and homozygous calls only in SCOOP (n = 46) 
• GS5: Genes with FC ≥ 2 for pathogenic alleles (n = 35) 
o GS5b: Genes with FC ≥ 2 plus unique for pathogenic alleles (n = 36) 
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• GS6: Genes with FC ≤ −2 for pathogenic alleles (n = 38) 
o GS6b: Genes with FC ≤ −2 plus unique for pathogenic alleles (n = 45) 
• GS9: Genes with FC ≥ 2 for alleles in variants with CADD ≥ 30 (n = 478) 
o GS9b: Genes with FC ≥ 3 for alleles in variants with CADD ≥ 30 (n = 140) 
o GS9c: Genes with FC ≥ 2 plus unique for alleles in variants with CADD ≥ 30 (n = 
489) 
o GS9d: Genes with FC ≥ 3 plus unique for alleles in variants with CADD ≥ 30 (n = 
151) 
• GS10: Genes with FC ≤ −2 for alleles in variants with CADD ≥ 30 (n = 370) 
o GS10b: Genes with FC ≤ −3 for alleles in variants with CADD ≥ 30 (n = 111) 
o GS10c: Genes with FC ≤ −2 plus unique for alleles in variants with CADD ≥ 30 (n 
= 481) 
o GS10d: Genes with FC ≤ −3 plus unique for alleles in variants with CADD ≥ 30 (n 
= 222) 
• GS11: Genes with homozygous calls only in CHD for variants with CADD ≥ 30 (n = 50) 
• GS12: Genes with homozygous calls only in SCOOP for variants with CADD ≥ 30 (n = 
43) 
• GS13: Genes with FC ≥ 2 for loss-of-function (LOF) alleles (n = 117) 
o GS13b: Genes with FC ≥ 2 + unique for LOF alleles (n = 120) 
• GS14: Genes with FC ≤ −2 for LOF alleles (n = 82) 
o GS14b: Genes with FC ≤ −2 plus unique for LOF alleles (n = 105) 
• GS15: CGC genes with FC ≥ 2 for variants with CADD ≥ 30 (n = 24) 
• GS16: CGC genes with FC ≤ −2 for variants with CADD ≥ 30 (n = 12) 
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o GS16b: CGC genes with FC ≤ −2 plus unique for variants with CADD ≥ 30 (n = 
16) 
• GS17: CGC genes with FC ≥ 2 overall (n = 60) 
• GS18: CGC genes with FC ≤ −2 overall (n = 41) 
o GS18b CGC genes with FC ≤ −2 plus unique overall (n = 49) 
• GS19: Genes with cancer phenotype and FC ≥ 2 plus unique (n = 20) 
• GS20: Genes with cancer phenotype and FC ≤ −2 plus unique (n = 24) 
• GS21: Genes with cancer phenotype and FC ≥ 2 plus unique for variants curated as 
pathogenic or with CADD ≥ 30 (n = 3 + 11 – 1 duplicate = 14) 
• GS22: Genes with cancer phenotype and FC ≤ −2 plus unique for variants curated as 
pathogenic or with CADD ≥ 30 (n = 4 + 18 – 2 duplicates = 20) 
Appendix C.2 ToppGene Parameters 
ToppGene provides a variety of analysis and filtering options allowing you to modify the 
types of results you get.  The p-value method can be set as either probability density function or 
cumulative distribution function while offering Bonferroni, Benjamini-Hochberg, and Benjamini-
Yekutieli corrections.  The p-value cutoff can also be adjusted as can the maximum and minimum 
number of genes associated with output terms.  The “Feature options” settings provide a list of 
databases against which your gene set will be queried to search for enrichment, some of which 
have subcategories.  By default, all of these are checked, however some of these were unchecked 
as they were deemed not relevant or did not produce any relevant results.  Below are the parameters 
that were used for all ToppGene Analyses in this dissertation. 
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• Calculations 
o p-value method: Probability density function 
o Correction: FDR (Benjamini-Hochberg) 
o p-value cutoff: 0.05 
o Gene limits: 1 ≤ n ≤ 2000 
• Feature options 
o GO: Molecular Function 
o GO: Biological Process 
o GO: Cellular Component 
o Human Phenotype 
o Mouse Phenotype 
o Pathways 
▪ BioSystems: BIOCYC 
▪ BioSystems: KEGG 
▪ BioSystems: Pathway Interaction Database 
▪ BioSystems: REACTOME 
▪ GenMAPP 
▪ MSigDB C2 BIOCARTA (v6.0) 
▪ PantherDB 
▪ Pathway Ontology 
▪ SMPDB 
o Transcription Factor Binding Site 
o Gene Family 
156 
o Disease 
▪ Clinical Variations 
▪ DisGeNET BeFree 
▪ DisGeNET Curated 
▪ GWAS 
▪ OMIM 
Appendix C.3 IPA Parameters 
Ingenuity Pathway Analysis (IPA) provides a large number of options to modify your 
parameters within each of the analysis types.  For this project, which was only looking at gene set 
enrichment, the Variant Effect Analysis was used.  General settings allow you to choose the 
reference set and what types of relationships to consider.  “Network interactions” allow you to 
define the size and number of networks that will be generated as well as how they will be scored.  
“Node type” defines the types of molecules that will be included in networks.  A large number of 
data sources are also available against which input gene sets will be queried for enrichment.  There 
are also options to select the confidence level, restrict the species for which gene sets are compared, 
select the tissue types and cell lines to be considered, and the types of mutations to be considered.  
The parameters used for IPA analyses in this study are as follows. 
• General Settings 
o Reference Set: Ingenuity Knowledge Base (Genes Only) 
o Relationships to Consider: Direct and Indirect 
• Network Interactions 
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o Interaction networks 
▪ Include endogenous chemicals: No 
▪ Molecules per network: 35 
▪ Networks per analysis: 25 
o Causal networks 
▪ Score using causal paths only: Yes 
• Node types 





o G-protein-coupled receptor 
o Group 
o Growth factor 
o Ion channel 
o Kinase 
o Ligand-dependent nuclear receptor 
o Peptidase 
o Phosphatase 
o Transcription regulator 
o Translation regulator 




• Data sources 
o Ingenuity-supported 3rd party information 
▪ Additional sources 
• An open access database of Genome-Wide Association Results 
• BioGRID: An Online Interaction Respository With Data Compiled 
Through Comprehensive Curation Efforts 
• COSMIC 
• ClinVar 
• Gene Ontology (GO) 
• HumanCyc: Curated database of human metabolic pathways, 
enzymes, metabolites, and reactions 
• IntAct: Freely available, open source database system and analysis 
tools for molecular interaction data 
• Mouse Genome Database (MGD) 
• Obesity Gene Map Database 
• OMIM 
o Ingenuity expert information 
▪ Ingenuity Expert Findings 
▪ Ingenuity ExpertAssist Findings 
• Confidence: Experimentally observed 
• Species: Human, Mouse 
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• Tissues and Cell Lines Activated 
o Tissues and primary cells: Check all 
o Cell lines: Uncheck all 
• Mutation 
o Functional effect 
▪ Gain of function 
▪ Knockout 
▪ Loss of function 
▪ Null 





o Translation impact 
▪ Frameshift 










o Wild type 
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Appendix D Scripts 
Below is the original unmodified script ManyFishersTest.R found on an online message 
board and freely available.  This script allows the calculation of many Fisher’s exact tests from 
data arranged in a large table such that the values for each cell of the 2×2 table constructed for 
each individual test corresponds to a column in the large table. 






#create example data 
## I created this to look like the data you have a screenshot of. 
genes.table <- data.frame(gene = paste0("gene", 1:10), 
                           mut.cont = runif(10, 0, 10) %>% round(), 
                           WT.cont = runif(10, 0, 10) %>% round(), 
                           mut.dis = runif(10, 0, 10) %>% round(), 
                           WT.dis = runif(10, 0, 10) %>% round()) 
 
# Tidy the data 
## this makes it easier to convert to 2x2 tables later, which are needed 
for fisher.test 
genes.tidy <- genes.table %>% 
  gather(-gene, key = treatment, value = expression) %>% #gathers 
treatments into one column 
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  separate(treatment, into = c("genotype", "treatment")) #splits into a 
genotype and treatment column 
 
 
# Split by gene 
## this creates a list of dataframes 
gene.list <- genes.tidy %>% 
  split(.$gene) 
 
# Create tables 
## This makes 2x2 tables for each gene 
gene.tables <- map(gene.list, ~xtabs(expression ~ genotype + treatment, 
data = .)) 
 
 
# Do fisher test and get p.value 
output <- map_dfr(gene.tables, 
                  ~fisher.test(.) %>% tidy(), .id = "gene") %>% 
  select(gene, p.value) %>%  
  mutate(p.adj = p.adjust(p.value, "fdr")) 
 
output 
This script was modified into a script called PolyExact.R by removing the block to create 
example data and changing the variable names to match my data. 
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